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UraemiaPruritus is a sensory phenomenon accompanying a broad range of systemic disorders including hematologic and
lymphoproliferative disorders, metabolic and endocrine diseases, solid tumours, and infectious diseases. The
molecular mechanisms involved in itch sensation remain enigmatic in most of these diseases. However, from
studies in patients and animal models a large number of mediators and receptors responsible for scratching
behaviour have been identiﬁed in recent years. New insights into the interplay between neuronal and non-
neuronal cells in the initiation, modulation and sensitization of itch sensation have been acquired. This review
highlights the current knowledge of the molecular mechanism involved in pruritus of systemic disorders and
summarizes the signalling pathways of biogenic amines, neuropeptides, proteases, eicosanoids, cytokines,
opioids, endocannabinoids, neurotrophins, phospholipids and other signalling molecules participating in
pruritus.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Acute pruritus serves as an alarm signal to protect the body against
potentially harmful environmental threats such as parasites, noxious
plants or other irritants. The scratch response helps to remove these
harmful agents from the skin and diminishes itch sensation. These
acute forms of pruritus are mainly mediated by histamine-responsive
sensory neurons in the skin that are relatively insensitive tomechanical
pain stimuli but also respond to noxious chemicals such as capsaicin [1].
Chronic pruritus can be a seriously debilitating symptom accompanying
various cutaneous and systemic disorders [2], butmay also be caused by
drugs such as the anti-malaria drug chloroquine or the volume expand-
er hydroxyethyl starch [3]. As antihistamines do not improve itching in
most of these conditions, it is likely that itch sensation is mediated via
histamine-independent pathways. Recently discovered receptors in-
volved in itch signalling of rodents such as the Mas-related G protein-
coupled receptors (Mrg) for chloroquine, BAM8-22 and β-alanine
[4,5], the μ-opioid receptor 1D for morphine-induced pruritus [6],
endothelin-A-receptor for endothelin-1 [7], as well as the interleukin-
13 [8] and interleukin-31 receptor [9] have been shown to mediate
itch sensation in a histamine-independent fashion. Some of these and
other receptors are G protein-coupled to phospholipase C (PLC),
among which histamine-1- and serotonin-(5-HT2)-receptors activatespeciﬁcally the beta 3 isoform (PLCβ3) [10,11]. Formation of intracellu-
lar signalling molecules such as diacylglycerol (DAG) and inositol-3-
phosphate causes intracellular calcium release and activation of protein
kinase C (PKC) resulting in opening of transient receptor potential (TRP)
receptors such as the vanilloid 1 receptor (TRPV1) or ankyrin 1 channel
(TRPA1) which is required for neuronal excitation [12,13] (Figs. 1–4).
These primary sensory neurons signal to the dorsal horn of the spinal
cordwhere secondary neurons are activated by the release of glutamate
and the neuropeptide natriuretic polypeptide b (Nppb) [14]. These
secondary, Nppb receptor expressing, neurons are suggested to release
gastrin releasing peptide (GRP) which activates the GRP receptor of a
third neuron in the spinal cord [14–16]. Besides the GRP-receptor also
the neuromedin B-receptor has been shown to be responsible for
mediating itch signals [17,18]. Ablation of either the Nppb- or GRP-
receptor expressing neurons by intrathecal application of a toxin
bound to the respective signallingmolecule largely abolished scratching
behaviour after intradermal application of various pruritogens [14,16].
Noteworthy, nociceptive (pain) stimuli were unaltered by the ablation
of these neurons, indicating that a selective itch pathway exists on
spinal cord level [14,16]. However, pain and itch signalling are closely
intertwined processes: activation of pain neurons inhibits itch sensa-
tion, e.g. by scratching, cooling or heating of the skin [19,20], whereas
antinociception can cause itch sensation, e.g. by epidural or intrathecal
application of opioids or anaesthetics [21–23]. Thus, the itch circuitry
was assumed to stand under a tonic inhibitory control of mechano-
sensitive neurons. This hypothesiswas recently strengthened by the ob-
servation of spontaneous intense scratching behaviour in mice lacking
Fig. 1. Putative signalling pathway of histamine in itch neurons. For abbreviations see text.
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These interneurons are believed to be activated by glutamate, as the de-
letion of the glutamate transporter VGLUT2 caused increased spontane-
ous as well as induced scratching activity after application of
pruritogens (Fig. 5) [26,27]. In spite of this growing knowledge of recep-
tors and pathways responsible for itch signalling in mice, rats and other
species, the responsible ligands and receptors for itch sensation in
human beings remain unidentiﬁed for most disorders associated with
chronic pruritus.
Pruritus represents one of the most prominent clinical features in a
wide range of systemic disorders including (i) hematologic and lympho-
proliferative disorders such as polycythemia vera, essential throm-
bocytosis, primary myeloﬁbrosis, and lymphoma, (ii) metabolic and
endocrine diseases such as hepatobiliary diseases, chronic renal disorders,
thyroid and parathyroid disorders and diabetes mellitus, (iii) solid
tumours, (iv) infectious diseases, and (v) pruritus in the elderly.
This review summarizes the current knowledge onmolecularmech-
anisms of pruritus associatedwith systemic disorders. Furthermore, the
growing insight into receptors and pathways responsible for itch signal-
ling is outlined in detail.Fig. 2. Putative signalling pathway of serotonin2. Molecular signalling pathways of pruritogens
2.1. Biogenic amines
2.1.1. Histamine
The biogenic amine histamine which is derived from the amino acid
histidine, is certainly the classic itch mediator and best studied
pruritogen. Intradermal application of histamine by either iontophore-
sis or intradermal injection causes itching after a characteristic latency
of up to 1 min which is accompanied by a wheal and surrounding
ﬂare. Noteworthy, the location of application is important whether
histamine acts as a pruritoceptive or nociceptive compound. Superﬁcial
cutaneous application of histamine induces pruritus whereas a deeper
subcutaneous injection causes mainly pain [28]. This difference is also
clinically well known: histamine release from mast cells in the dermis
causes itching urticaria characterized by skin rash and wheals. In
contrast, histamine liberated in subcutis, mucosa or submucosal tissue
provokes angioedema being characterized by swelling of the affected
tissue. This swelling is commonly painful, at least hyperalgesic and not
itchy.in itch neurons. For abbreviations see text.
Fig. 3. Putative signalling pathway for endothelin in itch neurons. For abbreviations see text.
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1-receptors (H1-receptors) on sensory nerve endings. The H1-receptor
is linked to a G-protein (Gq), which – upon binding of histamine –
activates phospholipase C β3 (PLCβ3), which in turn cleaves
phosphaditylinositol-4,5-bisphosphate (PIP2) into the second messen-
gers diacylglycerol (DAG) and inositol-triphosphate (IP3) [10] (see
Fig. 1 for schematic representation). DAG activates proteinkinase Cε
(PKCε) which phosphorylates and thereby opens the transient receptor
potential vanilloid receptor 1 (TRPV1). Although controversially
discussed, removal of PIP2 has been shown to disinhibit TRPV1 [29].
TRPV1 is activated by several other signalling molecules, including ki-
nases (PKC, PKA and CamKII) and desensitized by Ca2+-dependent
phosphatase 2B (calcineurin), that are brought into spatial proximity
by the AKAP scaffolding protein. Activation of TRPV1 leads to channel
openingwhich allows passage of the positively charged ions sodium, po-
tassium and calcium resulting in depolarization. Thereby voltage-
dependent sodium channels are activated generating action potentials
along the nerveﬁbrewhich lead to sensation of itch [30,31]. The resultant
increase in cytosolic calcium subsequently desensitizes the channel lead-
ing to a transient hyperpolarization of the cell [32]. Histamine-induced
pruritus is partiallymediated by activation of TRPV1 [11,30] and requires
phosphoinositide-interacting regulator of transient receptor potential
channels (PIRT), a membrane protein modulating TRPV1 function [33].
PIRT is required for a PIP2-dependent activation of TRPV1 [34]. In addi-
tion, activation of TRPV1 in histamine-induced scratching behaviour re-
lates to activation of phospholipase A2 and lipooxygenase generated
products including 12-hydroxyeicosatetraenoic acid (12-HETE) [30].Fig. 4. Putative signalling pathway for chloroquinTRPV1 can be activated by increased temperature (N43 °C), protons
and the prototypic agent capsaicin (red hot chili pepper) but also by a
host of endogenous and exogenous compounds like vanilloids, phorbol
esters, camphor, endogenous lipids such as anandamide and 12-HETE
or lipid metabolic products such as LPA [32].
Wheal and ﬂare are typical skin alterations seen in histamine-
mediated prurituswhich aremainly due to secondary release of vasoac-
tive substances such as calcitonin gene-related peptide (CGRP) and sub-
stance P from axon collaterals. Thewheal ismediated by histamine itself
and substance P binding to NK1-receptors on endothelial cells, whereas
the ﬂare reaction is mediated by CGRP [35].Wheal and ﬂare are also ob-
served in patients with urticaria, cutaneous mastocytosis, acute drug
rashes and allergic skin reactions due to contact with certain parasites,
insects or plants. Antagonists of the H1-receptor, so called H1-antihista-
mines, effectively alleviate pruritus in these conditions. However, these
typical skin changes are not observed in most patients with chronic
pruritus due to systemic disorders and, accordingly, antagonists of the
H1-receptor are mostly ineffective in these patients. Furthermore,
tachyphylaxis is observed after repeated application of histamine to
the skin, indicating that histamine is less likely to be responsible for
chronic pruritus [36]. Although histamine levels have been reported to
be slightly increased in systemic diseases including cholestasis and
uraemia [37–39], other mediators seem to cause pruritus in these
disorders.
For decades the histamine receptors H1 and H2 were known and
have been studied. Using speciﬁc agonists it could be shown that itch
is caused by activation of H1-receptors, whereas H2-receptor agonistse In itch neurons. For abbreviations see text.
Fig. 5. Neurotransmitters, receptors and channels that play a role in itch and pain signalling. Abbreviations: TRP: transient receptor channel; Mrg:Mas related gene (protein receptor); H:
histamine (receptor); 5-HT-2: serotonine (receptor); ET: endothelin (receptor); PAR: protease activated receptor; GLUT: glutamate; NPPB: natriuretic polypeptide b; GRP: gastrin releas-
ing peptide; NMBR: neuromedin B receptor; MOR: μ opioid receptor; SP: substance P; CGRP: calcitonin gene related protein; Bhlhb5: basic helix-loop-helix b5 (transcription factor);
PRDM8: PR domain zinc ﬁnger protein 8.
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receptor agonists [40]. Notably, Davies and Greaves demonstrated al-
most 30 years ago that the itch threshold for a speciﬁc H1-receptor ag-
onist was consistently higher than for histamine itself even in the
presence of a H2-receptor antagonist. The authors suggested that
histamine-induced pruritus was mediated via H1-receptors and partly
via an additional non-H2-receptor [41,42]. In recent years, two further
histamine receptors, H3-receptor and H4-receptor, have been discov-
ered [43]. The H3-receptor is mainly expressed in the peripheral and
central nervous system, whereas H4-receptors are found on sensory
neurons, keratinocytes, mast cells and CD4+ T-cells [44–47]. The activa-
tion of H3-receptor seems to suppress itch sensation, as receptor antag-
onists have been shown to cause scratching behaviour in mice [48]. H4-
receptors could indeed represent the subclass of histamine receptors,
Davies and Greaves have speculated on. A H4-receptor agonist
(clobenpropit) caused scratching behaviour in Balb/c mice in a dose-
dependent manner which was not inhibited by H1- or H2-receptor
antagonists [49]. Combining H1- and H4-receptor antagonists has been
reported to be more effective than either one alone, indicating that
these receptors have non-redundant roles in itch sensation [50,51].
Pharmacological inhibition of H4-receptors by the speciﬁc inhibitor
JNJ-7777120 diminished histamine-induced scratching behaviour
more effectively than common H1-receptor antagonists [52]. Moreover,
this compound reduced scratch activity, diminished lymphocyte prolif-
eration and attenuated TH2-speciﬁc cytokine release in an animalmodel
of atopic dermatitis [53] and diminished existing airway inﬂammation
in a mouse model of asthma [54]. If H4-receptor antagonists prove
their beneﬁcial effects in clinical trials, they represent a promising
novel class of antihistamines [55].2.1.2. Serotonin
The biogenic amine serotonin (=5-hdyroxytryptamine) which is
derived from the amino acid tryptophan is a neurotransmitter in the
central nervous system and present in high concentrations in platelets
[56]. Upon intradermal injection serotonin provokes itching albeit to a
much lower extent than histamine, and even high concentrations did
not induce pruritus but burning pain in some healthy subjects [57]. No-
tably, a combined injection of serotonin and prostaglandin E2 markedly
increased itch severity and caused itching even in those subjects not
responding to serotonin alone [57]. In humans, intradermal application
of serotonin had a shorter latency of inducing itch sensation than hista-
minewhichmay indicate a direct effect of serotonin on sensory neurons
[58]. Intradermal application of serotonin causes scratching behaviour
in mice by activation of metabotropic Gq/G11-protein coupled 5-HT2 re-
ceptors [59], which is in line with the observation that α-methyl-
serotonin, a selective 5-HT2 receptor agonist, but not 5-HT1 or 5-HT3 re-
ceptor agonists, cause a similar scratching behaviour [59]. In line with
this, serotonin-mediated scratching behaviour was not altered in 5-
HT3 receptor deﬁcient mice [11]. Similar to histamine, serotonin-
induced scratching behaviour requires activation of phospholipase C
β3 (PLCβ3) [10] and TRPV1 [11] as shown in knock-out animals
(Fig. 2). Recently, endocannabinoids have been reported to attenuate
serotonin-induced scratching behaviour of spinally innervated skin,
whereas that of trigeminally innervated skin was augmented [60].
Peripheral endocannabinoids seem to have opposed effects on itch-
related scratching behaviours depending on the location of the affected
skin. Furthermore, serotonin-induced scratching behaviour inmicemay
in part involve the central opioid neurotransmitter system as it is dimin-
ished by the μ-opioid-antagonist naloxonewhich has antipruritic effects
873A.E. Kremer et al. / Biochimica et Biophysica Acta 1842 (2014) 869–892also in other murine models of acute pruritus [59]. An interaction
between the opioidergic and serotoninergic system was suggested
by the observation that the speciﬁc 5-HT3 receptor antagonist
ondansentron abolished pruritus caused by spinally administered opi-
oids [61]. However, in systemic disorders associated with pruritus in-
cluding chronic liver disorders and uraemia, ondansentron was of no
or only of minimal beneﬁt in randomized, placebo-controlled trials
[62–66]. Conversely, the selective serotonin re-uptake inhibitors
(SSRI) sertraline, paroxetine and ﬂuvoxamine have been reported to
exert some beneﬁcial anti-pruritic effects in chronic liver disorders
[67], atopic dermatitis, lymphoma and solid tumours [68,69] presum-
ably via modulation of neurotransmitter levels in the central nervous
system. Similarly, the selective norepinephrine re-uptake inhibitor
(SNRI) mirtazapine could reduce itch severity in uncontrolled case se-
ries [70,71]. Randomized, placebo-controlled trials are warranted to
strengthen these positive observations.
2.2. Neuropeptides
2.2.1. Substance P
The undecapeptide substance P is an extensively studied neuropep-
tide which is an important signalling co-transmitter of afferent neurons
in the peripheral and central nervous system [72]. Upon activation of
sensory neurons located in the skin, substance P is released which indi-
rectly causes itch sensation – only at high, presumably unphysiological
concentrations– by activation of neurokinin-receptors on non-neuronal
cells located in the skin such as keratinocytes and mast cells [1,73].
Indeed, intradermal injection of substance P in humans activated mast
cells to secrete histamine which was accompanied by a wheal and
ﬂare reaction as observed after histamine injections [74–77]. These re-
sponses were inhibited by pre-treatment of antihistamines or the hista-
mine liberator compound 48/80, which depletes local histamine stores,
suggesting that substance P-induced pruritus is mast cell-dependent
[74–76]. Mast cells being activated by substance P can additionally re-
lease further inﬂammatory mediators such as leukotriene B4, prosta-
glandin D2, and TNF-α which induce further release of substance P
from sensory nerve endings and in turn lead to stronger mast cell acti-
vation [31,78–80]. On the other hand, tryptase and chymase being re-
leased from mast cells are capable to degrade substance P [81]. Beside
mast cells substance P may trigger the release of pruritogenic com-
pounds from other cell types such as keratinocytes, endothelial cells,
and immune cells [82,83].
In mice, intradermal injection of substance P caused a similar
scratching response in mast-cell deﬁcient mice as compared to wild-
type mice [84]. The contention that substance P-mediated itch is mast
cell dependent in humans is questioned by the observation that
scratching behaviour was reduced in wild-type and mast cell deﬁcient
mice to a similar extent by pre-treatment with compound 48/80. Addi-
tionally, it could be shown that scratch responsesweremediated via the
neurokinin-1-receptor (NK1-receptor — although not present on
DRGs), but not NK2- or NK3-receptor [84]. Notably, substance P induced
scratching behaviour in mice was strongly reduced by glycyrrhetinic
acid, a pentacyclic triterpenoid derivative obtained by hydrolysis of
glycyrrhizic acid, possibly via inhibition of leukotriene B4 synthesis in
the skin [85]. Besides its release from sensory neurons substance P
was shown to play a central role in signalling of itch sensations in the
spinal cord of rats via theNK1-receptor. These second order, postsynap-
tic neurons undergo facilitation of their synaptic transmission (“spinal/
central sensitization”) which may contribute to alloknesis (light me-
chanical stimuli, brushing or stroking evoking itch) [86]. Inmice lacking
TRPA1 the indirect activation of sensory neurons by substance P was
hampered and scratching activity to substance P abolished [87]. TRPA1
is amember of the TRP-family (which also includes TRPV1), that is acti-
vated by cold (b17 °C) as well as by a plethora of chemical compounds
such as isothiocyanates (the pungent compounds in mustard oil, wasa-
bi, and horseradish), methyl salicylate (in winter green oil),cinnamaldehyde (in cinnamon), allicin and diallyl disulphide (in garlic),
acrolein (an irritant in wood ﬁre and tobacco smoke) and Δ9 tetra-
hydrocannabinol (Δ9THC, the psychoactive compound in marijuana)
andmanyothers [88]. Activation of TRPA1 generates pain signals but re-
cent evidence suggests that it also plays a role in transduction of itch
([12], also see below).
In patients with atopic dermatitis increased serum levels of
substance P were described, which correlatedwith the reported itch in-
tensity [89]. Moreover, lesional skin of patients with atopic dermatitis
and prurigo nodularis is characterized by increased substance P positive
sensory neurons [90,91]. Recently, the antiemetic NK1-receptor antago-
nist aprepitant was shown in uncontrolled case series to effectively re-
duce pruritus in patients with various dermatological and some
systemic disorders [92], Sézary syndrome [93], solid tumours [94], and
pruritus due to the epidermal growth factor inhibitor erlotinib [95].
These very promising results warrant conﬁrmation in randomized,
placebo-controlled trials.
2.2.2. Calcitonin-gene related peptide
The polypeptide calcitonin-gene related peptide (CGRP) is abun-
dantly expressed in somatic and vagal sensory neurons but may also
be expressed in Langerhans cells or keratinocytes [96]. In contrast to
substance Pwhich indirectly causes pruritus after intradermal injection,
CGRP is controversially discussed as pruritogen [84,97]. CGRP modu-
lates itch sensation and inﬂammation rather than directly causing pru-
ritus [98–100]. Intradermal injected CGRP rather had an itch-inhibitory
effect and prolonged the itch latency of subsequently injected substance
P, whereas no effect was observed on wheal and ﬂare reaction [101].
In patients with atopic dermatitis, prurigo nodularis and nummular
eczema an increased number of CGRP positive nerve ﬁbres have been
described in affected skin areas [91,102]. Furthermore, CGRP increased
IL-13 levels in cutaneous lymphocyte-associated antigen positive T-
cells (CDA+ T-cells) from patients with atopic dermatitis but not
healthy controls. The more IL-13 was released from T-cells the higher
were total IgE levels and percentage of inﬂamed skin [103]. Thus,
CGRP seems to modulate CLA+ T-cells towards a TH2 pattern and may
contribute to exacerbating clinical symptoms in itchy skin disorders.
The function of peptidergic CGRPα-expressing sensory neurons
could recently be revealed by genetic ablation of these sensory neurons.
Mice lacking CGRPα+ sensory neurons exhibited an attenuated
histamine- and chloroquine-induced scratching behaviour while that
to β-alanine was unaltered [104]. These mice also showed an impaired
sensitivity to noxious heat and capsaicin, but enhanced behaviour to
cold stimuli including activation of TRPM8, indicating that CGRPα+ sen-
sory neurons encode for heat and certain itch stimuli and tonically
cross-inhibit cold-responsive spinal neurons [104].
2.2.3. Endothelin-1
Endothelin-1 (ET-1) is a polypeptidewhich is synthesized by various
cell types, including endothelial cells, vascular smooth muscle cells,
keratinocytes and inﬂammatory cells [105,106]. Of note, at lower con-
centrations ET-1 exerts vasodilatory effects presumably by the release
of nitric oxide and prostacyclin, and only higher levels induce a power-
ful vasoconstriction [105]. ET-1 is also capable of directly activating
mast cells, keratinocytes, subsets of sensory neurons and glia cells
[107,108]. Subcutaneous injection of ET-1 caused nociceptive behav-
iours in animals [109–111] and induced burning pain in human beings
[112]. However, ET-1 has also been reported to cause scratch responses
in mice [11,111,113,114] as well as itching associated with a burning
character in humans [115,116]. A well-performed microneurography
study in human volunteers proved that ET-1 activated and sensitized
mechanosensitive C ﬁbres concentration-dependently causing itching
and pain, which was only in part mediated by histamine release [116].
Intradermal application of ET-1 caused a scratching response mainly
via the activation of endothelin-A-receptors (ETA-receptor, present on
mast cells and sensory neurons) as shown by the use of speciﬁc agonists
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pruritogens as it elicits scratching behaviour in animals in the picomolar
range, whereas other pruritogens requiremicromolar concentration, in-
dicating that endothelin-1 is likely to directly act on its cognate receptor
on sensory neurons [11]. The ETA-receptor is thought to predominantly
act via a Gq/11-PCR stimulating phospholipase C, but may also activate
phospholipases A2 and D [117]. ET-1-induced scratching behaviour
was virtually abolished inmice that had lost TRPV1-expressing neurons
[11] (see Fig. 3 for schematic representation). A recent study suggested
that inhibition of TRPA1 would increase endothelin-induced scratch re-
sponse [118]. Further analyses in knock-out animals are warranted to
reveal the role of TRPA1 in scratch response induced by ET-1 and
other mediators.
2.3. Proteases
More than 50 years ago Shelley and Arthur reported about spicules
of the tropical legumeMucuna pruriens (cowhage) that caused itching
after rubbing into the skin without a visible wheal or ﬂare
reaction [119–121]. Thus, itchingwas believed to be independent of his-
tamine which was later underlined by the fact that cowhage still pro-
duced intense pruritus in skin rendered tachyphylactic to histamine
[41]. The enzymatic action of a protease isolated from the spiculae,
which was named mucunain by Shelley and Arthur, was believed to
cause histamine-independent pruritus [120]. Shortly afterwards various
endogenous proteases such as trypsin, chymotrypsin, and, ﬁbrolysin as
well as exogenous proteases including papain and streptokinase were
reported to induce pruritus [36,122]. In recent years it was uncovered
that the responsible receptors for histamine-independent itch signalling
by proteases were the G protein-coupled receptors called protease-
activated receptor 2 (PAR2) and 4 (PAR4) [123,124]. It was shown
that the activation of PAR2 depends on proteolytic cleavage of the N-
terminal extracellular part of the receptor bywhich a peptide is released
that activates the receptor as a tethered ligand. The free six amino acid
residue Ser-Leu-Ile-Gly-Arg-Leu (SLIGRL-NH2), which is widely used
to induce nonhistaminergic, protease-mediated itching, was found to
cause scratching behaviour by activating PAR2 [125]. Thus, it was con-
cluded that PAR2 may be activated by various endogenous (trypsin,
tryptase, kallikreins, cathepsin S, etc.) and exogenous proteases
(house-dust mite, bacteria, etc.) [126,127]. However, Liu and colleagues
could recently clearly show that the scratch response caused by thepep-
tide SLIGRL is due to activation of Mas-related G protein-coupled recep-
tor C11 (MrgC11; see also later in this review) rather than PAR2 [128].
Hence, the target of the liberated peptide does not seem to be PAR2 it-
self but rather theMrgC11 receptor. Notably, the one amino acid shorter
peptide SLIGR speciﬁcally activated PAR2 which caused thermal pain
hypersensitivity but not a scratch response in mice. Furthermore,
scratching behaviour after intradermal application of trypsin was not
reduced in PAR2−/− mice [128], indicating that proteases cause an
itch–scratch response by a yet to be determined receptor which could
be e.g. PAR4. Another recent study indicated that the pruritic effect of
proteases may at least partly be mediated by the release of
endothelin-1 from keratinocytes [129].
PAR2was shown to be expressed on primary spinal afferent neurons
which released the neuropeptides substance P and CGRP upon stimula-
tion with tryptase [130,131]. Binding of the ligand to PAR2 activates a
phospholipase C (but not PLCβ3) which in turn cleaves PIP2 into DAG
and IP3 [31]. DAG activates protein kinase C (PKC) which phosphory-
lates and activates the transient receptor potential vanilloid receptor 1
(TRPV1) [132,133]. Of note, PAR2 activation has been shown to sensitize
TRPV1 in various states of pain sensation [132–134], instead of playing a
role in itch signalling and sensitization [128].
In humans, the endogenous PAR2 activator tryptase was found to be
elevated in skin of atopic dermatitis patients, whereas histamine levels
were not different from healthy controls [123]. Furthermore, PAR2 ex-
pression on afferent sensory neurons was markedly increased in skinof atopic dermatitis patients compared to healthy controls [123]. PAR2
expression on keratinocytes was similarly up-regulated in the epider-
mis of atopic dermatitis patients with the highest expression in skin le-
sions [135]. Furthermore, speciﬁc PAR2 agonists provoked enhanced
and prolonged itch in such patients upon intralesional application
[123]. These observations stand in contrast to the ﬁndings in mice by
Liu and colleagues (mentioned above) [128] and could be due to species
differences in effective ligands or a release of pruritogens by activation
of PAR2 in keratinocytes (and potentially other skin cells) in patients
with atopic dermatitis.
2.4. Eicosanoids
2.4.1. Prostaglandins
Prostaglandins are synthesized by the enzyme cyclooxygenase
(COX) from arachidonic acid, which is liberated from phospholipids by
the action of phospholipase A2. Prostaglandins have been well-studied
in inﬂammation and pain; however, the role in itch sensation is rather
unclear. Prostaglandins are regarded as modulators of pruritus rather
than being direct pruritogens. Intradermally injected prostaglandin E1
(PGE1), E2 (PGE2) and H2 had no or only a weak pruritogenic effect,
whereas they markedly enhanced histamine-induced pruritus
[136,137]. The effect of PGE2 was not altered by pre-treatment with
the H1-antihistamine clemastine suggesting that PGE2 acts downstream
of the histamine receptor, potentiates a non-histaminergic itch pathway
or acts via other histamine-receptors [138]. Similarly, PGE1 could poten-
tiate protease-induced itching of papain [139] and PGE2 augmented
serotonin-induced pruritus in healthy controls [56]. The weak direct
pruritic effect of PGE2 was comparable in healthy controls and patients
with atopic dermatitis [140]. Non-steroidal anti-inﬂammatory drugs
(=NSAID = COX-inhibitors) which are widely prescribed suppress
the synthesis of prostaglandins. In systemic disorders with pruritus,
however, NSAID have only been reported to attenuate itching in pa-
tients with polycythemia vera and HIV infection [141–143]. Thus, the
impact of prostaglandins on pathogenesis of pruritus seems to be
limited.
Inmice, prostaglandin D2 suppressed IgE-mediated scratch response
of ovalbumine-sensitized mice which was explained by reduced hista-
mine release from mast cells [144]. The increased scratching behaviour
induced by a selective COX-1-inhibitor inNC/Ngamicewhich spontane-
ously develop eczematous atopic dermatitis-like skin lesions was ex-
plained by the diminished PGD2-synthesis [145]. Indeed, when PGD2
was applied topically to these mice the COX-1-inhibitor induced
scratching behaviour was suppressed [145]. Inhibition of itch sensation
by PGD2 was shown to be mediated via the prostanoid D receptor 1
(PD1) and activation of the p38-MAPK pathway [146]. In humans, how-
ever, PGD2 did neither diminish histamine-induced pruritus nor the ac-
companying wheal and ﬂare reaction [147].
2.4.2. Leukotrienes
Leukotrienes also belong to the group of eicosanoids, but are synthe-
sized from arachidonic acid by the enzyme lipooxygenase (LO). Leuko-
triene B4 (LTB4) has been reported to induce scratching behaviour in
mice [148]. Furthermore, substance P-induced scratching may in part
be mediated by the release of LTB4 from keratinocytes [149]. Similarly,
sphingosine phosphorylcholine (SPC)-induced pruritus was in part ex-
plained by synthesis and secretion of LTB4 from keratinocytes, as
scratching behaviour was diminished by the 5-lipoxygenase inhibitor
zileuton and the LTB4-antagonist ONO-4057 [150]. Recently, the
MrgC11-agonist SLIRGL-NH2 was shown to increase synthesis and re-
lease of LTB4 and PGE2 from keratinocytes in vitro and in vivo [151].
The authors observed that topically applied tacrolimus attenuated
SLIRGL-NH2-induced scratch responses in mice and suggested that
this effect was due to a diminished synthesis and/or release of LTB4
and PGE2 from keratinocytes [151]. The underlyingmechanisms behind
this observation remain unclear and it should be mentioned that
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In contrast to mice, intradermally injected leukotrienes including
LTB4, LTC4, LTD4 and LTE4 did not evoke itch in healthy human subjects
[152,153]. However, LTB4-levels were increased in lesional skin of pa-
tients with atopic dermatitis and psoriasis [154,155]. Notably, the leu-
kotriene antagonist montelukast attenuated pruritus in a randomized,
placebo-controlled trial in atopic dermatitis patients [156] and in a
placebo-controlled, cross-over trial of ureamic patients on haemo-
dialysis [157]. Leukotrienes might therefore modulate itch severity in
patients with atopic dermatitis and uraemia.
2.5. Cytokines
Certain cytokines released from leukocytes are capable of eliciting
itch sensations. Intradermal injection of interleukin-2 (IL-2) caused
itching and erythema in both, healthy subjects and atopic dermatitis pa-
tients, which lasted for 48–72 h [158]. Intravenous IL-2 which has been
used to treat metastatic carcinoma often induced severe pruritus
[159–161]. In serum of haemodialysis patients with pruritus enhanced
levels of IL-2 but not IL-4 or IFN-γweremeasured implicating TH1 over-
activity in the pathogenesis of uraemic pruritus [162]. Calcineurin is
protein phosphatase 2B which induces IL-2 expression in T-cells by ac-
tivation of the transcription factor NFATc. The calcineurin-inhibitor cy-
closporine A down-regulates IL-2 synthesis and rapidly improved
pruritus in patients with atopic dermatitis [163] and therapy-resistant
Sézary-syndrome [164]. In rats, a discrete population of cutaneous C-
polymodal nociceptors was activated by IL-2 [165]. These cutaneous
C-ﬁbres also responded to bradykinin and histamine, and bradykinin in-
creased their responsiveness to IL-2 [166]. Transgenic mice over-
expressing IL-4 in the epidermismanifestedwith a pruritic skin disorder
that fulﬁlled the clinical diagnostic criteria established for atopic derma-
titis in patients [167]. In patients with pruritus due to HIV infection
levels of TH2-cytokine levels including IL-4, IL-5 and IL-10 were in-
creased [143]. Furthermore, IL-6 levels were reported to be increased
in haemodialysis patients with pruritus compared to those patients
without pruritus indicating a role of inﬂammation in the pathogenesis
of uraemic itch [168]. In the dermis of prurigo nodularis lesions clusters
of nerve-like ﬁbres with enhanced IL-6-like immunoreactivity were ob-
served which co-localized with CGRP expression [169].
The level of the TH2-cytokine interleukin-13 has been reported to be
increased in serum of atopic dermatitis patients [170]. IL-13 signals
through a receptor dimer consisting of IL-13Rα1 and IL-4Rαwhich ac-
tivates members of the JAK/STAT pathway resulting in phosphorylation
of STAT-6 as well as induction of PI3-kinase and MAP kinase signalling
cascades [171]. A functional link of IL-13 to pruritus has been made by
Zheng et al. [8] using an inducible IL-13 transgenic mouse model in
which IL-13 was overexpressed exclusively in keratinocytes. These
mice developed a chronic inﬂammatory phenotype similar to atopic
dermatitis characterized by xerosis, pruritic eczematous lesions and in-
creased scratchingbehaviour associatedwith increased synthesis of IL-4
and IL-13 by CD4+ T-cells [8].
More recently, a novel interleukin, IL-31, was described which is
produced by TH2-cells as well asmast cells and signals through a recep-
tor complex composed of IL-31 receptor A and oncostatin M subunits
[9,172]. Upon binding of IL-31 the receptor activates members of the
JAK family of tyrosine kinases which cause activation of the transcrip-
tion factor STAT-1 and -5, Erk-1/2 as well as induction of PI3-kinase
and MAP kinase signalling cascades [173,174]. Mice overexpressing IL-
31 developed severe pruritus, alopecia and skin inﬂammation [9]. In
Nc/Nga mice which spontaneously develop atopic dermatitis-like skin
lesions mRNA levels of IL-31 correlated with the number of scratch
bouts [175] and intraperitoneally applied monoclonal anti-IL-31 anti-
bodies ameliorated scratching behaviour without improving skin le-
sions and dermatitis [176]. In humans, IL-31 levels were also increased
in serum of patients with chronic urticaria and atopic dermatitis andeven correlated with disease severity in atopic dermatitis patients
[177,178]. IL-31 expression was increased in prurigo nodularis and
lesional skin of atopic dermatitis patients [179]. IL-31 expressing T-
cells could recently be identiﬁed in lesional skin of atopic dermatitis pa-
tients which were in part co-expressing IL-13 and to a lesser extent IL-
22 [180]. Notably, a substantial part of these IL-31 expressing T-cells
did not co-express any typical cytokine indicating a novel entity of yet
undeﬁned T-cells [180]. Furthermore, treatment of skin with staphylo-
coccal superantigens rapidly induced IL-31 expression in atopic individ-
uals [179]. The antimicrobial peptides human β-defensin and
cathelicidin have been shown to induce IL-31 expression in human
mast cells [172]. Mast cells generated from CD34+ mononuclear cells
from polycythemia vera patients released higher amounts of
interleukin-31 resulting in increased IL-31 plasma levels in these pa-
tients [181]. Next to keratinocytes, IL-31 receptors have also been de-
scribed on DRG neurons [179,182] indicating that IL-31 could directly
activate sensory nerve ﬁbres. These results underline that IL-31 and its
receptors represent a novel target for anti-pruritic therapy.
2.6. Opioids
In 1975, Hughes and colleagues identiﬁed two endogenous peptides,
Leu- andMet-enkephaline,with a potent opiate-like activity [183]. Later
it was shown that these enkephalines and their receptors were present
in central and peripheral neuronal tissue [184]. Administration of these
peptides and other opioid agonists relieves pain, but causes itching as a
side-effect — the mode of action, however, differs between peripheral
and central application [56]. Intradermal injection of morphine and
other opioid agonists caused local itching which was associated by a
wheal and ﬂare reaction [185]. Of note, H1-antihistamines but not the
μ-opioid-antagonist naloxone effectively attenuated local itch sensation,
indicating that pruritus due to intradermal injection of opioids is medi-
ated by histamine release [185,186]. Interestingly, low doses of opioids
which did not produce itch sensation when injected alone, potentiated
histamine-induced pruritus when co-injected with histamine (as simi-
larly described for prostaglandins) [187]. On the other hand itch sensa-
tion was neither attenuated by local pretreatment with compound 48/
80 to deplete histamine from mast cells nor by oral pretreatment with
indomethacin to inhibit prostaglandin synthesis indicating that the po-
tentiating effect of histamine-induced itching was not caused by hista-
mine release or prostaglandin formation [187]. Similarly, naloxone did
not diminish pruritus in this study suggesting that the peripheral prurit-
ic effects of opioids are mediated via others than μ-opioid receptors.
Generalized pruritus after oral, subcutaneous or intravenous appli-
cation of opioid agonists is observed in around 1% of patients, whereas
up to 90% report itching after epidural or intrathecal injection
[22,188]. Itching upon epidural injection may be conﬁned to the seg-
mental area of anti-nociception but often also spreads rostrally and af-
fects in particular the nose and the face of the patients [21]. As wheal
or ﬂare reactions are not observed in these areas and antihistamines
do not relieve pruritus, this form of itching is histamine-independent.
In contrast, naloxone effectively inhibited itching from spinal opioids
[21]. Similar observations were made in various animal models
[189–192]. Thus, central opioid receptors are capable of mediating itch
sensation. This effectwas previously explained by the occlusion hypoth-
esis which assumed that itch and pain signals are selectively mediated
via nociceptive and pruriceptive spinal neurons [193] and that itch sig-
nalling is under inhibitory control of pain neurons which fails upon in-
activation of pain signalling, e.g. by morphine [21,193,194]. This
theory was supported by the analysis of mice lacking the vesicular glu-
tamate transporter 2 (VGLUT2) in subsets of nocicptive DRG neurons
disconnecting them from their spinal targets that resulted in markedly
increased scratch behaviour accompanied by an attenuated responsive-
ness to thermal pain [195]. However, an elegant study [6] could recently
clearly show that long lastingmorphine-induced itching occurred inde-
pendently of themorphine-induced analgesia andwasmediated via the
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scratching was mediated speciﬁcally via the isoform D of this receptor
(MOR1D) which is located on distinct sets of neurons [6]. Intriguingly,
MOR1D forms a heterodimer with the gastrin-releasing peptide recep-
tor (GRPR) and morphine-induced scratching was mediated by activa-
tion of GRPR [6]. As morphine-induced analgesia remains unaffected
in GRPR deﬁcient mice, GRPR seems to characterize a purely itch-
related spinal interneuron [15]. These observations strongly favour a
modiﬁed labelled line hypothesis, in which itch and pain sensation are
mediated via distinct sets not only of presynaptic but also of postsynap-
tic neurons, and GRPR-expressing interneurons are likely to represent
the itch-speciﬁc relays in the spinal cord [16]. In contrast to μ-opioid ag-
onists which cause scratching, κ-opioid agonists such as nalfuraﬁne
have been shown to inhibit scratching in animal models [196,197] and
patients suffering from uraemic pruritus [198,199]. By which mode of
action and via which receptor(s) κ-opioid agonists suppress pruritus
and cause analgesia at the same time remains to be elucidated.
Interestingly, the bovine adrenalmedulla peptide BAM(8–22) that is
derived from proenkephalin A [200] was proven to induce scratch re-
sponses after intradermal injection in mice via activation of MrgC11
[128] (see below). Thus, peripherallymediated itch sensation by certain
opioids may be mediated by others than opioid receptors.
2.7. Endocannabinoids
Endocannabinoids which are derived from the essential fatty acid ar-
achidonic acid comprise a group of substances that modulate pain and
itch sensation by binding to cannabinoid (CB) receptors [201]. CB1-
receptors are found in the CNS, whereas CB2-receptors are mainly
expressed in peripheral tissues. Interestingly, CB1- and TRPV1-
receptors showed a marked co-localisation in primary afferent C-ﬁbres
[202,203]. In addition, both receptors are expressed in cells of the skin in-
cluding keratinocytes andmast cells [203]. Cannabinoid agonists strong-
ly attenuated histamine-induced scratching behaviour in mice [204] and
could reduce itch severity in humans [205]. In rats, activation of
keratinocytes located around nerve endings in the epidermis via a
CB2 receptor agonist caused secretion of β-endorphin. The released
β-endorphins bound to μ-opioid receptors of afferent nerve ﬁbres
thereby inhibiting nociception [206]. Moreover, endocannabinoids like
anandamide – which in higher concentrations may also act as an
endovanilloid – have been shown to activate and eventually desensitize
TRPV1 demonstrating the complex role of cannabinoids in the modula-
tion of pruritus and pain [207]. Thus, endocannabinoids do not only
participate in pain sensation, but may also modulate pruritoception.
2.8. Neurotrophins
Neurotrophins such as nerve growth factor (NGF), brain-derived
neurotropic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4
(NT-4) belong to a class of growth factors whichmodulate survival, dif-
ferentiation, and maintenance of nerve cells [208]. In the skin, these
proteins are synthesized and released by mast cells, eosinophils,
keratinocytes and ﬁbroblasts [209–212]. Of note, expression of NGF
was markedly increased in lesional skin of patients with atopic derma-
titis or psoriasis which caused sensitization as well as sprouting of sen-
sory nerve ﬁbres by activation of p75 and tyrosine kinase neurotrophin
receptors (TrkA receptors) [212–215]. Several studies showed that NGF
can upregulate the expression of sensory neuropeptides such as sub-
stance P or CGRP, may sensitize the transient receptor potential
vanilloid-1 (TRPV1) and potently cause degranulation of mast cells
thereby leading to acute itch sensation [214,216,217]. In addition, sub-
stance P and CGRP increased synthesis of NGF in human cultured
keratinocytes, indicating that a positive forward loop could be responsi-
ble for sensitization of sensory neurons [218]. Furthermore, serum
levels of NGF and BDNFwere increased in patients with atopic dermati-
tis and correlated with disease severity [219,220]. In mouse models ofatopic dermatitis NGF and glial cell line-derived neurotrophic factor
(GDNF), another neurotropic factor, were upregulatedwhich could con-
tribute to scratching behaviour [221]. Thus, neurotrophins play an im-
portant role in the sensitization of afferent neurons in various skin
disorders and it would be interesting to investigate their role in system-
ic diseases associated with pruritus.
2.9. Phospholipids
2.9.1. Lysophosphatidic acid
Lysophosphatidic acid (LPA) is a potent lipid mediator exerting its
effects via at least six distinct LPA-receptors [222]. Intradermally
injected LPA induced a scratch response in mice [223] in a dose-
dependentmanner [224]. Screening sera of cholestatic patients for neu-
ronal activation revealed LPA as major activator (see also hepatobiliary
disorders) [224].
2.9.2. Sphingosinephosphorylcholine
Intradermally injected sphingosinephosphorylcholine (SPC) caused
scratching behaviour in mice [225]. Interestingly, SPC concentrations
were increased in lesional skin of NC/Nga mice [226]. SPC-induced
pruritus was partly explained by synthesis and secretion of LTB4 from
keratinocytes as scratching behaviour was diminished by a 5-
lipoxygenase inhibitor and a LTB4-antagonist [150]. On the other hand
SPC increased cytosolic free calcium concentrations in DRG neurons in-
dicating that SPC is capable of directly activating sensory neurons [150].
2.9.3. Platelet-activated factor
Intradermal injection of platelet-activated factor (PAF) caused vaso-
dilatation and increased vascular permeability, producing a weal and
ﬂare response with accompanying pruritus [227]. Thus, PAF-induced
pruritus is thought to be caused by liberation of histamine from mast
cells. PAF may also play a role in pruritus associated with allergic con-
junctivitis [228].
2.10. Others
2.10.1. Acetylcholine
Acetylcholine (ACh) is a major neurotransmitter of the peripheral
and central nervous system and exerts its effects via muscarinergic
and nicotinergic acetylcholine receptors.Whereas intracutaneous injec-
tion of high concentrations of acetylcholine caused pain sensation in
healthy volunteers, a pure itching sensationwas reported after injection
in lesional skin of patients with atopic dermatitis [229,230]. Blockade of
H1-receptors did neither diminish acetylcholine-induced itch severity
nor reduce erythema in patients with atopic dermatitis, but reduced
pain sensation and erythema in healthy controls [231]. In line, patients
with atopic dermatitis exhibit a reduced sensitivity to histamine com-
pared to healthy controls and pruritus does not respond to H1-
antihistamines [232]. Hence, in patients with atopic dermatitis pruritus
can be elicited by a cholinergic, histamine-independent mechanism. In
mice, acetylcholine was shown to cause scratch responses mainly via
the activation of muscarinergic acetylcholine receptor M3 [233],
which is amember of Gαq GPCRs and thus signals via activation of phos-
pholipase C. M3 receptors are expressed on keratinocytes but not der-
mal and epidermal nerve endings — in contrast to inhibitory M2
receptors [234]. In addition, it should be noted that excitatory and
CGRP-releasing effects are evoked by nicotinergic AChRs [234].
2.10.2. Bradykinin
Bradykinin is a nonapeptide which is liberated from kininogens
through hydrolytic cleavage by kallikreins. Kallikreins, the enzymes
forming bradykinin, are serine proteases which have for decades been
known to cause severe itching [122] without inducing a signiﬁcant
ﬂare or wheal reaction [235] (see also proteases). Bradykinin is known
as an inﬂammatory painmediator by activating bradykinin B2 receptors
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cause pruritus [235–237]. Bradykinin and kallidin (also entitled
lysylbradykinin as it has the same amino acid sequence of bradykinin
with an additional lysine), a decapeptide which is also generated by
the action of kallikreins on kininogens, are potent histamine releasers
from mast cells, and itch sensations caused are inhibited by antihista-
mines [75,235]. Furthermore, bradykinin sensitized sensory afferents
for various chemical stimuli and augmented their response to subse-
quent histamine application [238,239]. This effect may be caused by
the bradykinin-mediated release of substance P, CGRP and PGE2 after
application to the skin [98]. Furthermore, bradykinin – similar to acetyl-
choline [230,231] – has been reported to induce intense itching in
lesional skin of atopic dermatitis patients which was not diminished
by antihistamines [240]. In inﬂamed skin induced by complete Freund's
adjuvant bradykinin caused robust scratching behaviour which was
mediated via B1 receptors which are induced upon inﬂammation
[241]. Thus, the algogen bradykinin may under certain circumstances
cause histamine-independent pruritus.
Interestingly, bradykinin has been shown by several groups to acti-
vate both TRPV1 and TRPA1 channels which have been associated
with pain and itch signalling. This activation appears to be mediated
by phospholipase C [242].
2.10.3. Mrg receptors
The antimalaria drug chloroquine induces pruritus in humans,
particularly in those persons with dark skin such as black Africans. In
experimental itch research chloroquine has long been used for the
induction of histamine-independent pruritus; however, the molecular
mechanisms of itch induction remained unresolved until recently. Liu
and colleagues elegantly proved that chloroquine elicits scratching
behaviour in mice by binding to a GPCR (Gαq) called MrgA3 (Mas-
related gene GPCR subtype A3) [4]. Its human correlate is MrgX1. Con-
versely, the peptide BAM8-22 elicited itch through MrgC11. The Mrg
receptors constitute a subfamily of GPCRs that are largely orphan recep-
tors but recently have been associated to sensory functions. In contrast
to the extensive sequence diversity exhibited by the MrgA, MrgB, and
MrgC subfamilies in mice (n N 50), the related complement in humans
is composed of only a few MrgX genes (n ~ 9), while that in rats counts
one each of the MrgA, MrgC, and MrgD genes and ten MrgB genes.
Although the human MrgX genes have no direct orthologs in rodents,
humanMrgX1 has been suggested to share some features of expression,
binding proﬁle and structural homology with rat MrgC and mouse
MrgC11. Expression of many of these receptors under normal condi-
tions seems to be conﬁned to neurons and mast cells [243].
Induction of a scratch response via MrgA3 does neither activate
phospholipase C β3 (PLCβ3) [10] nor requires TRPV1 [11] as shown in
knock-out animals, making it distinct from the histamine-1-receptor
pathway (see Fig. 4 for schematic representation). Still, MrgA3+
neurons also respond to histamine [4]. In fact, a different TRP effector
is required for chloroquine-induced scratching behaviour, namely
TRPA1 [12]. Scratch responses after intradermal injection of chloroquine
were almost abolished in TRPA1 deﬁcient mice [12]. Activation of
MrgA3was shown to act through liberation of Gβγ, a signallingmolecule
which modulates several ion channels by direct binding [12]. Whether
Gβγ directly opens TRPA1 channels or acts via an indirect mechanism
remains to be elucidated. Furthermore, PIRT, a phosphoinositide-
interacting regulator of transient receptor potential channels, is re-
quired for chloroquine-induced scratch responses [33]. Thus, coupling
of GPCR to TRP channels seems to represent a common event in various
itch (and pain) signalling pathways. Han and colleagues genetically
modiﬁed and ablated MrgA3+ DRG neurons (representing around 5%
of sensory neurons) resulting in attenuation of scratching behaviour
to multiple pruritogens while pain behaviour was unaltered [13].
Using an elegant approach this group expressed TRPV1 solely in
MrgA3+ neurons in TRPV1−/− mice. Activation of these MrgA3+
sensory neurons by the algogen and TRPV1-agonist capsaicin elicitedonly hindpaw scratching but no pain-related forepaw wiping [13].
These ﬁndings suggest that MrgA3 deﬁnes a speciﬁc subpopulation of
DRG neurons responsible for itch signalling underlying the labelled
line theory initially suggested by Johannes Müller in 1826 [244]. Still,
Han and co-workers could not test cowhage in these mice, although
in vitro all MrgA3+ neurons were activated by cowhage. Species differ-
ences complicate the picture as cowhage does excite all polymodal
nociceptors in humans, but only a subset of histamine-sensitive ones
in mice [245]. Thus, MrgA3 is likely to represent a suitable candidate
for novel anti-pruritic treatment strategies for several but not all
forms of pruritus.
3. Haematologic disorders
3.1. Polycythemia vera
Polycythemia vera (PV) is a rare haematological disorder character-
ized by Janus kinase 2 (JAK2) mutations resulting in a erythroid-
weighted trilineage myeloproliferation [246,247]. The most common
JAK 2 mutation results in a substitution of valine to phenylalanine at
codon 617 (JAK2V617F) and renders the kinase constitutively active
and makes hematopoetic cells more sensitive to growth factors. Nota-
bly, pruritus appears to correlate with homozygosity for the gain-of-
function mutation JAK2V617F. Two independent studies [247,248]
showed that patients with cellular homozygosity suffered more often
from pruritus than patients with cellular heterozygosity. The mutation
has not been detected in either control subjects or germline tissue,
conﬁrming that the allele is not a commonpolymorphism in the general
population. Generalized pruritus is reported by 30–65% of patients suf-
fering from polycythemia vera and typically described as aquagenic
pruritus [249–252]. Besides polycythemia vera, aquagenic pruritus
may also occur in other myeloproliferative disorders such as essential
thrombocytosis, primary myeloﬁbrosis and the hypereosinophilic syn-
drome (see below) or as an isolated symptom in healthy people [252].
Aquagenic pruritus in patients with polycythemia vera is reported to
have a typical prickling, stinging or burning characterwhichparticularly
occurs directly after exposure to water and lasts for 10–120 min (aver-
age 30–45 min) [250,253].
The pathophysiology of polycythemia vera-associated pruritus re-
mains largely unknown, but several hypothesesmainly based on clinical
observations have beenmade. The sudden onset and limited duration of
itch sensation with characteristic occurrence after (but not during) ex-
posure to water indicates that a sudden decrease in skin temperature
triggers the initiation of pruritus. Cooling down the skin by evaporating
humidity from the skin might cause a release of adenosine diphosphate
from red blood cells and catecholamines from adrenergic vasoconstric-
tor nerves resulting in blood vessel contraction and activation of plate-
lets [57]. Platelets may then release pruritogenic factors such as
prostaglandin E2 (PGE2) and serotonin. Although both substances are
weak pruritogens upon single intradermal application, an intradermally
injected mixture of PGE2 and serotonin caused strong pruritus in
healthy controls [56]. The beneﬁcial effect of pitozifen [254], a serotonin
and weak histamine antagonist, was explained by reducing the
pruritogenic effect of released serotonin from platelets [56]. The selec-
tive serotonin re-uptake inhibitor paroxetine and ﬂuoxetine also
strongly reduced polycythemia vera-associated pruritus [250,255]. As
these drugs mainly act centrally, they might inﬂuence the central itch
signalling pathway rather than acting directly on peripheral nerve end-
ingswhich do not re-uptake 5-HT but express 5-HT receptors. However,
platelets cannot synthesize 5-HT but take it up from enterochromafﬁne
cells during passage through the gut. Degranulation of platelets is
known to be selectively inhibited by the cyclooxygenase inhibitor
acetylsalicylic acid [256], which could explain the beneﬁcial anti-
pruritic effect of this drug in polycythemia vera patients [57,141]. It is
intriguing to speculate whether platelet-derived lysophosphatidic acid
[257], another potential pruritogen (see above), is involved in
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acid may be released from endothelial cells to cause contraction of
smoothmuscle cells thereby restoring vascular tone and it could addition-
ally activate platelets to release further lysophosphatidic acid and other
pruritogens [258,259]. Mast cells may be another potential source of
pruritogens in polycythemia vera patients. Various pruritogenic media-
tors can be secreted bymast cells amongwhich are histamine, tryptase,
interleukins and prostaglandins. Although serum levels of histamine
were raised in polycythemia vera [249,260], which could be explained
by an increased number of basophile granulocytes in those patients
[261], they do not develop urticaria and antihistamines are not or only
partially effective in these patients [141,250,262]. Tryptase levels as a
speciﬁc marker for mast cell degranulation were not found to be in-
creased 1 h after showering [263]; however, a subtle or local release
of mast cell granula may not be detected in peripheral blood. Jackson
et al. found an increased number of skin mast cells in patients suffering
from pruritus compared to those without pruritus and healthy controls
[141]. These mast cells were located throughout the dermis, but con-
centrated in particular around small blood vessels [141]. A more recent
study could histologically show thatmast cells degranulated after expo-
sure to warm water in polycythemia vera patients but not in healthy
controls, although their number was not increased compared to con-
trols [264]. Interestingly, the number of cutaneous mononuclear cells
and eosinophils was highly elevated after water exposure [264]. An
older publication reported about a similar increase in mononuclear
cells in the dermis and epidermis in a female polycythemia vera patient
who underwent biopsies before and after warm water challenge [265].
Mast cells generated from CD34+ mononuclear cells of polycythemia
vera patients released higher amounts of pruritogenic substances such
as histamine, leukotrienes, and interleukin-31 and had an increasedmi-
gratory behaviour compared to mast cells of healthy controls [181].
Noteworthy, a greater number of mast cells could be generated from
polycythemia vera patients suffering from pruritus compared to
patients without pruritus. These mast cells were less prone to apoptosis
and released more pruritogenic cytokines such as IL-31, resulting in
increased IL-31 plasma levels in these patients [181]. Finally, the same
group demonstrated that all mast cells of polycythemia vera patients
had the malignant gene mutation JAK2 617V N F. This could explain
the beneﬁcial anti-pruritic effect of newly developed JAK inhibitors such
as erlotinib [266], ruxolitinib (INCB018424) [267–269] or TG101348
[270]. One could also argue that the anti-pruritic effect of these sub-
stances may be due to their efﬁcient decrease in disease burden. A
strong improvement of pruritus is often reached by an effective treat-
ment of the underlyingdisease – indicated by correction of haematolog-
ical parameters – as shown by various trials using busulphan [141],
hydroxyurea [271], interferon-α or its pegylated form (reviewed in
[272]) or recently by a phase II trial using the histone-deacetylase inhib-
itor givinostat [273]. Besides IL-31, other interleukins have been
suggested to cause pruritus of PV. A recent study could, however, not
ﬁnd any correlation between IL-10, IL-22 or IL-23 and the presence of
pruritus [274].
Phlebotomy is performed to treat polycythemia vera, but might
cause iron deﬁciency anaemia in these patients. As iron deﬁciency is
also associated with pruritus (see also section iron deﬁciency of this re-
view), iron supplementation has been given to polycythemia vera pa-
tients with iron deﬁciency anaemia and relieved pruritus in some of
these patients [275–277]. However, when iron treatment had to be
stopped because of unacceptably high haemoglobin concentrations,
pruritus recurred [277]. Thus, iron supplementation should be restrict-
ed to those iron deﬁciency anaemia patientswith otherwise untreatable
pruritus.
3.2. Essential thrombocytosis
Essential thrombocytosis (ET) is a clonal disorder arising from a plu-
ripotent hematopoietic stem cell characterized by a platelet-weightedtrilineage myeloproliferation [278]. Similar to polycythemia vera the
gain-of-function mutation JAK2V617F, which renders hematopoetic
cells more sensitive to growth factors, has been described in approxi-
mately 30% of patients with essential thrombocytosis [246,279]. In an
international internet-based survey of 1179 patients suffering from dif-
ferent myeloproliferative diseases, pruritus was reported in 40% of es-
sential thrombocytosis patients [252]. Interestingly, in contrast to
polycythemia vera, pruritus was reported in a similar frequency by es-
sential thrombocytosis patients being homozygotic for the JAKV617F
mutation compared to heterzygotic patients [247]. Pruritus in patients
with essential thrombocytosis is described as an aquagenic pruritus
similar to polycythemia vera-associated pruritus indicating that the
pathogenesis of this agonizing sensation may be similar in both disor-
ders (see polycythemia vera). This is further strengthened by the fact
that in ﬁrst clinical trials the JAK1 and JAK2 inhibitor ruxolitinib
(INCB018424) [267–269] also remarkably improved pruritus in essen-
tial thrombocytosis patients suggesting that certain pruritogenic cyto-
kines signalling via the JAK–STAT-pathway might be involved in the
pathogenesis of pruritus.
3.3. Primary myeloﬁbrosis
Primary myeloﬁbrosis (PMF) is characterized by ﬁbrotic changes of
the bone marrow and an extramedullary hematopoesis. It represents
the third large entity of myeloproliferative diseases which is commonly
associated with pruritus. Approximately every second patient with pri-
mary myeloﬁbrosis reported about itching in a large survey of more
than 450 patients [252]. Myeloﬁbrosis might also occur in the spent
phase of polycythemia vera and essential thrombocytosis possibly due
to bone marrow stem cell toxic drugs such as hydroxyurea. Similar to
polycythemia vera and essential thrombocytosis, the valine-to-
phenylalanine change mutation in the JAK2 gene (JAK2V617F) is
found in 50% of primary myeloﬁbrosis patients. Selective JAK inhibitors
erlotinib [266], ruxolitinib (INCB018424) [267–269] or TG101348 [270]
have been reported to consistently improve pruritus and other constitu-
tional symptoms such as fatigue in these patients. Similarly, everolimus,
an inhibitor of the rapamycin target mTOR [280] and the histone-
deacetylase inhibitor givinostat (ITF2357) [273] also signiﬁcantly re-
duced pruritus in PMF patients; however, the underlying mechanism
remains elusive. As itch sensation in all myeloproliferative disorders is
commonly reported as aquagenic pruritus similar underlying pathogen-
ic causes (see polycythemia vera) may be presumed.
3.4. Hypereosinophilic syndrome
The hypereosinophilic syndrome (HES) consists of a very rare and
heterogeneous group of syndromes deﬁned as persistently increased
eosinophil count greater than 1.5 × 109/L for more than six months
without any recognizable cause and eosinophil-associated organ dam-
age [281,282]. Recent advances in the understanding of the underlying
pathogenesis have established that hypereosinophilia may – among
other causes – be due to (i) an increased interleukin-5 synthesis by a
T cell clone (lymphocytic HES), (ii) a chromosomal rearrangement
resulting in fusion of the two genes, FIP1-like 1 (FIP1L1) and platelet de-
rived growth factor alpha (PDGFRA) on chromosome 4q12 in
hematopoetic stem cells, which results in clonal hypereosinophilia or
(iii) a myeloproliferative disorders (m-HES) of which the causes have
not been elucidated yet [281,282]. Besides IL-5 other cytokines such as
IL-3 or granulocyte-macrophage stimulating colony factor (GM-CSF)
have been discussed as causing pruritogenicity. Itch sensation in HES
patients may present as aquagenic pruritus [283], but could also be
caused by pruritic papules and eczema-like nodules [284]. Efﬁcient
treatment of the underlying disease resolves the constitutive symptoms
such as prurituswhich can be achieved by either corticosteroids [285] or
the monoclonal anti-IL-5 antibody mepolizumab [286].
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Themyelodysplastic syndromes comprise a group of diverse haema-
tological conditions characterized by ineffective or dysplastic produc-
tion of blood cells associated with an increased risk for acute
leukaemia [287,288]. Pruritus has occasionally been reported in these
patients and, similar to the myeloproliferative syndromes, has many
features of aquagenic pruritus [289–292]. Psoralen phototherapy has
in casuistics been described to effectively improve pruritus in these pa-
tients; however, the underlying beneﬁcial mechanisms remain unclear
[289,291].
3.6. Mastocytosis
The termmastocytosis refers to a group of rare disorders being char-
acterized by too many mast cells and their CD34+ progenitors [293].
Mastocytosis is subdivided into cutaneous forms which are conﬁned to
the skin and preferentially seen in children and systemic mastocytosis
in which mast cells inﬁltrate extracutaneous organs with or without
skin involvement [294]. Mast cells express a speciﬁc tyrosine kinase re-
ceptor called c-kit (CD117), which is activated by stem cell factor (SCF)
[295]. Mutations in c-kit have been linked to the pathogenesis of
mastocytosis and the most common mutation which is seen in more
than 90% of systemic mastocytosis patients consists of the substitution
of valine for aspartate in codon 816 (D816V) [296,297]. This mutation
causes ligand-independent auto-phosphorylation of c-kit and induces
constitutive activation of the Stat5–PI3K–Akt signalling cascade [298].
Pruritus is one of themost common symptoms reported bymastocytosis
patients and arises from the release of various mediators by mast cells
[299,300]. Itch sensation can be triggered in those patients by a variety
of stimuli amongwhich are physical factors such asmechanical and ther-
mal stimuli including pressure or massage of the skin, extremes in tem-
perature or sudden changes in temperature, exercise, emotional stress,
infections, surgery or certain medications [299–302]. Histamine might
play an essential role in the pathogenesis of pruritus in mastocytosis as
H1-histamine receptor blockers [303] and themast cell stabilizer sodium
chromoglycate [304] have been effective in treating pruritus. However,
one report questioned the role of histamine as main pruritogenic agent
as blocking histamine synthesis in twomastocytosis patients did not im-
prove pruritus [305]. Treatment with the irreversible histidine-
decarboxylase inhibitor α-ﬂuoromethylhistidine resulted in decreased
levels of plasma histamine and urinary metabolites but solely diarrhoea
improved and seemed thus to be the only histamine-related symptom
[305]. Those patients who are unresponsive to histamine receptor
blockers may be treated by anti-leukotriene agents such as montelukast
to improve pruritus [306].
3.7. Hodgkin's lymphoma
Hodgkin's lymphoma, also known as Hodgkin's disease, is a malig-
nancy of lymphocytes characterized by multi-nucleated CD30+/
CD15+ Reed-Sternberg and Hodgkin cells [307]. The prevalence of pru-
ritus in Hodgkin's disease has been reported in 15–30% of patients
[308–310]. Pruritus tends to be located in the area drained by the lym-
phatic vessels of affected lymph nodes, butmay also be generalized par-
ticularly in patients with the nodular sclerosis type of Hodgkin's disease
[311]. It may present with ichthyosiform skin changes on the extremi-
ties or as eczema lesion, but is often only associated with secondary
skin lesions due to intense scratching [312].
The followingmechanisms have been suggested in the pathogenesis
of pruritus in Hodgkin lymphoma: (i) release of bradykinin and cyto-
kines as immune response to the malignant lymphoid cells [311,313],
(ii) histamine release from eosinophils observed in the pleotropic inﬁl-
trates of Hodgkin lymphomas [311,313], and (iii) high serum levels of
IgE with speciﬁc cutaneous IgE deposits seen in 10–20% of patients
with lymphoma [311,313]. Furthermore, it is intriguing to speculateon the role of autotaxin in relation to pruritus and tumour progression
in patients with Hodgkin's disease. Recently, Epstein–Barr virus-
infected Hodgkin lymphoma cells have been shown to highly express
the lysophospholipase D, ATX. This enzyme is responsible for the forma-
tion of LPA, which has been shown to induce pruritus in a dose-
dependent manner in mice [223,224]. These cells might thus release
high levels of ATX, leading to high local concentrations of LPA that
may not only promote tumour growth [314] but also activate the
pruritoceptive C ﬁbres (see below). The role of these factors in patho-
genesis of itch and tumour progression in lymphoma patients warrants
further investigations.
Speciﬁc therapeutic options for pruritus in Hodgkin lymphoma pa-
tients are lacking, but effective tumour treatment is regularly associated
with attenuation or relief of itching. Corticosteroids are commonly re-
ported in textbooks to be effective in these patients; however, studies
supporting this observation are lacking. As this drug class is part of the
regular treatment regimen it is unclear whether its effectiveness is
due to tumour eradication or a real anti-pruritic effect. Interestingly,
H2-antihistamines such as cimetidine were reported as effective symp-
tomatic anti-pruritic drugs [315].
3.8. Other haematological malignancies
The prevalence of chronic pruritus in other haematological diseases
has never been studied in detail and numbers are based on small studies
and case series. It is estimated that up to 10% of patients with non-
Hodgkin's lymphoma and up to 5% of leukemic patients suffer from
itching [316]. Pruritus is more frequently observed in lymphocytic
than in myeloid leukaemia and more common in chronic than in
acute disease [313]. Severe itching is common in CD4+ mycosis
fungoides and its leukemic form, the Sézary's syndrome, which are
non-Hodgkin T-cell lymphoma with primary manifestation in the skin.
These tumours are characterized by a constitutive STAT3 expres-
sion [317], a key transcription factor for the Th2 cytokine production,
resulting in increased levels of Th2 cytokines such as IL-4, IL-5, and IL-
10 [318,319]. Beside these cytokines, pruritus in patients with the
Sézary syndrome may be caused by increased levels of substance P as
aprepitant, a selective neurokinin-1-receptor antagonist, largely dimin-
ished itch severity in three patients [93].
3.9. Iron deﬁciency
The association of iron deﬁciencywith generalized pruritus is known
for decades [320], which is often believed to be a rare phenomenon.
However, a prospective French study revealed that 5% of patients with
generalized pruritus in the absence of a dermatological disorder suf-
fered from iron deﬁciency [321]. A large Finish cohort of several ten
thousand adults revealed that 13.6% of men and 7.4% of women with
anaemia due to iron deﬁciency experienced pruritus [322]. As iron deﬁ-
ciency can be associated with a malignant disorder [323], itching may
represent a paraneoplastic symptom [312]. However, restoring serum
iron and ferritin to normal levels by oral iron supplementation normally
resolves pruritus in anaemic patients within days to weeks. In male pa-
tientswith generalized pruritus and low serum iron levels, screening for
myeloproliferative disorders is indicated.
4. Metabolic and endocrine disorders
4.1. Hepatobiliary disorders
Pruritus is a frequently observed symptom accompanying many
hepatobiliary disorders, particularly those with cholestatic features
[324–326]. This form of itching is designated cholestatic pruritus, as
bile secretion and/or ﬂow is impaired in these disorders [327]. In
these disorders, cholestasis may be caused by a pure hepatocellular se-
cretory failure as seen in intrahepatic cholestasis of pregnancy (ICP),
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intrahepatic cholestasis, toxin- or drug-induced cholestasis, and chronic
viral hepatitis B and C infections. Intrahepatic bile duct damage and sec-
ondary hepatocyte secretory failure are causing cholestasis in primary
biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and paedi-
atric cholestatic syndromes such as the Alagille syndrome. Finally, cho-
lestasis due to obstruction of the intrahepatic or extrahepatic bile duct
system is observed in cholestasis caused by gallstones, PSC,
cholangiocellular carcinoma, obstructive tumours of the pancreatic
head or enlarged lymph nodes located in the hilar region, bile duct ad-
enomas, or biliary atresia [328]. Interestingly, the prevalence of pruritus
varies considerably between these hepatobiliary disorders. Pruritus is
the deﬁning symptom of women suffering from ICP [329] and is experi-
enced by up to 80% of patients with PBC and PSC at any time during the
course of their disease [330–333]. In contrast, pruritus is less frequently
reported by patients with obstructive cholestasis [334], chronic hepati-
tis C infections [335–337], and rarely associatedwith chronic hepatitis B
patients, non-alcoholic fatty liver disease, alcoholic or non-alcoholic
steatohepatitis even when cholestasis is present [338].
Pruritus of cholestasis is characterized by a circadian rhythm with
patients reporting the highest intensity in the evening and early at
night [328], a predilection site at the limbs and in particular at the
palms and soles [332,339], and the phenomenon that scratching barely
alleviates itch sensations. Furthermore, female cholestatic patients com-
monly report pruritus worsening during the progesterone phase of the
menstrual cycle, in late pregnancy, and during hormone replacement
therapy [328,340]. In multivariate analysis, serum alkaline phosphatase
and theMayo risk scorewere found to be independent indicators for the
occurrence of pruritus in 335 PBC patients [341]. The Mayo risk score is
derived from an equation containing clinical variables including patient
age, serum total bilirubin, albumin, prothrombin time, and the
presence/absence of edema or ascites. Various substances among
which are histamine, bile salts, endogenous opioids and progesterone
metabolites have been proposed, albeit with limited evidence, as
pruritogens in the past. Recently, we could identify the potent neuronal
activator lysophosphatidic acid as potential pruritogen in cholestasis
[224]. Still the molecular mechanisms of cholestatic pruritus remain to
be unravelled. The current understanding of the potential pruritogen(s)
is mirrored by the effects of therapeutic approaches aiming i) to remove
the pruritogen(s) from the enterohepatic cycle by non-absorbable,
anion exchange resins such as cholestyramine, colestipol, and
colesevelam in mild pruritus or interventions such as external biliary
diversion, nasobiliary and transcutaneous drainage in desperate cases;
ii) to remove the potential pruritogen(s) from the systemic circulation
by invasive procedures such as anion absorption, plasmapheresis or
extracorporeal albumin dialysis; iii) to alter the metabolism of the
presumed pruritogen(s) in the liver and/or the gut by biotransforma-
tion enzyme inducers such as rifampicin or iv) to modify central
itch and/or pain signalling by inﬂuencing the endogenous opioidergic
and serotoninergic system via μ-opioid-antagonists and selective
serotonin re-uptake inhibitors, respectively [324,342]. The presence
of direct or indirect pruritogens in the enterohepatic circulation is
highlighted by the dramatic effects of interruption of this circulation
either by nasobiliary drainage, which usually relieves itch within 24 h
[343,344].
4.1.1. Potential factors involved in cholestatic pruritus
4.1.1.1. Histamine. Elevated levels of histamine have been found in plas-
ma of patients with chronic cholestatic liver disorders [37] and in chole-
static animal models [345]. Hydrophobic bile salts, in particular
deoxycholate, chenodeoxycholate, and their conjugates, are capable to
release histamine from mast cells, albeit at concentrations that are
much higher than those generally observed in cholestatic patients
[346,347]. Cholestatic patients do not present with typical histamine-
induced skin alterations such as erythema, urticaria and ﬂares andantihistamines are commonly ineffective in this form of pruritus [348].
Furthermore, we could show that tryptase levels which represent a spe-
ciﬁc marker for activation of mast cells, were similar in cholestatic pa-
tients with and without pruritus [224]. Thus, histamine is unlikely to
represent a direct pruritogen in cholestatic pruritus.
4.1.1.2. Bile salts. For decades bile salts have been held responsible for
cholestatic itch [338,348–350] as bile salts accumulate during cholesta-
sis, caused pruritus in healthy volunteers upon intradermal injection
[351,352], and aggravated pruritus of cholestatic patients after oral
supplementation [353,354]. This hypothesis was strengthened by the
observation that binding of bile salts inside the intestinal lumen by
anion exchange resins such as cholestyramine and colestipol ameliorat-
ed pruritus [355–358] and removal of bile from the body by ileal exclu-
sion surgery [359,360], transcutaneous [361–365] and nasobiliary
drainage [343,344,366] rapidly alleviated long-lasting intractable pruri-
tus. A recent study suggested that cholestatic pruritus is mediated by
the bile salt GPCR TGR5 which was detected in peptidergic neurons of
mouse dorsal root ganglia [367]. Indeed, intradermal injection of high
concentrations of the bile salts deoxycholate and lithocholate induced
scratching behaviour which was attenuated in TGR5−/− mice [367].
However, the applied concentrations of these hydrophobic bile salts
were far beyond the pathophysiological levels observed during chole-
stasis. Other, agonists of TGR5 such as neurosteroids might, however,
be capable of activating this receptor leading to itch sensation. This re-
mains to be investigated.
Several studies could not prove any correlation between severity of
pruritus and concentrations of any naturally occurring bile salt in the
circulation, urine or skin [224,338,368–370]. Furthermore, frequency
and intensity of cholestatic itch does not correlate with the severity of
cholestasis [371]. This is underlined by the fact that pruritus may be
the initial presenting symptom in early stages of PBC patients when
bile salts are low, but is often lost in terminal liver failure when bile
salts reach their highest concentrations [328]. Patients with obstructive
cholestasis may have highly increased bile salt levels but never experi-
ence itching [372]. In contrast, women with ICP have marginally in-
creased serum bile salts but do by deﬁnition suffer from pruritus
[329]. Itching can ameliorate spontaneously ormay even vanish despite
ongoing cholestasis and unaltered raised levels of bile salts [371,372].
Cholestyramine improved pruritus not only in cholestasis but also in
polycythemia rubra vera, a haematological disorder which is not associ-
ated with elevated bile salts [373]. Colesevelam efﬁciently decreased
serum bile salt concentrations by approximately 50% in a randomized,
multicenter study but improvement of pruritus was similar to that of
placebo [374]. The enzyme inducers phenobarbital and rifampicin effec-
tively improved pruritus without changing the levels of serum bile salts
[375,376]. Anecdotal treatments included androgens such as
methandrostenolone which relieved pruritus but worsened cholestasis
and raised serum bile salts [377,378]. Finally, bile salt concentrations
did not correlate with itch intensity in PBC patients undergoing
nasobiliary drainage [344]. In summary, bile salts and their metabolites
play at best an indirect role in the pathogenesis of pruritus of
cholestasis.
4.1.1.3. Steroids. Female steroid hormones and their metabolites have
been implied in the pathogenesis of cholestatic pruritus [328] based
on several observations. Intradermal application of pruritogens caused
stronger scratching behaviour in female compared to male mice [379].
Similarly, female cholestatic patients reported pruritus to be more in-
tense and more frequent compared to men [380]. During pregnancy
concentrations of steroids and steroid metabolites continuously rise
[381] reaching the highest levels during the last trimenon when
intrahepatic cholestasis of pregnancy typically occurs [329,382,383].
One study found a slight correlation between reduction of urinary levels
of disulphated progesterone metabolites and improvement of pruritus
in ICP patients treated with ursodeoxycholic acid, whereas neither bile
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tion [382,384]. In addition, Abu Hayyeh et al. [385] recently reported a
signiﬁcant increase in the serum epiallopregnanolone sulphate concen-
tration in ICP women as compared to normal pregnant women. As ste-
roid hormones and their metabolites are capable of inﬂuencing many
ionotropic receptors such as transient receptor potential vanilloid 1
(TRPV1) [386], GABA-A [387], glycine [388], glutamate [389–392], and
serotonin receptors [393], they might modulate neuronal excitability
and thereby inﬂuence pruritoception and/or nociception in cholestatic
patients.
4.1.1.4. Endogenous opioids. Since the report of Bernstein and Swift that
the pruritus of cholestasis in awomanwith PBC disappeared after an in-
travenous infusion of the μ-opioid antagonist naloxone [394], endoge-
nous opioids such as Met- and Leu-enkephalins have been discussed
as pruritogens in cholestasis [395]. The central administration of opiate
agonist drugs can induce itching in human beings [21] and scratching
activity in animals [396]. Levels of endogenous opioids were raised in
bile duct resected rats [397,398] as well as in plasma of cholestatic
PBC patients [399,400]. Furthermore, spinally administered plasma
extracts from pruritic cholestatic patients induced facial scratching
behaviour inmonkeys, whichwas abolished by co-administering nalox-
one [401]. The liver may be the source of increased opioid levels during
cholestasis as mRNA expression of preproenkephalin was increased in
liver of bile duct-resected rats [402] andMet-enkephalin immunohisto-
chemical staining was raised in the periportal areas and proliferating
bile ductules of cholestatic rat livers [403]. The importance of the altered
endogenous opioid system in pruritus of cholestatic patients is
underlined by themoderate anti-pruritic effect of μ-opioid receptor an-
tagonists such as naloxone, naltrexone, and nalmefene [399,404–411].
Nonetheless, several facts argue against a direct role of endogenous
opioids as pruritogens in cholestasis. A correlation between itch intensi-
ty and endogenous opioid concentrations has never been shown [400].
Similar opioid levels were measured in PBC patients with and without
pruritus [224] showing a relation with the stage of disease in PBC pa-
tients rather than with the presence of pruritus [400]. In PBC patients
Met-enkephalin concentrations were signiﬁcantly raised in histological
stages 3 and 4, whereas pruritus is commonly reported in early stages of
this disease and rather improves in end-stage liver disease [328,400].
Women with ICP who by deﬁnition suffer from pruritus, had a similar
μ-opioid activity compared to gestation-matched pregnant controls
[224]. The antinociceptive and pruritocepitve effect seen in cholestasis
was explained by an increased central opioidergic tone [412]. However,
a recent study proved that the antinociceptive effect of endogenous opi-
oids in a cholestaticmousemodelwas caused by local effects at the level
of peripheral sensory nerve endings, but not a centralmechanism [413].
There is evidence to suggest that endogenous opioids may partly con-
tribute to pruritus in cholestasis, but are not likely to represent the caus-
ative pruritogens.
4.1.1.5. Autotaxin and lysophosphatidic acid. Screening serum of
cholestatic patients with pruritus for changes in cytosolic free calcium
concentrations in neuronal cell lines we could recently identify
lysophosphatidic acid (LPA), a potent neuronal activator, as potential
pruritogen [224]. Concentrations of LPA were raised in patients suffer-
ing from cholestatic pruritus. Extracellular LPA is synthesized by hydro-
lysis of the choline-group of lysophosphorylcholine through the
lysophospholipase autotaxin (ATX) [414]. Intriguingly, LPA and
autotaxin levels were only increased in cholestatic patients suffering
frompruritus irrespective of the underlyingdisorder [224,415]. Further-
more, in contrast to all other substances discussed as potential
pruritogens in the past, ATX activity signiﬁcantly correlated with the
itch intensity [416]. Furthermore, ATX levels correlated with treatment
efﬁcacy of various medicamentous and invasive therapies such as
colesevelam, rifampicin, MARS therapy and nasobiliary drainage. Strik-
ingly, ATX activity also returned to increased levels when pruritus hadreturned in patients undergoing MARS therapy or nasobiliary drainage
[224,415]. These data strongly support that autotaxin and its product,
LPA, play a key role in the pathogenesis of pruritus of cholestasis.
4.2. Chronic renal disorders
Chronic kidney disease (CKD) carries substantial morbidity and mor-
tality and can contribute to the dysfunction of many organ systems. The
cutaneous manifestations of renal failure and dialysis are wide-ranging
but most commonly include dyspigmentation, pruritus, ecchymosis, per-
forating dermatosis, xerosis, acne, bullous disorders, calciphylaxis, pallor,
and hair and nail abnormalities [417–419]. Pruritus often occurs in pa-
tients with chronic kidney disease (15–49%) and is present in a majority
(50–90%) of patients with end-stage renal disease on dialysis [417,420].
The prevalence of uraemic pruritus in patients receiving peritoneal dialy-
sis versus haemodialysis is comparable [421]. It occurs independent of
age, sex, race, aetiology of renal failure and has been described to occur
at all times throughout the day, worsening at night, and affecting large
non-dermatomal based and symmetric skin areas [422,423]. Uraemic
pruritus can be severely debilitating, negatively impacting sleep quality,
overall quality of life, and mortality [420,421,424–427], but nonetheless
is often under-recognized throughout the nephrology community [428].
The pathogenesis of uraemic pruritus remains largely unknown.
Many hypotheses have been generated in attempt to explain this poorly
understood but highly present and persistent symptom. Some of these
include metabolic by-product accumulation, immune system dysfunc-
tion, endogenous opioidergic system dysregulation, cutaneous barrier
dysfunction, alterations in afferent nerve function, increased number
of dermalmast cells and their products, increased formation of insoluble
calcium phosphate, hyperparathyroidism, and hypervitaminosis A
[39,425,429–437].
Blood levels of urea nitrogen and creatinine has been utilized as
markers for accumulation of yet unidentiﬁed metabolic products. Re-
cently, there have been signiﬁcant advances in haemodialysis technolo-
gy and membrane ﬁltration has become more sophisticated; it is now
possible toﬁlter awider range ofmoleculeswith lagermolecularweight
such as β2-microglobulin and others that are implicated in contributing
to uraemic pruritus [425,438–440]. Data comparing the effects of these
newer synthetic ﬁltration methods on pruritus reduction have been
mixed. However, a recent randomized, prospective, double-blind
study was performed to compare the efﬁcacy of high permeability
haemodialysis against conventional haemodialysis on uraemic pruritus.
A decrease in parathyroid hormone and β2-microglobulin and pruritus
was demonstrated [439]. To that end, another study showed a modest
reduction in pruritus in patients who underwent haemodialysis daily
versus three times weekly (34% vs. 13%) [420].
A complex interplay between the immune system and the nervous
system is increasingly recognized in the pathophysiology of inﬂamma-
tion. An imbalance of the highly regulated interactions of the skin, im-
mune, and nervous systems in the skin contribute to inﬂammation
and itch sensation. Chronic renal failure is thought to initiate and
maintain a state of chronic low-grade inﬂammation that contributes
to pruritus. Tachykinins such as substance P can activate transcription
factors producing proinﬂammatory cytokines (e.g. IL-2) and when
injected intradermally, substance P causes pruritus [158]. There have
been several studies investigating non-speciﬁc markers of inﬂammation
in patients onhaemodialysis. In pruritic patients requiring haemodialysis
(approximately one-third of patients in the study), elevated c-reactive
protein (CRP) levels were found as compared to those on haemodialysis
without pruritus [420]. The authors also noted that other inﬂammatory
markers including α1-acid-glycoprotein, β2-microglobulin, ferritin, and
albumin were equivalent in both groups. In another study, patients on
chronic haemodialysis with moderate or severe pruritus as measured
using a visual analogue scale (VAS) also had elevated CRP levels with
equivalent levels for TNF-α. These patients had a higher all-cause mor-
tality rate than those without pruritus, further supporting a role for
882 A.E. Kremer et al. / Biochimica et Biophysica Acta 1842 (2014) 869–892chronic inﬂammation bridging uraemic pruritus and poor outcome
[441]. Serum CRP and IL-6 levels were elevated in plasma of patients
with uraemic pruritus compared to patients without pruritus [168],
although an older study found no differences between these cytokines
[442]. Many immunosuppressive therapies including ultraviolet light,
γ-linolenic acid, thalidomide, and tacrolimus improve pruritus thus pro-
viding complementary support for inﬂammation in the genesis of
uraemic pruritus [168,426,443,444]. Interestingly, patients with glomer-
ulopathies have a statistically signiﬁcant lower prevalence of pruritus
compared to patientswith renal failure due to other etiologies. Those pa-
tients are often treated with immunosuppressive therapies which may
serve to globally suppress the low-grade inﬂammation associated with
classical renal failure and the development of pruritus. Finally, post-
renal transplant patients rarely experience pruritus during the period
in which they are taking systemic immunosuppressive medications,
even with recurrent renal failure [420,426].
The dermis of patients with chronic kidney disease maintains an
increased number of mast cells and this has been thought to contrib-
ute to the prevalence of pruritus in CKD [434]. Mast cells are known
to release many (putative) pruritogens including histamine, cyto-
kines (e.g. TNF-α and IL-2), and proteases (e.g. tryptase and
chymase). Although many studies have attempted to demonstrate
a correlation between serum histamine levels and uraemic pruritus,
no consistent relationship has been observed [38,445]. In addition,
oral antihistamines are not effective in treating uraemic pruritus. In
parallel, there is a clear elevation of serum tryptase levels in patients
on haemodialysis as compared to the general population [429,446].
In one study, the mast cell stabilizer cromalyn sodium was used to
treat uraemic pruritus over an 8-week period; the treatment group
experienced a signiﬁcant decrease in mean pruritus as measured
on a VAS [429]. Notably, with treatment and symptomatic improve-
ment there was only a slight decrease in serum tryptase values.
These observations leave the possibility that other mast cell media-
tors besides histamine or tryptase contribute to pruritus or that the
local dermal concentrations of these molecules and not the serum
levels are determining stimulation of small afferent C-ﬁbre neurons
involved in itch sensation.
Xerosis is a common dermatologic condition and its incidence is
increased in patients with renal failure. Xerosis is even more in-
creased (up to 85% of patients) in those receiving haemodialysis
[447]. It is not often seen in acute renal failure and does not correlate
with plasma urea levels; however, it often resolves after renal trans-
plantation. A distinct causal relationship between uraemic xerosis
and uraemic pruritus has been suggested in the literature, but is
not undisputed [447–450]. Clinical observations showed that many
patients with marked xerosis do not suffer from itch. Still, pruritus
is often reported to be improved by moisturizing and rehydrating
the skin [447]. The skin of patients with uraemic xerosis displays
low hydration of the stratum corneum and atrophy of the sebaceous
and secretory sweat glands with decreased sweating, but normal
barrier function [447,450–452]. Based upon this and other histo-
pathologic differences, uraemic xerosis is an independent feature
of dialysis patients and can be distinguished from other causes of
dry skin. Lipid imbalance has been postulated to contribute to the
xerosis of renal failure. Finally, stratum corneum pH was shown to
be elevated in haemodialysis patients [449]. These skin alterations
may contribute to the intensity chronic kidney disease associated
pruritus, however, do not represent the cause of induction of itch
sensation.
Special attention has been focused on neuropathic changes, nerve
proliferations of the pruritus-mediating cells, and central nervous al-
terations [427]. In patients with chronic kidney disease a correlation
between paraesthesia and presence of uraemic pruritus has been de-
scribed [453]. Accumulation of uraemic toxins may result in damage
of sensory nerve ﬁbres resulting in uraemic neuropathy and central
sensitization to itch [454]. Histamine iontophoresis in patientsundergoing haemodialysis caused smaller ﬂare reactions but in-
creased itch sensation compared to healthy volunteers conﬁrming
an altered neurophysiological response [455]. Furthermore, the anti-
convulsant gabapentin, which is widely used as pain-modulating
drug in patients with neuropathic pain, has been shown to exert
strong anti-pruritic effect in chronic kidney disease-associated pru-
ritus [456–458]. Similar beneﬁcial results have recently been report-
ed for pregabalin [459]. Thus, neuropathic changes seem at least in
part be responsible for the agonizing pruritus in chronic kidney
disease.
Iron deﬁciency, iron deﬁciency anaemia, and anaemia of chronic
disease have also been hypothesized to contribute to pruritus of
renal failure. In states of iron deﬁciency, there is an up-regulation
of interleukin-6 and induction of hepcidin and thus can be regarded
as a state of chronic inﬂammation [460]. It has been proposed that
zinc deﬁciency may contribute to uraemic pruritus via activation of
the histamine pathway, but a recent case–control study did not
ﬁnd any correlation between zinc levels, parathyroid hormone levels
and pruritus [461].
Hyperparathyroidism has also been implicated in contributing to
uraemic pruritus, although there have not been many reliable stud-
ies showing a positive association. In fact, recent data suggest that
there is no correlation between parathyroid hormone levels and in-
tensity of pruritus in uraemia [417,462]. Nonetheless, in two small
independent studies almost 35 years apart, parathyroidectomy has
been curative for the symptoms of itch in most cases. The symptom-
atic relief occurred within 1–4 weeks post-operatively, and correlat-
ed with normalization of the parathyroid hormone levels [437,463].
Chronic renal failure is often accompanied by hyperphosphataemia,
hypocalcaemia, and decreased calcitrol thus causing secondary hy-
perparathyroidism. In addition, only when the calcium-phosphorus
product is exceedingly high there is an increase in uraemic pruritus
[464]. The consequences of this are largely unknown, with the dis-
tinct possibility of an increased calcium-phosphorus product leading
to increased dermal calcium deposition [465], which may cause
modulation of neuronal signalling in C ﬁbres.
Opioid peptides have long been implicated as mediators of pruritus
in chronic kidney disease [466,467]. Pruritus caused by cutaneous injec-
tion of compounds including histamine, substance P, serotonin, and ace-
tylcholine has been shown to be suppressed by naloxone and
naltrexone [466,468,469]. However, no correlation could ever be
established between opioid levels and severity of pruritus or serum
levels of β-endorphins before and after dialysis [470]. Still, clinical stud-
ies have shown that suppression of the activity of opioid responsive
neurons by μ-opioid receptor antagonists results in attenuation of
itch sensation in cholestasis, uraemia, and generalized pruritus
[466,471,472]. A placebo-controlled, double-blind crossover study of
uraemic patients with persistent, treatment-resistant pruritus naltrex-
one did, however, not improve itching [473]. Recently, an imbalance be-
tween μ- and κ-opioid tone has been hypothesized to contribute to
uraemia associated and generalized pruritus. κ-opioid agonists alone
have demonstrated an inhibition of substance P and histamine induced
scratching in mice, and to reduce pruritus associated with uraemia in
humans, albeit to a mild extent [198,199]. Modulation of the endoge-
nous opioidergic tone in the nervous system may be caused by
substances accumulating during chronic kidney disease; however,
these substances seem not to represent the causal pruritogens of
uraemic pruritus.
The pathogenesis of uraemic pruritus remains obscure [453]. Var-
ious substances have been discussed as potential pruritogens in
chronic renal diseases; however, a causal relation could never be
established. Over the past few decades, numerous treatment ap-
proaches have been employed in an attempt to alleviate renal pruri-
tus. Like other sub-classes of pruritus, there is no magic bullet that
can be used to treat this problem and a treatment ladder is often ap-
plied [474].
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4.3.1. Diabetes mellitus
Two independent large cohorts of several hundred diabetic patients
indicated that only up to 3% suffered from generalized pruritus
[475,476]. Increased glucose levels cause non-enzymatic glycation of
various structures in the body among which are neurons. Neuropathy
is commonly observed in diabetic patients mainly as distal symmetric
polyneuropathy associated with abnormal, nociceptive, burning or
prickling sensations and less often with pruritus. In a diabetic rat
model it was recently shown that dorsal root ganglia had a reduced ex-
pression of cannabinoid (CB) 1-receptors [477]. Diabetic neuropathy
might therefore be explained by the loss of the neuroprotective effect
of cannabinoids.
4.4. Thyroid disorders
Pruritus has been reported in up to 11% of patients with
hyperthyreosis and in particular of those with thyrotoxicosis due to
long-lasting, untreated Graves' disease [478,479]. The pathophysiologi-
cal mechanisms leading to itch sensation in hyperthyreosis are unclear.
It was suggested that excessive amounts of thyroid hormones may acti-
vate kinins due to increased tissue metabolism or that the threshold of
itch sensation could be lowered due to warmth and vasodilatation
[313]. Pruritus may also be triggered by chronic urticaria which are
caused by the underlying thyroid immunity. Notably, up to 12% of
patients with chronic urticaria suffered from autoimmune thyroid
disorder [480]. It is likely that pruritus is caused by xerosis cutis as
most patients respond to emollients [316]. Pruritus in dry skin may be
caused by a complex cross-talk between dysregulated keratinocytes,
pruritogenic cytokines such as thymic stromal lymphopoietin (TSLP)
or TNF-α and epidermal sensory nerve endings [481,482].
4.5. Parathyroid disorders
Pruritus can be a symptom of primary hyperparathyroidism; how-
ever, pruritus has mainly been studied in the context of secondary hy-
perparathyroidism in uraemic patients (see also renal disorders).
Secondary hyperparathyroidism is induced in these patients by reduced
calcium levels due to (i) diminished renal conversion of vitamin D into
its active form and (ii) increased circulating levels of phosphate leading
to the formation of insoluble calcium phosphate in the body. Subtotal
parathyroidectomy in uraemic patients was associated with partial or
complete relief of pruritus [483,484]. In addition, increased levels of
parathyroid hormone (PTH) were found in uraemic patients with
pruritus compared to those without [485]. However, PTH seems not to
be the causative pruritogen as (i) immunohistochemical investigations
of skin biopsies from uraemic patients against PTH were negative,
(ii) pruritus was not seen in all patients with secondary hyperparathy-
roidism, (iii) increased PTH levels were not always associated with
pruritus, and (iv) levels of PTH did not correlate with itch severity
[462,485,486]. Thus, clear evidence for PTH as a direct role in the path-
ogenesis of pruritus in hyperparathyroidism and uraemia is lacking.
5. Solid tumours
Patientswith solid tumours rarely report of generalized pruritus and
the incidence seems to be less than 1% [487]. Generalized pruritus has
been reported in case reports, case series and larger studies in pa-
tients with thyroid carcinoma [488], laryngeal cancer [489,490], me-
tastasized squamous cell carcinoma of the tongue [491], lung cancer
[321,488,492–494], (metastasized) breast cancer [493,494], stomach
cancer [490,494], pancreas cancer [495], metastatic colon cancer
[493], sarcoma [496], uterine cancer [493], prostate [497] and renal
cancer [494]. Pruritus may precede the diagnosis of malignancy up
to several years [490,494]. One study investigating 125 patientswith generalized pruritus were followed over a time period of six
years. Malignancy was diagnosed in eight patients, among most
were lymphoma [494]. Also in several other studies lymphoma ap-
peared to be higher represented as a cause for pruritus compared
to solid tumours [321,488,495,497].
In general, pruritus rapidly resolves if the tumour is removed after
surgery or successfully treated by chemo- and/or radiotherapy
[313,492,498]. If pruritus reappears this may be a sign of tumour recur-
rence and formation of metastasis [492,498]. The pathogenesis of
pruritus in solid tumours is unknown but may be due to (i) localized
invasion of the malignancy associated with compression of sensory
nerve ﬁbres, (ii) substances or metabolites released from necrotic
tumour cells, (iii) immune reaction against cutaneous micrometastasis,
(iv) obstruction of the bile duct system causing cholestasis, (v) xerosis
cutis, and (vi) neuropathic itch as an adverse effect of anti-tumour
therapy [313,316,499].
6. Infectious diseases
6.1. Human immunodeﬁciency virus
Themajority of patients infectedwith the human immunodeﬁciency
virus (HIV)will suffer frompruritus during their course of disease [500].
Pruritus may be caused by typical HIV-associated skin disorders such
as, papulosquamous disorders, skin infections including scabies,
photodermatitis, xerosis, drug reactions, and lymphoproliferative disor-
ders [501]. However, itching is also seen in the absence of any HIV-
associated skin disorder and may be the presenting symptom of this
infection [500,502]. Furthermore, itch severity might intensify as the
disease progresses. Notably, with the advance of the disease a switch
from TH1- to TH2-cytokines with increased levels of IL-4, IL-5 and IL-
10 was observed [143]. Interestingly, HIV-patients with pruritus had
higher serum level cytokines such as TNF-α and IL-10 [503]. The under-
lying mechanisms of generalized pruritus in patients with HIV-
infections remain unknown, but may be related to (i) increased serum
levels of pruritogenic cytokines [503], (ii) cytokine-induced synthesis
of PGE2 [143], (iii) hypereosinophilia and hyperimmunogloulinaemia
E observed in patients with intractable pruritus, and (iv) neuropathy
due to disease mechanism and the neurotoxic anti-retroviral therapy
[504].
6.2. Varicella zoster virus
Reactivation of the varicella zoster virus (shingles) is known as her-
pes zoster. The best known complication of herpes zoster is postherpetic
neuralgia in the affected dermatoma; however, many patients also suf-
fer from localized postherpetic pruritus [505,506]. Postherpetic pruritus
is presumably caused by unprovoked ﬁring of the peripheral and/or
central neurons that mediate itch sensation. It has been reported that
postheraptic itch occurring in neurons innervating skin left severely
deafferented from shingles, so-called numbs; patients can give them-
selves painless injuries from chronic scratching [506,507].
7. Conclusions
Pruritus research has largely emerged over the past few years and
important advances in the understanding of the peripheral receptors,
intracellular signalling pathways, cells, circuitries and central transmit-
ters have beenmade. Many receptors on sensory neurons are capable of
mediating exogenous and endogenous chemical itch signals among
which are MrgA3, MrgC11, MrgD and likely other Mrg subtypes, H1,
H4, 5-HT2, PAR4, ET-A and B1/B2. TheseGPCRs appear to relay to down-
stream effector channels such as TRPV1 and TRPA1 which are required
for translation into action potentials in these neurons. On spinal cord
level transmitters of the itch pathways include glutamate, Nppb, GRP
and neuromedin B. The discovery of these novel therapeutic targets
884 A.E. Kremer et al. / Biochimica et Biophysica Acta 1842 (2014) 869–892has opened new avenues for development of causative treatment strat-
egies for this agonizing symptom. The relevance of these receptors and
signalling molecules in chronic pruritus of systemic diseases, however,
still remains to be elucidated.
Conﬂict of interest
None of the authors has any conﬂicts of interest to disclose.
References
[1] M. Schmelz, R. Schmidt, A. Bickel, H.O. Handwerker, H.E. Torebjork, Speciﬁc
C-receptors for itch in human skin, J. Neurosci. 17 (1997) 8003–8008.
[2] A. Ikoma, M. Steinhoff, S. Stander, G. Yosipovitch, M. Schmelz, The neurobiology of
itch, Nat. Rev. Neurosci. 7 (2006) 535–547.
[3] A. Reich, S. Stander, J.C. Szepietowski, Drug-induced pruritus: a review, Acta Derm.
Venereol. 89 (2009) 236–244.
[4] Q. Liu, Z. Tang, L. Surdenikova, S. Kim, K.N. Patel, A. Kim, F. Ru, Y. Guan, H.J.Weng, Y.
Geng, B.J. Undem, M. Kollarik, Z.F. Chen, D.J. Anderson, X. Dong, Sensory neuron-
speciﬁc GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus,
Cell 139 (2009) 1353–1365.
[5] Q. Liu, P. Sikand, C. Ma, Z. Tang, L. Han, Z. Li, S. Sun, R.H. LaMotte, X. Dong, Mecha-
nisms of itch evoked by beta-alanine, J. Neurosci. Off. J. Soc. Neurosci. 32 (2012)
14532–14537.
[6] X.Y. Liu, Z.C. Liu, Y.G. Sun, M. Ross, S. Kim, F.F. Tsai, Q.F. Li, J. Jeffry, J.Y. Kim, H.H. Loh,
Z.F. Chen, Unidirectional cross-activation of GRPR by MOR1D uncouples itch and
analgesia induced by opioids, Cell 147 (2011) 447–458.
[7] D.S. McQueen, M.A. Noble, S.M. Bond, Endothelin-1 activates ETA receptors to
cause reﬂex scratching in BALB/c mice, Br. J. Pharmacol. 151 (2007) 278–284.
[8] T. Zheng, M.H. Oh, S.Y. Oh, J.T. Schroeder, A.B. Glick, Z. Zhu, Transgenic expression
of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling, J.
Invest. Dermatol. 129 (2009) 742–751.
[9] S.R. Dillon, C. Sprecher, A. Hammond, J. Bilsborough, M. Rosenfeld-Franklin, S.R.
Presnell, H.S. Haugen, M. Maurer, B. Harder, J. Johnston, S. Bort, S. Mudri, J.L.
Kuijper, T. Bukowski, P. Shea, D.L. Dong, M. Dasovich, F.J. Grant, L. Lockwood, S.D.
Levin, C. LeCiel, K. Waggie, H. Day, S. Topouzis, J. Kramer, R. Kuestner, Z. Chen, D.
Foster, J. Parrish-Novak, J.A. Gross, Interleukin 31, a cytokine produced by activated
T cells, induces dermatitis in mice, Nat. Immunol. 5 (2004) 752–760.
[10] S.K. Han, V. Mancino, M.I. Simon, Phospholipase Cbeta 3 mediates the scratching
response activated by the histamine H1 receptor on C-ﬁber nociceptive neurons,
Neuron 52 (2006) 691–703.
[11] N. Imamachi, G.H. Park, H. Lee, D.J. Anderson, M.I. Simon, A.I. Basbaum, S.K. Han,
TRPV1-expressing primary afferents generate behavioral responses to pruritogens
via multiple mechanisms, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 11330–11335.
[12] S.R. Wilson, K.A. Gerhold, A. Bifolck-Fisher, Q. Liu, K.N. Patel, X. Dong, D.M. Bautista,
TRPA1 is required for histamine-independent, Mas-related G protein-coupled
receptor-mediated itch, Nat. Neurosci. 14 (2011) 595–602.
[13] L. Han, C. Ma, Q. Liu, H.J. Weng, Y. Cui, Z. Tang, Y. Kim, H. Nie, L. Qu, K.N. Patel, Z. Li,
B. McNeil, S. He, Y. Guan, B. Xiao, R.H. Lamotte, X. Dong, A subpopulation of
nociceptors speciﬁcally linked to itch, Nat. Neurosci. 16 (2013) 174–182.
[14] S.K. Mishra, M.A. Hoon, The cells and circuitry for itch responses in mice, Science
340 (2013) 968–971.
[15] Y.G. Sun, Z.F. Chen, A gastrin-releasing peptide receptor mediates the itch sensa-
tion in the spinal cord, Nature 448 (2007) 700–703 (Epub 2007 Jul 2025).
[16] Y.G. Sun, Z.Q. Zhao, X.L. Meng, J. Yin, X.Y. Liu, Z.F. Chen, Cellular basis of itch sensa-
tion, Science 325 (2009) 1531–1534.
[17] P.Y. Su, M.C. Ko, The role of central gastrin-releasing peptide and neuromedin B re-
ceptors in the modulation of scratching behavior in rats, J. Pharmacol. Exp. Ther.
337 (2011) 822–829.
[18] M.S. Fleming, D. Ramos, S.B. Han, J. Zhao, Y.J. Son, W. Luo, The majority of dorsal
spinal cord gastrin releasing peptide is synthesized locally whereas neuromedin
B is highly expressed in pain- and itch-sensing somatosensory neurons, Mol.
Pain 8 (2012) 52.
[19] G. Yosipovitch, J.D. Bernhard, Clinical practice. Chronic pruritus, N. Engl. J. Med. 368
(2013) 1625–1634.
[20] E. Weisshaar, J.C. Szepietowski, U. Darsow, L. Misery, J. Wallengren, T. Mettang, U.
Gieler, T. Lotti, J. Lambert, P. Maisel, M. Streit, M.W. Greaves, A.J. Carmichael, E.
Tschachler, J. Ring, S. Stander, European guideline on chronic pruritus, Acta
Derm. Venereol. 92 (2012) 563–581.
[21] J.C. Ballantyne, A.B. Loach, D.B. Carr, Itching after epidural and spinal opiates, Pain
33 (1988) 149–160.
[22] J.C. Ballantyne, A.B. Loach, D.B. Carr, The incidence of pruritus after epidural mor-
phine, Anaesthesia 44 (1989) 863.
[23] P.G. Atanassoff, S.J. Brull, J. Zhang, K. Greenquist, D.G. Silverman, R.H.
Lamotte, Enhancement of experimental pruritus and mechanically evoked
dysesthesiae with local anesthesia, Somatosens. Mot. Res. 16 (1999)
291–298.
[24] S.E. Ross, A.R. Mardinly, A.E. McCord, J. Zurawski, S. Cohen, C. Jung, L. Hu, S.I. Mok,
A. Shah, E.M. Savner, C. Tolias, R. Corfas, S. Chen, P. Inquimbert, Y. Xu, R.R. McInnes,
F.L. Rice, G. Corfas, Q. Ma, C.J. Woolf, M.E. Greenberg, Loss of inhibitory interneu-
rons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice, Neuron
65 (2010) 886–898.[25] S.E. Ross, A.E. McCord, C. Jung, D. Atan, S.I. Mok, M. Hemberg, T.K. Kim, J.
Salogiannis, L. Hu, S. Cohen, Y. Lin, D. Harrar, R.R. McInnes, M.E. Greenberg,
Bhlhb5 and Prdm8 form a repressor complex involved in neuronal circuit assem-
bly, Neuron 73 (2012) 292–303.
[26] Y. Liu, O. Abdel Samad, L. Zhang, B. Duan, Q. Tong, C. Lopes, R.R. Ji, B.B. Lowell, Q.
Ma, VGLUT2-dependent glutamate release from nociceptors is required to sense
pain and suppress itch, Neuron 68 (2010) 543–556.
[27] M.C. Lagerstrom, K. Rogoz, B. Abrahamsen, E. Persson, B. Reinius, K. Nordenankar,
C. Olund, C. Smith, J.A. Mendez, Z.F. Chen, J.N. Wood, A. Wallen-Mackenzie, K.
Kullander, VGLUT2-dependent sensory neurons in the TRPV1 population regulate
pain and itch, Neuron 68 (2010) 529–542.
[28] S.R. Rosenthal, Histamine as the chemical mediator for cutaneous pain, J. Invest.
Dermatol. 69 (1977) 98–105.
[29] E.D. Prescott, D. Julius, A modular PIP2 binding site as a determinant of capsaicin
receptor sensitivity, Science 300 (2003) 1284–1288.
[30] W.S. Shim, M.H. Tak, M.H. Lee, M. Kim, M. Kim, J.Y. Koo, C.H. Lee, M. Kim, U. Oh,
TRPV1 mediates histamine-induced itching via the activation of phospholipase
A2 and 12-lipoxygenase, J. Neurosci. 27 (2007) 2331–2337.
[31] R. Paus, M. Schmelz, T. Biro, M. Steinhoff, Frontiers in pruritus research: scratching
the brain for more effective itch therapy, J. Clin. Invest. 116 (2006) 1174–1186.
[32] F. Touska, L. Marsakova, J. Teisinger, V. Vlachova, A “cute” desensitization of TRPV1,
Curr. Pharm. Biotechnol. 12 (2011) 122–129.
[33] K.N. Patel, Q. Liu, S. Meeker, B.J. Undem, X. Dong, Pirt, a TRPV1 modulator, is re-
quired for histamine-dependent and -independent itch, PLoS One 6 (2011)
e20559.
[34] A.Y. Kim, Z. Tang, Q. Liu, K.N. Patel, D. Maag, Y. Geng, X. Dong, Pirt, a
phosphoinositide-binding protein, functions as a regulatory subunit of
TRPV1, Cell 133 (2008) 475–485.
[35] C. Weidner, M. Klede, R. Rukwied, G. Lischetzki, U. Neisius, P.S. Skov, L.J. Petersen, M.
Schmelz, Acute effects of substance P and calcitonin gene-related peptide in human
skin — a microdialysis study, J. Invest. Dermatol. 115 (2000) 1015–1020.
[36] S.T. Denman, A review of pruritus, J. Am. Acad. Dermatol. 14 (1986) 375–392.
[37] S.D. Gittlen, E.S. Schulman, W.C. Maddrey, Raised histamine concentrations in
chronic cholestatic liver disease, Gut 31 (1990) 96–99.
[38] T. Mettang, P. Fritz, J. Weber, C. Machleidt, E. Hubel, U. Kuhlmann, Uremic pruritus
in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).
The role of plasma histamine and skin mast cells, Clin. Nephrol. 34 (1990)
136–141.
[39] G.C. Francos, Y.C. Kauh, S.D. Gittlen, E.S. Schulman, A. Besarab, S. Goyal, J.F. Burke Jr.,
Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus, In-
ternational journal of dermatology 30 (1991) 884–889.
[40] R. Marks, M.W. Greaves, Vascular reactions to histamine and compound 48/80 in
human skin: suppression by a histamine H2-receptor blocking agent, Br. J. Clin.
Pharmacol. 4 (1977) 367–369.
[41] M.G. Davies, M.W. Greaves, The current status of histamine receptors in human
skin: therapeutic implications, Br. J. Dermatol. 104 (1981) 601–606.
[42] M.W. Greaves, M.G. Davies, Histamine receptors in human skin: indirect evidence,
Br. J. Dermatol. 107 (Suppl. 23) (1982) 101–105.
[43] U. Lippert, M. Artuc, A. Grutzkau, M. Babina, S. Guhl, I. Haase, V. Blaschke, K.
Zachmann, M. Knosalla, P. Middel, S. Kruger-Krasagakis, B.M. Henz, Human skin
mast cells express H2 and H4, but not H3 receptors, J. Invest. Dermatol. 123
(2004) 116–123.
[44] Y. Kajihara, M.Murakami, T. Imagawa, K. Otsuguro, S. Ito, T. Ohta, Histamine poten-
tiates acid-induced responses mediating transient receptor potential V1 in mouse
primary sensory neurons, Neuroscience 166 (2010) 292–304.
[45] K. Yamaura, M. Oda, E. Suwa, M. Suzuki, H. Sato, K. Ueno, Expression of histamine
H4 receptor in human epidermal tissues and attenuation of experimental pruritus
using H4 receptor antagonist, J. Toxicol. Sci. 34 (2009) 427–431.
[46] R. Gutzmer, S. Mommert, M. Gschwandtner, K. Zwingmann, H. Stark, T. Werfel, The
histamine H4 receptor is functionally expressed on T(H)2 cells, J. Allergy Clin.
Immunol. 123 (2009) 619–625.
[47] M.I. Strakhova, A.L. Nikkel, A.M. Manelli, G.C. Hsieh, T.A. Esbenshade, J.D. Brioni, R.S.
Bitner, Localization of histamine H4 receptors in the central nervous system of
human and rat, Brain Res. 1250 (2009) 41–48.
[48] Y. Sugimoto, Y. Iba, Y. Nakamura, R. Kayasuga, C. Kamei, Pruritus-associated re-
sponse mediated by cutaneous histamine H3 receptors, Clin. Exp. Allergy 34
(2004) 456–459.
[49] J.K. Bell, D.S. McQueen, J.L. Rees, Involvement of histamine H4 and H1 receptors in
scratching induced by histamine receptor agonists in Balb C mice, Br. J. Pharmacol.
142 (2004) 374–380.
[50] K. Rossbach, S. Wendorff, K. Sander, H. Stark, R. Gutzmer, T. Werfel, M. Kietzmann,
W. Baumer, Histamine H4 receptor antagonism reduces hapten-induced
scratching behaviour but not inﬂammation, Exp. Dermatol. 18 (2009) 57–63.
[51] Y. Ohsawa, N. Hirasawa, The antagonism of histamine H1 and H4 receptors amelio-
rates chronic allergic dermatitis via anti-pruritic and anti-inﬂammatory effects in
NC/Nga mice, Allergy 67 (2012) 1014–1022.
[52] R.L. Thurmond, P.J. Desai, P.J. Dunford, W.P. Fung-Leung, C.L. Hofstra, W. Jiang, S.
Nguyen, J.P. Riley, S. Sun, K.N. Williams, J.P. Edwards, L. Karlsson, A potent and se-
lective histamine H4 receptor antagonist with anti-inﬂammatory properties, J.
Pharmacol. Exp. Ther. 309 (2004) 404–413.
[53] J.M. Cowden, M. Zhang, P.J. Dunford, R.L. Thurmond, The histamine H4 receptor
mediates inﬂammation and pruritus in Th2-dependent dermal inﬂammation, J. In-
vest. Dermatol. 130 (2010) 1023–1033.
[54] J.M. Cowden, J.P. Riley, J.Y. Ma, R.L. Thurmond, P.J. Dunford, Histamine H4 receptor
antagonism diminishes existing airway inﬂammation and dysfunction via modula-
tion of Th2 cytokines, Respir. Res. 11 (2010) 86.
885A.E. Kremer et al. / Biochimica et Biophysica Acta 1842 (2014) 869–892[55] R. Kiss, G.M. Keseru, Histamine H4 receptor ligands and their potential therapeutic
applications: an update, Expert Opin. Ther. Pat. 22 (2012) 205–221.
[56] O. Hagermark, Peripheral and central mediators of itch, Skin Pharmacol. 5
(1992) 1–8.
[57] B. Fjellner, O. Hagermark, Pruritus in polycythemia vera: treatment with aspirin
and possibility of platelet involvement, Acta Derm. Venereol. 59 (1979) 505–512.
[58] A. Rausl, K. Nordlind, C.F. Wahlgren, Pruritic and vascular responses induced by se-
rotonin in patients with atopic dermatitis and in healthy controls, Acta Derm.
Venereol. 93 (2013) 277–280.
[59] T. Yamaguchi, T. Nagasawa, M. Satoh, Y. Kuraishi, Itch-associated response induced
by intradermal serotonin through 5-HT2 receptors in mice, Neurosci. Res. 35
(1999) 77–83.
[60] J.M. Spradley, A. Davoodi, L.B. Gee,M.I. Carstens, E. Carstens, Differences inperipheral
endocannabinoidmodulation of scratching behavior in facial vs. spinally-innervated
skin, Neuropharmacology 63 (2012) 743–749.
[61] A. Borgeat, H.R. Stirnemann, Ondansetron is effective to treat spinal or epidural
morphine-induced pruritus, Anesthesiology 90 (1999) 432–436.
[62] E.V. Balaskas, G.I. Bamihas, M. Karamouzis, G. Voyiatzis, A. Tourkantonis, Histamine
and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients,
Nephron 78 (1998) 395–402.
[63] J.W. O'Donohue, S.P. Pereira, A.C. Ashdown, C.G. Haigh, J.R. Wilkinson, R. Williams,
A controlled trial of ondansetron in the pruritus of cholestasis, Aliment. Pharmacol.
Ther. 21 (2005) 1041–1045.
[64] C. Muller, S. Pongratz, J. Pidlich, E. Penner, A. Kaider, M. Schemper, M. Raderer, W.
Scheithauer, P. Ferenci, Treatment of pruritus in chronic liver disease with the
5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized,
placebo-controlled, double-blind cross-over trial, Eur. J. Gastroenterol. Hepatol.
10 (1998) 865–870.
[65] M. Murphy, D. Reaich, P. Pai, P. Finn, A.J. Carmichael, A randomized,
placebo-controlled, double-blind trial of ondansetron in renal itch, Br. J. Dermatol.
148 (2003) 314–317.
[66] E.A. Jones, H.A. Molenaar, J. Oosting, Ondansetron and pruritus in chronic liver dis-
ease: a controlled study, Hepatogastroenterology 54 (2007) 1196–1199.
[67] M.J. Mayo, I. Handem, S. Saldana, H. Jacobe, Y. Getachew, A.J. Rush, Sertraline as a
ﬁrst-line treatment for cholestatic pruritus, Hepatology 45 (2007) 666–674.
[68] S. Stander, B. Bockenholt, F. Schurmeyer-Horst, C. Weishaupt, G. Heuft, T.A. Luger,
G. Schneider, Treatment of chronic pruritus with the selective serotonin re-uptake
inhibitors paroxetine and ﬂuvoxamine: results of an open-labelled, two-arm
proof-of-concept study, Acta Derm. Venereol. 89 (2009) 45–51.
[69] Z. Zylicz, M. Krajnik, A.A. Sorge,M. Costantini, Paroxetine in the treatment of severe
non-dermatological pruritus: a randomized, controlled trial, J. Pain Symptom
Manag. 26 (2003) 1105–1112.
[70] Z. Zylicz, C. Smits, M. Krajnik, Paroxetine for pruritus in advanced cancer, J. Pain
Symptom Manag. 16 (1998) 121–124.
[71] M.P. Davis, J.L. Frandsen, D. Walsh, S. Andresen, S. Taylor, Mirtazapine for pruritus,
J. Pain Symptom Manag. 25 (2003) 288–291.
[72] C. De Felipe, J.F. Herrero, J.A. O'Brien, J.A. Palmer, C.A. Doyle, A.J. Smith, J.M. Laird, C.
Belmonte, F. Cervero, S.P. Hunt, Altered nociception, analgesia and aggression in
mice lacking the receptor for substance P, Nature 392 (1998) 394–397.
[73] M.K. Church, Y. Okayama, S. el-Lati, Mediator secretion from human skin mast cells
provoked by immunological and non-immunological stimulation, Skin Pharmacol.
4 (Suppl. 1) (1991) 15–24.
[74] O. Hagermark, T. Hokfelt, B. Pernow, Flare and itch induced by substance P in
human skin, J. Invest. Dermatol. 71 (1978) 233–235.
[75] B. Fjellner, O. Hagermark, Studies on pruritogenic and histamine-releasing effects
of some putative peptide neurotransmitters, Acta Derm. Venereol. 61 (1981)
245–250.
[76] J.L. Jorizzo, A.A. Coutts, R.A. Eady, M.W. Greaves, Vascular responses of human skin
to injection of substance P and mechanism of action, Eur. J. Pharmacol. 87 (1983)
67–76.
[77] H.P. van der Kleij, D. Ma, F.A. Redegeld, A.D. Kraneveld, F.P. Nijkamp, J. Bienenstock,
Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and
stem cell factor, J. Immunol. 171 (2003) 2074–2079.
[78] T.A. Luger, Neuromediators — a crucial component of the skin immune system, J.
Dermatol. Sci. 30 (2002) 87–93.
[79] M. Steinhoff, S. Stander, S. Seeliger, J.C. Ansel, M. Schmelz, T. Luger, Modern aspects
of cutaneous neurogenic inﬂammation, Arch. Dermatol. 139 (2003) 1479–1488.
[80] K. Furutani, O. Koro, M. Hide, S. Yamamoto, Substance P- and antigen-induced re-
lease of leukotriene B4, prostaglandin D2 and histamine from guinea pig skin by
different mechanisms in vitro, Arch. Dermatol. Res. 291 (1999) 466–473.
[81] G.H. Caughey, F. Leidig, N.F. Viro, J.A. Nadel, Substance P and vasoactive intestinal
peptide degradation by mast cell tryptase and chymase, J. Pharmacol. Exp. Ther.
244 (1988) 133–137.
[82] T. Biro, B.I. Toth, R. Marincsak, N. Dobrosi, T. Geczy, R. Paus, TRP channels as novel
players in the pathogenesis and therapy of itch, Biochim. Biophys. Acta 1772
(2007) 1004–1021.
[83] M. Kulka, C.H. Sheen, B.P. Tancowny, L.C. Grammer, R.P. Schleimer, Neuropeptides
activate human mast cell degranulation and chemokine production, Immunology
123 (2008) 398–410.
[84] T. Andoh, T. Nagasawa, M. Satoh, Y. Kuraishi, Substance P induction of
itch-associated response mediated by cutaneous NK1 tachykinin receptors in
mice, J. Pharmacol. Exp. Ther. 286 (1998) 1140–1145.
[85] Y. Akasaka, T. Yoshida, M. Tsukahara, A. Hatta, H. Inoue, Glycyrrhetinic acid pre-
vents cutaneous scratching behavior in mice elicited by substance P or PAR-2 ago-
nist, Eur. J. Pharmacol. 670 (2011) 175–179.[86] E.E. Carstens, M.I. Carstens, C.T. Simons, S.L. Jinks, Dorsal horn neurons expressing
NK-1 receptors mediate scratching in rats, Neuroreport 21 (2010) 303–308.
[87] B. Liu, J. Escalera, S. Balakrishna, L. Fan, A.I. Caceres, E. Robinson, A. Sui, M.C. McKay,
M.A. McAlexander, C.A. Herrick, S.E. Jordt, TRPA1 controls inﬂammation and
pruritogen responses in allergic contact dermatitis, FASEB J. 27 (2013) 3549–3563.
[88] B. Nilius, G. Appendino, G. Owsianik, The transient receptor potential channel
TRPA1: from gene to pathophysiology, Pﬂugers Arch. 464 (2012) 425–458.
[89] J. Salomon, E. Baran, The role of selected neuropeptides in pathogenesis of atopic
dermatitis, J. Eur. Acad. Dermatol. Venereol. 22 (2008) 223–228.
[90] F. Abadia Molina, N.P. Burrows, R.R. Jones, G. Terenghi, J.M. Polak, Increased senso-
ry neuropeptides in nodular prurigo: a quantitative immunohistochemical analy-
sis, Br. J. Dermatol. 127 (1992) 344–351.
[91] A. Jarvikallio, I.T. Harvima, A. Naukkarinen, Mast cells, nerves and neuropeptides in
atopic dermatitis and nummular eczema, Arch. Dermatol. Res. 295 (2003) 2–7.
[92] S. Stander, D. Siepmann, I. Herrgott, C. Sunderkotter, T.A. Luger, Targeting the
neurokinin receptor 1 with aprepitant: a novel antipruritic strategy, PLoS One 5
(2010) e10968.
[93] A. Duval, L. Dubertret, Aprepitant as an antipruritic agent? N. Engl. J. Med. 361
(2009) 1415–1416.
[94] B. Vincenzi, M.E. Fratto, D. Santini, G. Tonini, Aprepitant against pruritus in patients
with solid tumours, Support Care Cancer 18 (2010) 1229–1230.
[95] B. Vincenzi, G. Tonini, D. Santini, Aprepitant for erlotinib-induced pruritus, N. Engl.
J. Med. 363 (2010) 397–398.
[96] Q. Hou, T. Barr, L. Gee, J. Vickers, J.Wymer, E. Borsani, L. Rodella, S. Getsios, T. Burdo,
E. Eisenberg, U. Guha, R. Lavker, J. Kessler, S. Chittur, D. Fiorino, F. Rice, P. Albrecht,
Keratinocyte expression of calcitonin gene-related peptide beta: implications for
neuropathic and inﬂammatory pain mechanisms, Pain 152 (2011) 2036–2051.
[97] J. Wallengren, R. Hakanson, Effects of substance P, neurokinin A and calcitonin
gene-related peptide in human skin and their involvement in sensory
nerve-mediated responses, Eur. J. Pharmacol. 143 (1987) 267–273.
[98] B. Averbeck, P.W. Reeh, Interactions of inﬂammatory mediators stimulating release
of calcitonin gene-related peptide, substance P and prostaglandin E(2) from isolat-
ed rat skin, Neuropharmacology 40 (2001) 416–423.
[99] B. Averbeck, P.W. Reeh, M. Michaelis, Modulation of CGRP and PGE2 release from
isolated rat skin by alpha-adrenoceptors and kappa-opioid-receptors, Neuroreport
12 (2001) 2097–2100.
[100] S. Hagner, R.V. Haberberger, D. Overkamp, R. Hoffmann, K.H. Voigt, G.P. McGregor,
Expression and distribution of calcitonin receptor-like receptor in human hairy
skin, Peptides 23 (2002) 109–116.
[101] A. Ekblom, T. Lundeberg, C.F. Wahlgren, Inﬂuence of calcitonin gene-related pep-
tide on histamine- and substance P-induced itch, ﬂare and weal in humans, Skin
Pharmacol. 6 (1993) 215–222.
[102] Y. Liang, H.H. Jacobi, C.M. Reimert, M. Haak-Frendscho, J.A. Marcusson, O.
Johansson, CGRP-immunoreactive nerves in prurigo nodularis — an exploration
of neurogenic inﬂammation, J. Cutan. Pathol. 27 (2000) 359–366.
[103] C. Antunez, M.J. Torres, S. Lopez, R. Rodriguez-Pena, M. Blanca, C. Mayorga, L.F.
Santamaria-Babi, Calcitonin gene-related peptide modulates interleukin-13 in cir-
culating cutaneous lymphocyte-associated antigen-positive T cells in patients with
atopic dermatitis, Br. J. Dermatol. 161 (2009) 547–553.
[104] E.S. McCoy, B. Taylor-Blake, S.E. Street, A.L. Pribisko, J. Zheng, M.J. Zylka, Peptidergic
CGRPalpha primary sensory neurons encode heat and itch and tonically suppress
sensitivity to cold, Neuron 78 (2013) 138–151.
[105] C.R. Gandhi, D.E. Berkowitz, W.D. Watkins, Endothelins. Biochemistry and patho-
physiologic actions, Anesthesiology 80 (1994) 892–905.
[106] T. Hirobe, Role of keratinocyte-derived factors involved in regulating the prolifera-
tion and differentiation of mammalian epidermal melanocytes, Pigment Cell Res.
18 (2005) 2–12.
[107] M. Metz, V. Lammel, B.F. Gibbs, M. Maurer, Inﬂammatory murine skin responses to
UV-B light are partially dependent on endothelin-1 and mast cells, Am. J. Pathol.
169 (2006) 815–822.
[108] V. Vellani, M. Prandini, C. Giacomoni, G. Pavesi, L. Ravegnani, P.C. Magherini, Func-
tional endothelin receptors are selectively expressed in isolectin B4-negative sen-
sory neurons and are upregulated in isolectin B4-positive neurons by neurturin
and glia-derived neurotropic factor, Brain Res. 1381 (2011) 31–37.
[109] A.P. Piovezan, P. D'Orleans-Juste, G.E. Souza, G.A. Rae, Endothelin-1-induced ET(A)
receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw:
modulation by simultaneous ET(B) receptor activation, Br. J. Pharmacol. 129
(2000) 961–968.
[110] A.P. Gokin, M.U. Fareed, H.L. Pan, G. Hans, G.R. Strichartz, G. Davar, Local injection
of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats, J.
Neurosci. Off. J. Soc. Neurosci. 21 (2001) 5358–5366.
[111] L.O. Gomes, D.B. Hara, G.A. Rae, Endothelin-1 induces itch and pain in the mouse
cheek model, Life Sci. 91 (2012) 628–633.
[112] G. Hans, K. Deseure, D. Robert, S. De Hert, Neurosensory changes in a humanmodel
of endothelin-1 induced pain: a behavioral study, Neurosci. Lett. 418 (2007)
117–121.
[113] P.G. Trentin, M.B. Fernandes, P. D'Orleans-Juste, G.A. Rae, Endothelin-1 causes pru-
ritus in mice, Exp. Biol. Med. (Maywood) 231 (2006) 1146–1151.
[114] J. Liang, T. Kawamata, W. Ji, Molecular signaling of pruritus induced by
endothelin-1 in mice, Exp. Biol. Med. (Maywood) 235 (2010) 1300–1305.
[115] R. Katugampola, M.K. Church, G.F. Clough, The neurogenic vasodilator response to
endothelin-1: a study in human skin in vivo, Exp. Physiol. 85 (2000) 839–846.
[116] B. Namer, M. Hilliges, K. Orstavik, R. Schmidt, C. Weidner, E. Torebjork, H.
Handwerker, M. Schmelz, Endothelin 1 activates and sensitizes human
C-nociceptors, Pain 137 (2008) 41–49.
886 A.E. Kremer et al. / Biochimica et Biophysica Acta 1842 (2014) 869–892[117] S.A. Douglas, E.H. Ohlstein, Signal transductionmechanismsmediating the vascular
actions of endothelin, J. Vasc. Res. 34 (1997) 152–164.
[118] J. Liang, Q. Ji, W. Ji, Role of transient receptor potential ankyrin subfamily member 1
in pruritus induced by endothelin-1, Neurosci. Lett. 492 (2011) 175–178.
[119] W.B. Shelley, R.P. Arthur, Studies on cowhage (Mucuna pruriens) and its
pruritogenic proteinase, mucunain, AMA Arch. Derm. 72 (1955) 399–406.
[120] W.B. Shelley, R.P. Arthur, Mucunain, the active pruritogenic proteinase of cowhage,
Science 122 (1955) 469–470.
[121] R.P. Arthur, W.B. Shelley, Experimental evidence for an enzymatic basis for itching
in man, Nature 175 (1955) 901–902.
[122] F.E. Cormia, J.W. Dougherty, S.A. Unrau, Proteolytic activity in dermatoses: prelim-
inary observations on inﬂammation and pruritus, J. Invest. Dermatol. 28 (1957)
425–433.
[123] M. Steinhoff, U. Neisius, A. Ikoma, M. Fartasch, G. Heyer, P.S. Skov, T.A. Luger, M.
Schmelz, Proteinase-activated receptor-2 mediates itch: a novel pathway for pru-
ritus in human skin, J. Neurosci. 23 (2003) 6176–6180.
[124] V.B. Reddy, A.O. Iuga, S.G. Shimada, R.H. LaMotte, E.A. Lerner, Cowhage-evoked itch
is mediated by a novel cysteine protease: a ligand of protease-activated receptors,
J. Neurosci. 28 (2008) 4331–4335.
[125] S.G. Shimada, K.A. Shimada, J.G. Collins, Scratching behavior inmice induced by the
proteinase-activated receptor-2 agonist, SLIGRL-NH2, Eur. J. Pharmacol. 530
(2006) 281–283.
[126] M. Steinhoff, J. Bienenstock, M. Schmelz, M. Maurer, E. Wei, T. Biro, Neurophysio-
logical, neuroimmunological, and neuroendocrine basis of pruritus, J. Invest.
Dermatol. 126 (2006) 1705–1718.
[127] V.B. Reddy, S.G. Shimada, P. Sikand, R.H. Lamotte, E.A. Lerner, Cathepsin S elicits
itch and signals via protease-activated receptors, J. Invest. Dermatol. 130 (2010)
1468–1470.
[128] Q. Liu, H.J. Weng, K.N. Patel, Z. Tang, H. Bai, M. Steinhoff, X. Dong, The distinct roles
of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia, Sci. Signal. 4 (2011)
ra45.
[129] T. Andoh, T. Yoshida, J.B. Lee, Y. Kuraishi, Cathepsin E induces itch-related response
through the production of endothelin-1 in mice, Eur. J. Pharmacol. 686 (2012)
16–21.
[130] M. Steinhoff, N. Vergnolle, S.H. Young, M. Tognetto, S. Amadesi, H.S. Ennes, M.
Trevisani, M.D. Hollenberg, J.L. Wallace, G.H. Caughey, S.E. Mitchell, L.M. Williams,
P. Geppetti, E.A.Mayer, N.W. Bunnett, Agonists of proteinase-activated receptor 2 in-
duce inﬂammation by a neurogenic mechanism, Nat. Med. 6 (2000) 151–158.
[131] N. Vergnolle, M. Ferazzini, M.R. D'Andrea, J. Buddenkotte, M. Steinhoff,
Proteinase-activated receptors: novel signals for peripheral nerves, Trends
Neurosci. 26 (2003) 496–500.
[132] S. Amadesi, J. Nie, N. Vergnolle, G.S. Cottrell, E.F. Grady, M. Trevisani, C. Manni, P.
Geppetti, J.A. McRoberts, H. Ennes, J.B. Davis, E.A. Mayer, N.W. Bunnett,
Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor
potential vanilloid receptor 1 to induce hyperalgesia, J. Neurosci. Off. J. Soc.
Neurosci. 24 (2004) 4300–4312.
[133] Y. Dai, T. Moriyama, T. Higashi, K. Togashi, K. Kobayashi, H. Yamanaka, M.
Tominaga, K. Noguchi, Proteinase-activated receptor 2-mediated potentiation of
transient receptor potential vanilloid subfamily 1 activity reveals a mechanism
for proteinase-induced inﬂammatory pain, J. Neurosci. Off. J. Soc. Neurosci. 24
(2004) 4293–4299.
[134] S. Amadesi, G.S. Cottrell, L. Divino, K. Chapman, E.F. Grady, F. Bautista, R. Karanjia, C.
Barajas-Lopez, S. Vanner, N. Vergnolle, N.W. Bunnett, Protease-activated receptor 2
sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats
and mice, J. Physiol. 575 (2006) 555–571.
[135] J. Buddenkotte, C. Stroh, I.H. Engels, C. Moormann, V.M. Shpacovitch, S. Seeliger, N.
Vergnolle, D. Vestweber, T.A. Luger, K. Schulze-Osthoff, M. Steinhoff, Agonists of
proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhe-
sionmolecule-1 in primary human keratinocytes via activation of NF-kappa B, J. In-
vest. Dermatol. 124 (2005) 38–45.
[136] O. Hagermark, K. Strandberg, M. Hamberg, Potentiation of itch and ﬂare responses
in human skin by prostaglandins E2 and H2 and a prostaglandin endoperoxide an-
alog, J. Invest. Dermatol. 69 (1977) 527–530.
[137] O. Hagermark, K. Strandberg, Pruritogenic activity of prostaglandin E2, Acta Derm.
Venereol. 57 (1977) 37–43.
[138] M. Boss, J.L. Burton, Lack of effect of the antihistamine drug clemastine on the
potentiation of itch by prostaglandin E1, Arch. Dermatol. 117 (1981)
208–209.
[139] C.R. Lovell, P.A. Burton, E.H. Duncan, J.L. Burton, Prostaglandins and pruritus, Br. J.
Dermatol. 94 (1976) 273–275.
[140] U. Neisius, R. Olsson, R. Rukwied, G. Lischetzki, M. Schmelz, Prostaglandin E2 in-
duces vasodilation and pruritus, but no protein extravasation in atopic dermatitis
and controls, J. Am. Acad. Dermatol. 47 (2002) 28–32.
[141] N. Jackson, D. Burt, J. Crocker, B. Boughton, Skin mast cells in polycythaemia vera:
relationship to the pathogenesis and treatment of pruritus, Br. J. Dermatol. 116
(1987) 21–29.
[142] B.M. Daly, S. Shuster, Effect of aspirin on pruritus, Br. Med. J. 293 (1986) 907.
[143] K.J. Smith, H.G. Skelton, J. Yeager, R.B. Lee, K.F. Wagner, Pruritus in HIV-1 disease:
therapy with drugs which may modulate the pattern of immune dysregulation,
Dermatology 195 (1997) 353–358.
[144] Y. Hashimoto, I. Arai, M. Tanaka, S. Nakaike, Prostaglandin D2 inhibits
IgE-mediated scratching by suppressing histamine release from mast cells, J.
Pharmacol. Sci. 98 (2005) 90–93.
[145] M. Sugimoto, I. Arai, N. Futaki, Y. Hashimoto, Y. Honma, S. Nakaike, COX-1 inhibi-
tion enhances scratching behaviour in NC/Nga mice with atopic dermatitis, Exp.
Dermatol. 15 (2006) 582–588.[146] S. Kaur, R. Sur, F.T. Liebel, M.D. Southall, Induction of prostaglandin D2 through the
p38 MAPK pathway is responsible for the antipruritic activity of sertaconazole ni-
trate, J. Invest. Dermatol. 130 (2010) 2448–2456.
[147] P.D. Maurice, R.M. Barr, O. Koro, M.W. Greaves, The effect of prostaglandin D2 on
the response of human skin to histamine, J. Invest. Dermatol. 89 (1987) 245–248.
[148] T. Andoh, Y. Kuraishi, Intradermal leukotriene B4, but not prostaglandin E2, in-
duces itch-associated responses in mice, Eur. J. Pharmacol. 353 (1998) 93–96.
[149] T. Andoh, N. Katsube, M. Maruyama, Y. Kuraishi, Involvement of leukotriene B(4)
in substance P-induced itch-associated response in mice, J. Invest. Dermatol. 117
(2001) 1621–1626.
[150] T. Andoh, A. Saito, Y. Kuraishi, Leukotriene B(4) mediates sphingosyl-
phosphorylcholine-induced itch-associated responses in mouse skin, J. Invest.
Dermatol. 129 (2009) 2854–2860.
[151] Y. Zhu, X.R. Wang, C. Peng, J.G. Xu, Y.X. Liu, L. Wu, Q.G. Zhu, J.Y. Liu, F.Q. Li, Y.H. Pan,
B.M. You, J.H. Hu, Induction of leukotriene B(4) and prostaglandin E(2) release
from keratinocytes by protease-activated receptor-2-activating peptide in ICR
mice, Int. Immunopharmacol. 9 (2009) 1332–1336.
[152] N.A. Soter, R.A. Lewis, E.J. Corey, K.F. Austen, Local effects of synthetic leukotrienes
(LTC4, LTD4, LTE4, and LTB4) in human skin, J. Invest. Dermatol. 80 (1983)
115–119.
[153] R. Camp, R.R. Jones, S. Brain, P. Woollard, M. Greaves, Production of intraepidermal
microabscesses by topical application of leukotriene B4, J. Invest. Dermatol. 82
(1984) 202–204.
[154] S. Brain, R. Camp, P. Dowd, A.K. Black, M. Greaves, The release of leukotriene
B4-like material in biologically active amounts from the lesional skin of patients
with psoriasis, J. Invest. Dermatol. 83 (1984) 70–73.
[155] T. Ruzicka, T. Simmet, B.A. Peskar, J. Ring, Skin levels of arachidonic acid-derived in-
ﬂammatory mediators and histamine in atopic dermatitis and psoriasis, J. Invest.
Dermatol. 86 (1986) 105–108.
[156] M.L. Rahman, A.M. Choudhury, M.M. Islam, Effectiveness of montelukast in the
treatment of atopic dermatitis, Mymensingh Med. J. 15 (2006) 85–88.
[157] A.R. Nasrollahi, A. Miladipour, E. Ghanei, P. Yavari, F. Haghverdi, Montelukast for
treatment of refractory pruritus in patients on hemodialysis, Iran J. Kidney Dis. 1
(2007) 73–77.
[158] C.F. Wahlgren, M. Tengvall Linder, O. Hagermark, A. Scheynius, Itch and inﬂamma-
tion induced by intradermally injected interleukin-2 in atopic dermatitis patients
and healthy subjects, Arch. Dermatol. Res. 287 (1995) 572–580.
[159] A.A. Gaspari, M.T. Lotze, S.A. Rosenberg, J.B. Stern, S.I. Katz, Dermatologic changes
associated with interleukin 2 administration, JAMA 258 (1987) 1624–1629.
[160] R.E. Lee, A.A. Gaspari, M.T. Lotze, A.E. Chang, S.A. Rosenberg, Interleukin 2 and pso-
riasis, Arch. Dermatol. 124 (1988) 1811–1815.
[161] B.G. Redman, L. Flaherty, T.H. Chou, A. al-Katib, M. Kraut, S. Martino, B. Chen, J.
Kaplan, M. Valdivieso, A phase I trial of recombinant interleukin-2 combined
with recombinant interferon-gamma in patients with cancer, J. Clin. Oncol. Off. J.
Am. Soc. Clin. Oncol. 8 (1990) 1269–1276.
[162] M.K. Fallahzadeh, J. Roozbeh, B. Geramizadeh, M.R. Namazi, Interleukin-2 serum
levels are elevated in patients with uremic pruritus: a novel ﬁnding with practical
implications, Nephrol. Dial. Transplant. 34 (1985) 196–203.
[163] C.F. Wahlgren, A. Scheynius, O. Hagermark, Antipruritic effect of oral cyclosporin A
in atopic dermatitis, Acta Derm. Venereol. 70 (1990) 323–329.
[164] T.H. Totterman, A. Scheynius, A. Killander, A. Danersund, G.V. Alm, Treatment of
therapy-resistant Sezary syndrome with Cyclosporin-A: suppression of pruritus,
leukaemic T cell activation markers and tumour mass, Scand. J. Haematol. 34
(1985) 196–203.
[165] H.A. Martin, P.R. Murphy, Interleukin-2 activates a sub-population of cutaneous
C-ﬁbre polymodal nociceptors in the rat hairy skin, Arch. Physiol. Biochem. 103
(1995) 136–148.
[166] H.A. Martin, Bradykinin potentiates the chemoresponsiveness of rat cutaneous
C-ﬁbre polymodal nociceptors to interleukin-2, Arch. Physiol. Biochem. 104
(1996) 229–238.
[167] L.S. Chan, N. Robinson, L. Xu, Expression of interleukin-4 in the epidermis of
transgenic mice results in a pruritic inﬂammatory skin disease: an experimen-
tal animal model to study atopic dermatitis, J. Invest. Dermatol. 117 (2001)
977–983.
[168] M. Kimmel, D.M. Alscher, R. Dunst, N. Braun, C. Machleidt, T. Kiefer, C. Stulten, H.
van der Kuip, C. Pauli-Magnus, U. Raub, U. Kuhlmann, T. Mettang, The role of
micro-inﬂammation in the pathogenesis of uraemic pruritus in haemodialysis pa-
tients, Nephrol. Dial. Transplant. 21 (2006) 749–755.
[169] K. Nordlind, L.B. Chin, A.A. Ahmed, J. Brakenhoff, E. Theodorsson, S. Liden, Immuno-
histochemical localization of interleukin-6-like immunoreactivity to peripheral
nerve-like structures in normal and inﬂamed human skin, Arch. Dermatol. Res.
288 (1996) 431–435.
[170] E.B. Brandt, U. Sivaprasad, Th2 cytokines and atopic dermatitis, J. Clin. Cell
Immunol. 2 (2011).
[171] M. Wills-Karp, F.D. Finkelman, Untangling the complex web of IL-4- and
IL-13-mediated signaling pathways, Sci. Signal. 1 (2008) e55.
[172] F. Niyonsaba, H. Ushio, M. Hara, H. Yokoi, M. Tominaga, K. Takamori, N. Kajiwara, H.
Saito, I. Nagaoka, H. Ogawa, K. Okumura, Antimicrobial peptides human
beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cyto-
kine IL-31 by human mast cells, J. Immunol. 184 (2010) 3526–3534.
[173] C. Cornelissen, J. Luscher-Firzlaff, J.M. Baron, B. Luscher, Signaling by IL-31 and
functional consequences, Eur. J. Cell Biol. 91 (2012) 552–566.
[174] S. Kasraie, M. Niebuhr, T.Werfel, Interleukin (IL)-31 activates signal transducer and
activator of transcription (STAT)-1, STAT-5 and extracellular signal-regulated ki-
nase 1/2 and down-regulates IL-12p40 production in activated human macro-
phages, Allergy 68 (2013) 739–747.
887A.E. Kremer et al. / Biochimica et Biophysica Acta 1842 (2014) 869–892[175] A. Takaoka, I. Arai, M. Sugimoto, Y. Honma, N. Futaki, A. Nakamura, S. Nakaike, In-
volvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like derma-
titis, Exp. Dermatol. 15 (2006) 161–167.
[176] O. Grimstad, Y. Sawanobori, C. Vestergaard, J. Bilsborough, U.B. Olsen, C.
Gronhoj-Larsen, K. Matsushima, Anti-interleukin-31-antibodies ameliorate
scratching behaviour in NC/Nga mice: a model of atopic dermatitis, Exp. Dermatol.
18 (2009) 35–43.
[177] U. Raap, D. Wieczorek, M. Gehring, I. Pauls, S. Stander, A. Kapp, B. Wedi, Increased
levels of serum IL-31 in chronic spontaneous urticaria, Exp. Dermatol. 19 (2010)
464–466.
[178] U. Raap, K. Wichmann, M. Bruder, S. Stander, B. Wedi, A. Kapp, T. Werfel, Correla-
tion of IL-31 serum levels with severity of atopic dermatitis, J. Allergy Clin.
Immunol. 122 (2008) 421–423.
[179] E. Sonkoly, A. Muller, A.I. Lauerma, A. Pivarcsi, H. Soto, L. Kemeny, H. Alenius, M.C.
Dieu-Nosjean, S. Meller, J. Rieker, M. Steinhoff, T.K. Hoffmann, T. Ruzicka, A. Zlotnik,
B. Homey, IL-31: a new link between T cells and pruritus in atopic skin inﬂamma-
tion, J. Allergy Clin. Immunol. 117 (2006) 411–417.
[180] K. Szegedi, A.E. Kremer, S. Kezic, M.B. Teunissen, J.D. Bos, R.M. Luiten, P.C. Res, M.A.
Middelkamp-Hup, Increased frequencies of IL-31-producing T cells are found in
chronic atopic dermatitis skin, Exp. Dermatol. 21 (2012) 431–436.
[181] T. Ishii, J. Wang, W. Zhang, J. Mascarenhas, R. Hoffman, Y. Dai, N. Wisch, M. Xu, Piv-
otal role of mast cells in pruritogenesis in patients with myeloproliferative disor-
ders, Blood 113 (2009) 5942–5950.
[182] R. Heise, J. Mey, M.M. Neis, Y. Marquardt, S. Joussen, H. Ott, T. Wiederholt, P.
Kurschat, M. Megahed, D.R. Bickers, H.F. Merk, J.M. Baron, Skin retinoid concentra-
tions are modulated by CYP26AI expression restricted to basal keratinocytes in
normal human skin and differentiated 3D skin models, J. Invest. Dermatol. 126
(2006) 2473–2480.
[183] J. Hughes, T.W. Smith, H.W. Kosterlitz, L.A. Fothergill, B.A. Morgan, H.R. Morris,
Identiﬁcation of two related pentapeptides from the brain with potent opiate ago-
nist activity, Nature 258 (1975) 577–580.
[184] J. Hughes, H.W. Kosterlitz, T.W. Smith, The distribution of methionine-enkephalin
and leucine-enkephalin in the brain and peripheral tissues, Br. J. Pharmacol. 61
(1977) 639–647.
[185] T.B. Casale, S. Bowman, M. Kaliner, Induction of human cutaneous mast cell
degranulation by opiates and endogenous opioid peptides: evidence for
opiate and nonopiate receptor participation, J. Allergy Clin. Immunol. 73
(1984) 775–781.
[186] R. Saucedo, S. Erill, Morphine-induced skin wheals: a possible model for the study
of histamine release, Clin. Pharmacol. Ther. 38 (1985) 365–370.
[187] B. Fjellner, O. Hagermark, Potentiation of histamine-induced itch and ﬂare re-
sponses in human skin by the enkephalin analogue FK-33-824, beta-endorphin
and morphine, Arch. Dermatol. Res. 274 (1982) 29–37.
[188] J. Katcher, D. Walsh, Opioid-induced itching: morphine sulfate and hydromorphone
hydrochloride, J. Pain Symptom Manag. 17 (1999) 70–72.
[189] B.L. Kieffer, Opioids: ﬁrst lessons from knockout mice, Trends Pharmacol. Sci. 20
(1999) 19–26.
[190] M.C. Ko, N.N. Naughton, An experimental itch model in monkeys: characterization
of intrathecal morphine-induced scratching and antinociception, Anesthesiology
92 (2000) 795–805.
[191] Y. Kuraishi, T. Yamaguchi, T. Miyamoto, Itch–scratch responses induced by opioids
through central mu opioid receptors in mice, J. Biomed. Sci. 7 (2000) 248–252.
[192] M.C. Ko, M.S. Song, T. Edwards, H. Lee, N.N. Naughton, The role of central mu opioid
receptors in opioid-induced itch in primates, J. Pharmacol. Exp. Ther. 310 (2004)
169–176.
[193] S.B. McMahon, M. Koltzenburg, Itching for an explanation, Trends Neurosci. 15
(1992) 497–501.
[194] E. Carstens, Responses of rat spinal dorsal horn neurons to intracutaneousmicroin-
jection of histamine, capsaicin, and other irritants, J. Neurophysiol. 77 (1997)
2499–2514.
[195] M.C. Lagerstrom, K. Rogoz, B. Abrahamsen, A.L. Lind, C. Olund, C. Smith, J.A.
Mendez, A. Wallen-Mackenzie, J.N. Wood, K. Kullander, A sensory subpopulation
depends on vesicular glutamate transporter 2 for mechanical pain, and together
with substance P, inﬂammatory pain, Proc. Natl. Acad. Sci. U. S. A. 108 (2011)
5789–5794.
[196] S. Inan, A. Cowan, Nalfuraﬁne, a kappa opioid receptor agonist, inhibits scratching
behavior secondary to cholestasis induced by chronic ethynylestradiol injections in
rats, Pharmacol. Biochem. Behav. 85 (2006) 39–43.
[197] M.C. Ko, S.M. Husbands, Effects of atypical kappa-opioid receptor agonists on intra-
thecal morphine-induced itch and analgesia in primates, J. Pharmacol. Exp. Ther.
328 (2009) 193–200.
[198] B. Wikstrom, R. Gellert, S.D. Ladefoged, Y. Danda, M. Akai, K. Ide, M. Ogasawara, Y.
Kawashima, K. Ueno, A. Mori, Y. Ueno, Kappa-opioid system in uremic pruritus:
multicenter, randomized, double-blind, placebo-controlled clinical studies, J. Am.
Soc. Nephrol. 16 (2005) 3742–3747 (Epub 2005 Oct 3726).
[199] H. Kumagai, T. Ebata, K. Takamori, T. Muramatsu, H. Nakamoto, H. Suzuki, Effect of
a novel kappa-receptor agonist, nalfuraﬁne hydrochloride, on severe itch in 337
haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled
study, Nephrol. Dial. Transplant. 25 (2010) 1251–1257.
[200] P.M. Lembo, E. Grazzini, T. Groblewski, D. O'Donnell, M.O. Roy, J. Zhang, C. Hoffert, J.
Cao, R. Schmidt, M. Pelletier, M. Labarre, M. Gosselin, Y. Fortin, D. Banville, S.H.
Shen, P. Strom, K. Payza, A. Dray, P. Walker, S. Ahmad, Proenkephalin A gene prod-
ucts activate a new family of sensory neuron-speciﬁc GPCRs, Nat. Neurosci. 5
(2002) 201–209.
[201] V. Di Marzo, L.D. Petrocellis, Plant, synthetic, and endogenous cannabinoids in
medicine, Annu. Rev. Med. 57 (2006) 553–574.[202] U. Binzen, W. Greffrath, S. Hennessy, M. Bausen, S. Saaler-Reinhardt, R.D. Treede,
Co-expression of the voltage-gated potassium channel Kv1.4 with transient recep-
tor potential channels (TRPV1 and TRPV2) and the cannabinoid receptor CB1 in rat
dorsal root ganglion neurons, Neuroscience 142 (2006) 527–539 (Epub 2006 Aug
2004).
[203] S. Stander, M. Schmelz, D. Metze, T. Luger, R. Rukwied, Distribution of cannabinoid
receptor 1 (CB1) and 2 (CB2) on sensory nerve ﬁbers and adnexal structures in
human skin, J. Dermatol. Sci. 38 (2005) 177–188.
[204] M. Dvorak, A. Watkinson, F. McGlone, R. Rukwied, Histamine induced responses
are attenuated by a cannabinoid receptor agonist in human skin, Inﬂamm. Res.
52 (2003) 238–245.
[205] S. Stander, H.W. Reinhardt, T.A. Luger, Topical cannabinoid agonists. An effective
new possibility for treating chronic pruritus, Hautarzt 57 (2006) 801–807.
[206] M.M. Ibrahim, F. Porreca, J. Lai, P.J. Albrecht, F.L. Rice, A. Khodorova, G. Davar, A.
Makriyannis, T.W. Vanderah, H.P. Mata, T.P. Malan Jr., CB2 cannabinoid receptor
activation produces antinociception by stimulating peripheral release of endoge-
nous opioids, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3093–3098 (Epub 2005
Feb 3010).
[207] H. Hermann, L. De Petrocellis, T. Bisogno, A. Schiano Moriello, B. Lutz, V. Di Marzo,
Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1
receptor-mediated response, Cell. Mol. Life Sci. 60 (2003) 607–616.
[208] V.A. Botchkarev, M. Yaar, E.M. Peters, S.P. Raychaudhuri, N.V. Botchkareva, A.
Marconi, S.K. Raychaudhuri, R. Paus, C. Pincelli, Neurotrophins in skin biology
and pathology, J. Invest. Dermatol. 126 (2006) 1719–1727.
[209] C. Pincelli, C. Sevignani, R. Manfredini, A. Grande, F. Fantini, L. Bracci-Laudiero, L.
Aloe, S. Ferrari, A. Cossarizza, A. Giannetti, Expression and function of nerve growth
factor and nerve growth factor receptor on cultured keratinocytes, J. Invest.
Dermatol. 103 (1994) 13–18.
[210] V.A. Botchkarev, M. Metz, N.V. Botchkareva, P. Welker, M. Lommatzsch, H. Renz, R.
Paus, Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 act
as “epitheliotrophins” in murine skin, Lab. Invest. 79 (1999) 557–572.
[211] H. Kobayashi, G.J. Gleich, J.H. Butterﬁeld, H. Kita, Human eosinophils produce
neurotrophins and secrete nerve growth factor on immunologic stimuli, Blood
99 (2002) 2214–2220.
[212] D.A. Groneberg, F. Serowka, N. Peckenschneider, M. Artuc, A. Grutzkau, A. Fischer,
B.M. Henz, P. Welker, Gene expression and regulation of nerve growth factor in
atopic dermatitis mast cells and the human mast cell line-1, J. Neuroimmunol.
161 (2005) 87–92.
[213] S.P. Raychaudhuri, W.Y. Jiang, E.M. Farber, Psoriatic keratinocytes express high
levels of nerve growth factor, Acta Derm. Venereol. 78 (1998) 84–86.
[214] J. Lazar, T. Szabo, R. Marincsak, L. Kovacs, P.M. Blumberg, T. Biro, Sensitization of re-
combinant vanilloid receptor-1 by various neurotrophic factors, Life Sci. 75 (2004)
153–163.
[215] Y.C. Dou, L. Hagstromer, L. Emtestam, O. Johansson, Increased nerve growth factor
and its receptors in atopic dermatitis: an immunohistochemical study, Arch.
Dermatol. Res. 298 (2006) 31–37.
[216] M. Schmelz, K. Michael, C. Weidner, R. Schmidt, H.E. Torebjork, H.O. Handwerker,
Which nerve ﬁbers mediate the axon reﬂex ﬂare in human skin? Neuroreport 11
(2000) 645–648.
[217] M. Schmelz, M. Hilliges, R. Schmidt, K. Orstavik, C. Vahlquist, C. Weidner, H.O.
Handwerker, H.E. Torebjork, Active “itch ﬁbers” in chronic pruritus, Neurology
61 (2003) 564–566.
[218] A. Dallos, M. Kiss, H. Polyanka, A. Dobozy, L. Kemeny, S. Husz, Effects of the
neuropeptides substance P, calcitonin gene-related peptide, vasoactive intes-
tinal polypeptide and galanin on the production of nerve growth factor and in-
ﬂammatory cytokines in cultured human keratinocytes, Neuropeptides 40
(2006) 251–263.
[219] M. Toyoda, M. Nakamura, T. Makino, T. Hino, M. Kagoura, M. Morohashi, Nerve
growth factor and substance P are useful plasma markers of disease activity in
atopic dermatitis, Br. J. Dermatol. 147 (2002) 71–79.
[220] U. Raap, T. Werfel, C. Goltz, N. Deneka, K. Langer, M. Bruder, A. Kapp, G. Schmid-Ott,
B. Wedi, Circulating levels of brain-derived neurotrophic factor correlate with dis-
ease severity in the intrinsic type of atopic dermatitis, Allergy 61 (2006)
1416–1418.
[221] K. Tokime, R. Katoh-Semba, K. Yamanaka, A. Mizoguchi, H. Mizutani, Enhanced
production and secretion of glial cell line-derived neurotrophic factor and nerve
growth factor from the skin in atopic dermatitis mouse model, Arch. Dermatol.
Res. 300 (2008) 343–352.
[222] K. Nakanaga, K. Hama, J. Aoki, Autotaxin — an LPA producing enzyme with diverse
functions, J. Biochem. 148 (2010) 13–24.
[223] T. Hashimoto, H. Ohata, K. Momose, Itch–scratch responses induced by
lysophosphatidic acid in mice, Pharmacology 72 (2004) 51–56.
[224] A.E. Kremer, J.J. Martens, W. Kulik, F. Rueff, E.M. Kuiper, H.R. van Buuren, K.J.
van Erpecum, J. Kondrackiene, J. Prieto, C. Rust, V.L. Geenes, C. Williamson,
W.H. Moolenaar, U. Beuers, R.P. Oude Elferink, Lysophosphatidic acid is a po-
tential mediator of cholestatic pruritus, Gastroenterology 139 (2010)
1008–1018.
[225] H.J. Kim, H. Kim, E.S. Han, S.M. Park, J.Y. Koh, K.M. Kim, M.S. Noh, J.J. Kim, C.H. Lee,
Characterizations of sphingosylphosphorylcholine-induced scratching responses
in ICR mice using naltrexon, capsaicin, ketotifen and Y-27632, Eur. J. Pharmacol.
583 (2008) 92–96.
[226] T. Andoh, S. Haza, A. Saito, Y. Kuraishi, Involvement of leukotriene B(4) in sponta-
neous itch-related behaviour in NC mice with atopic dermatitis-like skin lesions,
Exp. Dermatol. 20 (2011) 894–898.
[227] B. Fjellner, O. Hagermark, Experimental pruritus evoked by platelet activating fac-
tor (PAF-acether) in human skin, Acta Derm. Venereol. 65 (1985) 409–412.
888 A.E. Kremer et al. / Biochimica et Biophysica Acta 1842 (2014) 869–892[228] M. Kato, T. Kurose, T. Oda, S. Miyaji, The role of platelet activating factor and the
efﬁcacy of apafant ophthalmic solution in experimental allergic conjunctivitis, J.
Ocul. Pharmacol. Ther. 19 (2003) 315–324.
[229] M. Vogelsang, G. Heyer, O.P. Hornstein, Acetylcholine induces different cutaneous
sensations in atopic and non-atopic subjects, Acta Derm. Venereol. 75 (1995)
434–436.
[230] G. Heyer, M. Vogelgsang, O.P. Hornstein, Acetylcholine is an inducer of itching in
patients with atopic eczema, J. Dermatol. 24 (1997) 621–625.
[231] R. Rukwied, G. Heyer, Administration of acetylcholine and vasoactive intestinal
polypeptide to atopic eczema patients, Exp. Dermatol. 8 (1999) 39–45.
[232] R. Rukwied, G. Lischetzki, F. McGlone, G. Heyer, M. Schmelz, Mast cell mediators
other than histamine induce pruritus in atopic dermatitis patients: a dermal mi-
crodialysis study, Br. J. Dermatol. 142 (2000) 1114–1120.
[233] T. Miyamoto, H. Nojima, Y. Kuraishi, Intradermal cholinergic agonists induce
itch-associated response via M3 muscarinic acetylcholine receptors in mice, Jpn.
J. Pharmacol. 88 (2002) 351–354.
[234] N. Bernardini, S.K. Sauer, R. Haberberger, M.J. Fischer, P.W. Reeh, Excitatory nicotin-
ic and desensitizing muscarinic (M2) effects on C-nociceptors in isolated rat skin, J.
Neurosci. Off. J. Soc. Neurosci. 21 (2001) 3295–3302.
[235] O. Hagermark, Studies on experimental itch induced by kallikrein and bradykinin,
Acta Derm. Venereol. 54 (1974) 397–400.
[236] F.E. Cormia, J.W. Dougherty, Proteolytic activity in development of pain and
itching. Cutaneous reactions to bradykinin and kallikrein, J. Invest. Dermatol. 35
(1960) 21–26.
[237] M. Schmelz, R. Schmidt, C. Weidner, M. Hilliges, H.E. Torebjork, H.O. Handwerker,
Chemical response pattern of different classes of C-nociceptors to pruritogens
and algogens, J. Neurophysiol. 89 (2003) 2441–2448.
[238] E. Lang, A. Novak, P.W. Reeh, H.O. Handwerker, Chemosensitivity of ﬁne afferents
from rat skin in vitro, J. Neurophysiol. 63 (1990) 887–901.
[239] W. Koppert, P. Martus, P.W. Reeh, Interactions of histamine and bradykinin on
polymodal C-ﬁbres in isolated rat skin, Eur. J. Pain 5 (2001) 97–106.
[240] M. Hosogi, M. Schmelz, Y. Miyachi, A. Ikoma, Bradykinin is a potent pruritogen in
atopic dermatitis: a switch from pain to itch, Pain 126 (2006) 16–23.
[241] J. Liang, Y. He, W. Ji, Bradykinin-evoked scratching responses in complete Freund's
adjuvant-inﬂamed skin through activation of B1 receptor, Exp. Biol. Med. (May-
wood) 237 (2012) 318–326.
[242] K. Mizumura, T. Sugiura, K. Katanosaka, R.K. Banik, Y. Kozaki, Excitation and sensi-
tization of nociceptors by bradykinin: what do we know? Exp. Brain Res. 196
(2009) 53–65.
[243] L.R. Avula, R. Buckinx, H. Favoreel, E. Cox, D. Adriaensen, L. Van Nassauw, J.P.
Timmermans, Expression and distribution patterns of Mas-related gene receptor
subtypes A–H in the mouse intestine: inﬂammation-induced changes, Histochem.
Cell Biol. 139 (2013) 639–658.
[244] B. Namer, P. Reeh, Scratching an itch, Nat. Neurosci. 16 (2013) 117–118.
[245] C. Ma, H. Nie, Q. Gu, P. Sikand, R.H. Lamotte, In vivo responses of cutaneous
C-mechanosensitive neurons in mouse to punctate chemical stimuli that elicit
itch and nociceptive sensations in humans, J. Neurophysiol. 107 (2012) 357–363.
[246] R. Kralovics, F. Passamonti, A.S. Buser, S.S. Teo, R. Tiedt, J.R. Passweg, A. Tichelli, M.
Cazzola, R.C. Skoda, A gain-of-function mutation of JAK2 in myeloproliferative dis-
orders, N. Engl. J. Med. 352 (2005) 1779–1790.
[247] A.M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli,
R.M. Marﬁsi, G. Finazzi, V. Guerini, F. Fabris, M.L. Randi, V. De Stefano, S.
Caberlon, A. Tafuri, M. Ruggeri, G. Specchia, V. Liso, E. Rossi, E. Pogliani, L.
Gugliotta, A. Bosi, T. Barbui, Clinical proﬁle of homozygous JAK2 617V N F mutation
in patients with polycythemia vera or essential thrombocythemia, Blood 110
(2007) 840–846.
[248] A. Tefferi, T.L. Lasho, S.M. Schwager, J.S. Strand,M. Elliott, R. Mesa, C.Y. Li, M.Wadleigh,
S.J. Lee, D.G. Gilliland, The clinical phenotype of wild-type, heterozygous, and homo-
zygous JAK2V617F in polycythemia vera, Cancer 106 (2006) 631–635.
[249] H.S. Gilbert, R.R. Warner, L.R. Wasserman, A study of histamine in myeloprolifera-
tive disease, Blood 28 (1966) 795–806.
[250] F. Diehn, A. Tefferi, Pruritus in polycythaemia vera: prevalence, laboratory corre-
lates and management, Br. J. Haematol. 115 (2001) 619–621.
[251] K.S. Saini, M.M. Patnaik, A. Tefferi, Polycythemia vera-associated pruritus and its
management, Eur. J. Clin. Invest. 40 (2010) 828–834.
[252] R.A. Mesa, J. Niblack, M. Wadleigh, S. Verstovsek, J. Camoriano, S. Barnes, A.D. Tan,
P.J. Atherton, J.A. Sloan, A. Tefferi, The burden of fatigue and quality of life in mye-
loproliferative disorders (MPDs): an international Internet-based survey of 1179
MPD patients, Cancer 109 (2007) 68–76.
[253] A. Tefferi, Polycythemia vera: a comprehensive review and clinical recommenda-
tions, Mayo Clin. Proc. 78 (2003) 174–194.
[254] E.J. Fitzsimons, J.H. Dagg, E.J. McAllister, Pruritus of polycythaemia vera: a place for
pizotifen? Br. Med. J. (Clin. Res. Ed.) 283 (1981) 277.
[255] A. Tefferi, R. Fonseca, Selective serotonin reuptake inhibitors are effective in the
treatment of polycythemia vera-associated pruritus, Blood 99 (2002) 2627.
[256] J.B. Smith, A.L. Willis, Aspirin selectively inhibits prostaglandin production in
human platelets, Nat. New Biol. 231 (1971) 235–237.
[257] T. Eichholtz, K. Jalink, I. Fahrenfort, W.H. Moolenaar, The bioactive phospholipid
lysophosphatidic acid is released from activated platelets, Biochem. J. 291 (Pt 3)
(1993) 677–680.
[258] G. Gueguen, B. Gaige, J.M. Grevy, P. Rogalle, J. Bellan, M. Wilson, A. Klaebe, F. Pont,
M.F. Simon, H. Chap, Structure–activity analysis of the effects of lysophosphatidic
acid on platelet aggregation, Biochemistry 38 (1999) 8440–8450.
[259] Y.J. Xu, O.A. Aziz, P. Bhugra, A.S. Arneja, M.R. Mendis, N.S. Dhalla, Potential role of
lysophosphatidic acid in hypertension and atherosclerosis, Can. J. Cardiol. 19
(2003) 1525–1536.[260] H.K. Steinman, A. Kobza-Black, T.M. Lotti, L. Brunetti, E. Panconesi, M.W. Greaves,
Polycythaemia rubra vera and water-induced pruritus: blood histamine levels
and cutaneous ﬁbrinolytic activity before and after water challenge, Br. J. Dermatol.
116 (1987) 329–333.
[261] L. Pieri, C. Bogani, P. Guglielmelli, M. Zingariello, R.A. Rana, N. Bartalucci, A. Bosi,
A.M. Vannucchi, The JAK2V617 mutation induces constitutive activation and ago-
nist hypersensitivity in basophils from patients with polycythemia vera,
Haematologica 94 (2009) 1537–1545.
[262] G.L. Scott, R.J. Horton, Pruritus, cimetidine and polycythemia, N. Engl. J. Med. 300
(1979) 433–434.
[263] J.G. Buchanan, R.V. Ameratunga, R.C. Hawkins, Polycythemia vera and
water-induced pruritus: evidence against mast cell involvement, Pathology 26
(1994) 43–45.
[264] M.B. Abdel-Naser, M.S. Zaki, M.H. Mousa, H. Hamed, M.S. Rizk, H.E. Mohamed, M.A.
Habib, Cutaneous mononuclear cells and eosinophils are signiﬁcantly increased
after warm water challenge in pruritic areas of polycythemia vera, J. Cutan. Pathol.
34 (2007) 924–929.
[265] M.B. Abdel-Naser, H. Gollnick, C.E. Orfanos, Aquagenic pruritus as a presenting
symptom of polycythemia vera, Dermatology 187 (1993) 130–133.
[266] J. Wang, T. Ishii, W. Zhang, S. Sozer, Y. Dai, J. Mascarenhas, V. Najfeld, Z.J. Zhao, R.
Hoffman, N. Wisch, M. Xu, Involvement of mast cells by the malignant process in
patients with Philadelphia chromosome negative myeloproliferative neoplasms,
Leukemia 23 (2009) 1577–1586.
[267] S. Verstovsek, H. Kantarjian, R.A. Mesa, A.D. Pardanani, J. Cortes-Franco, D.A.
Thomas, Z. Estrov, J.S. Fridman, E.C. Bradley, S. Erickson-Viitanen, K. Vaddi, R.
Levy, A. Tefferi, Safety and efﬁcacy of INCB018424, a JAK1 and JAK2 inhibitor, in
myeloﬁbrosis, N. Engl. J. Med. 363 (2010) 1117–1127.
[268] R.A. Mesa, H. Kantarjian, A. Tefferi, A. Dueck, R. Levy, K. Vaddi, S. Erickson-Viitanen,
D.A. Thomas, J. Cortes, G. Borthakur, A.D. Pardanani, Z. Estrov, S. Verstovsek, Evalu-
ating the serial use of the Myeloﬁbrosis Symptom Assessment Form for measuring
symptomatic improvement: performance in 87 myeloﬁbrosis patients on a JAK1
and JAK2 inhibitor (INCB018424) clinical trial, Cancer 117 (2011) 4869–4877.
[269] R.A. Mesa, J. Gotlib, V. Gupta, J.V. Catalano, M.W. Deininger, A.L. Shields, C.B. Miller,
R.T. Silver, M. Talpaz, E.F. Winton, J.H. Harvey, T. Hare, S. Erickson-Viitanen, W. Sun,
V. Sandor, R.S. Levy, H.M. Kantarjian, S. Verstovsek, Effect of ruxolitinib therapy on
myeloﬁbrosis-related symptoms and other patient-reported outcomes in
COMFORT-I: a randomized, double-blind, placebo-controlled trial, J. Clin. Oncol.
Off. J. Am. Soc. Clin. Oncol. 31 (2013) 1285–1292.
[270] A. Pardanani, J.R. Gotlib, C. Jamieson, J.E. Cortes, M. Talpaz, R.M. Stone, M.H.
Silverman, D.G. Gilliland, J. Shorr, A. Tefferi, Safety and efﬁcacy of TG101348, a se-
lective JAK2 inhibitor, in myeloﬁbrosis, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29
(2011) 789–796.
[271] R. Sharon, I. Tatarsky, Y. Ben-Arieh, Treatment of polycythemia vera with hydroxy-
urea, Cancer 57 (1986) 718–720.
[272] J.J. Kiladjian, C. Chomienne, P. Fenaux, Interferon-alpha therapy in bcr-abl-negative
myeloproliferative neoplasms, Leukemia 22 (2008) 1990–1998.
[273] A. Rambaldi, C.M. Dellacasa, G. Finazzi, A. Carobbio, M.L. Ferrari, P. Guglielmelli, E.
Gattoni, S. Salmoiraghi, M.C. Finazzi, S. Di Tollo, C. D'Urzo, A.M. Vannucchi, G.
Barosi, T. Barbui, A pilot study of the histone-deacetylase inhibitor givinostat in pa-
tients with JAK2V617F positive chronic myeloproliferative neoplasms, Br. J.
Haematol. 150 (2010) 446–455.
[274] S. Gangemi, A. Allegra, E. Pace, A. Alonci, M. Ferraro, A. Petrungaro, S. Saitta, D.
Gerace, S. Russo, G. Penna, C. Musolino, Evaluation of interleukin-23 plasma levels
in patients with polycythemia vera and essential thrombocythemia, Cell. Immunol.
278 (2012) 91–94.
[275] P.R. Dallman, E. Beutler, C.A. Finch, Effects of iron deﬁciency exclusive of anaemia,
Br. J. Haematol. 40 (1978) 179–184.
[276] W.G. Rector Jr., N.J. Fortuin, C.L. Conley, Non-hematologic effects of chronic iron de-
ﬁciency. A study of patients with polycythemia vera treated solely with venesec-
tions, Medicine (Baltimore) 61 (1982) 382–389.
[277] H.H. Salem, M.B. Van der Weyden, I.F. Young, J.S. Wiley, Pruritus and severe iron
deﬁciency in polycythaemia vera, Br. Med. J. (Clin. Res. Ed.) 285 (1982) 91–92.
[278] J.L. Spivak, Narrative review: Thrombocytosis, polycythemia vera, and JAK2 muta-
tions: the phenotypicmimicry of chronic myeloproliferation, Ann. Intern. Med. 152
(2010) 300–306.
[279] E.J. Baxter, L.M. Scott, P.J. Campbell, C. East, N. Fourouclas, S. Swanton, G.S.
Vassiliou, A.J. Bench, E.M. Boyd, N. Curtin, M.A. Scott, W.N. Erber, A.R. Green, Ac-
quired mutation of the tyrosine kinase JAK2 in human myeloproliferative disor-
ders, Lancet 365 (2005) 1054–1061.
[280] P. Guglielmelli, G. Barosi, A. Rambaldi, R. Marchioli, A. Masciulli, L. Tozzi, F.
Biamonte, N. Bartalucci, E. Gattoni, M.L. Lupo, G. Finazzi, A. Pancrazzi, E.
Antonioli, M.C. Susini, L. Pieri, E. Malevolti, E. Usala, U. Occhini, A. Grossi, S.
Caglio, S. Paratore, A. Bosi, T. Barbui, A.M. Vannucchi, Safety and efﬁcacy of evero-
limus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with my-
eloﬁbrosis, Blood 118 (2011) 2069–2076.
[281] H.J. Wilkins, M.M. Crane, K. Copeland,W.V.Williams, Hypereosinophilic syndrome:
an update, Am. J. Hematol. 80 (2005) 148–157.
[282] F.E. Roufosse, M. Goldman, E. Cogan, Hypereosinophilic syndromes, Orphanet J.
Rare Dis. 2 (2007) 37.
[283] J.A. Newton, A.K. Singh, M.W. Greaves, C.J. Spry, Aquagenic pruritus associatedwith
the idiopathic hypereosinophilic syndrome, Br. J. Dermatol. 122 (1990) 103–106.
[284] H.U. Simon, S.G. Plotz, R. Dummer, K. Blaser, Abnormal clones of T cells producing
interleukin-5 in idiopathic eosinophilia, N. Engl. J. Med. 341 (1999) 1112–1120.
[285] P.U. Ogbogu, B.S. Bochner, J.H. Butterﬁeld, G.J. Gleich, J. Huss-Marp, J.E. Kahn, K.M.
Leiferman, T.B. Nutman, F. Pfab, J. Ring, M.E. Rothenberg, F. Roufosse, M.H. Sajous, J.
Sheikh, D. Simon, H.U. Simon, M.L. Stein, A. Wardlaw, P.F. Weller, A.D. Klion,
889A.E. Kremer et al. / Biochimica et Biophysica Acta 1842 (2014) 869–892Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical char-
acteristics and response to therapy, J. Allergy Clin. Immunol. 124 (2009)
1319–1325 (e1313).
[286] M.E. Rothenberg, A.D. Klion, F.E. Roufosse, J.E. Kahn, P.F. Weller, H.U. Simon, L.B.
Schwartz, L.J. Rosenwasser, J. Ring, E.F. Grifﬁn, A.E. Haig, P.I. Frewer, J.M. Parkin,
G.J. Gleich, Treatment of patients with the hypereosinophilic syndrome with
mepolizumab, N. Engl. J. Med. 358 (2008) 1215–1228.
[287] J.M. Bennett, D. Catovsky, M.T. Daniel, G. Flandrin, D.A. Galton, H.R. Gralnick, C.
Sultan, Proposals for the classiﬁcation of the myelodysplastic syndromes, Br. J.
Haematol. 51 (1982) 189–199.
[288] M. Albitar, T. Manshouri, Y. Shen, D. Liu, M. Beran, H.M. Kantarjian, A. Rogers, I.
Jilani, C.W. Lin, S. Pierce, E.J. Freireich, E.H. Estey, Myelodysplastic syndrome is
not merely “preleukemia”, Blood 100 (2002) 791–798.
[289] J.A. McGrath, M.W. Greaves, Aquagenic pruritus and the myelodysplastic syn-
drome, Br. J. Dermatol. 123 (1990) 414–415.
[290] J.A. McGrath, M.W. Greaves, A.P. Warin, Aquagenic pruritus and myelodysplastic
syndrome, Am. J. Hematol. 37 (1991) 63.
[291] H.D. Menage, P.G. Norris, J.L. Hawk, M.W. Graves, The efﬁcacy of psoralen
photochemotherapy in the treatment of aquagenic pruritus, Br. J. Dermatol. 129
(1993) 163–165.
[292] N. Khalifa, C.R. Singer, A.K. Black, Aquagenic pruritus in a patient associated with
myelodysplasia and T-cell non-Hodgkin's lymphoma, J. Am. Acad. Dermatol. 46
(2002) 144–145.
[293] C. Akin, D.D. Metcalfe, Systemic mastocytosis, Annu. Rev. Med. 55 (2004) 419–432.
[294] H.P. Horny, K. Sotlar, P. Valent, Mastocytosis: state of the art, Pathobiology 74
(2007) 121–132.
[295] A. Orfao, A.C. Garcia-Montero, L. Sanchez, L. Escribano, Recent advances in the un-
derstanding of mastocytosis: the role of KIT mutations, Br. J. Haematol. 138 (2007)
12–30.
[296] C. Akin, Clonality and molecular pathogenesis of mastocytosis, Acta Haematol. 114
(2005) 61–69.
[297] A.C. Garcia-Montero, M. Jara-Acevedo, C. Teodosio, M.L. Sanchez, R. Nunez, A.
Prados, I. Aldanondo, L. Sanchez, M. Dominguez, L.M. Botana, F. Sanchez-Jimenez,
K. Sotlar, J. Almeida, L. Escribano, A. Orfao, KIT mutation in mast cells and other
bone marrow hematopoietic cell lineages in systemic mast cell disorders: a pro-
spective study of the Spanish Network on Mastocytosis (REMA) in a series of
113 patients, Blood 108 (2006) 2366–2372.
[298] N. Harir, C. Boudot, K. Friedbichler, K. Sonneck, R. Kondo, S. Martin-Lanneree, L.
Kenner, M. Kerenyi, S. Yahiaoui, V. Gouilleux-Gruart, J. Gondry, L. Benit, I.
Dusanter-Fourt, K. Lassoued, P. Valent, R. Moriggl, F. Gouilleux, Oncogenic Kit con-
trols neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade,
Blood 112 (2008) 2463–2473.
[299] B.V. Kettelhut, D.D. Metcalfe, Pediatric mastocytosis, Ann. Allergy 73 (1994)
197–202 (quiz 202–197).
[300] M.K. Church, F. Levi-Schaffer, The human mast cell, J. Allergy Clin. Immunol. 99
(1997) 155–160.
[301] K. Hartmann, S.B. Bruns, B.M. Henz, Mastocytosis: review of clinical and experi-
mental aspects, J. Investig. Dermatol. Symp. Proc. 6 (2001) 143–147.
[302] T. Koide, T. Nakajima, T. Makifuchi, N. Fukuhara, Systemic mastocytosis and recur-
rent anaphylactic shock, Lancet 359 (2002) 2084.
[303] A.S. Worobec, Treatment of systemic mast cell disorders, Hematol. Oncol. Clin.
North Am. 14 (2000) 659–687 vii.
[304] N.A. Soter, K.F. Austen, S.I. Wasserman, Oral disodium cromoglycate in the treat-
ment of systemic mastocytosis, N. Engl. J. Med. 301 (1979) 465–469.
[305] G. Granerus, J.H. Olafsson, G. Roupe, Treatment of twomastocytosis patients with a
histidine decarboxylase inhibitor, Agents Actions 16 (1985) 244–248.
[306] J. Tolar, W.D. Tope, J.P. Neglia, Leukotriene-receptor inhibition for the treatment of
systemic mastocytosis, N. Engl. J. Med. 350 (2004) 735–736.
[307] P.M. Mauch, L.A. Kalish, M. Kadin, C.N. Coleman, R. Osteen, S. Hellman, Patterns of
presentation of Hodgkin disease. Implications for etiology and pathogenesis, Can-
cer 71 (1993) 2062–2071.
[308] P.G. Gobbi, G. Attardo-Parrinello, G. Lattanzio, S.C. Rizzo, E. Ascari, Severe pruritus
should be a B-symptom in Hodgkin's disease, Cancer 51 (1983) 1934–1936.
[309] S.S. Kumar, M. Kuruvilla, G.S. Pai, M. Dinesh, Cutaneous manifestations of
non-Hodgkin's lymphoma, Indian J. Dermatol. Venereol. Leprol. 69 (2003)
12–15.
[310] M. Rubenstein, M. Duvic, Cutaneous manifestations of Hodgkin's disease, Int. J.
Dermatol. 45 (2006) 251–256.
[311] B.D. Goldman, H.K. Koh, Pruritus and malignancy, in: J.D. Bernhard (Ed.), Itch.
Mechanisms and Management of Pruritus, McGraw-Hill, New York, 1994,
pp. 299–319.
[312] G. Yosipovitch, Chronic pruritus: a paraneoplastic sign, Dermatol. Ther. 23 (2010)
590–596.
[313] M. Krajnik, Z. Zylicz, Pruritus in advanced internal diseases. Pathogenesis and treat-
ment, Neth. J. Med. 58 (2001) 27–40.
[314] G.B. Mills, W.H. Moolenaar, The emerging role of lysophosphatidic acid in cancer,
Nat. Rev. Cancer 3 (2003) 582–591.
[315] J.P. Aymard, P. Lederlin, F. Witz, J.N. Colomb, R. Herbeuval, B. Weber, Cimetidine for
pruritus in Hodgkin's disease, Br. Med. J. 280 (1980) 151–152.
[316] E. Weisshaar, F. Dalgard, Epidemiology of itch: adding to the burden of skin mor-
bidity, Acta Derm. Venereol. 89 (2009) 339–350.
[317] K.W. Eriksen, K. Kaltoft, G. Mikkelsen, M. Nielsen, Q. Zhang, C. Geisler, M.H. Nissen,
C. Ropke, M.A. Wasik, N. Odum, Constitutive STAT3-activation in Sezary syndrome:
tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and
growth of leukemic Sezary cells, Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK 15
(2001) 787–793.[318] S.R. Lessin, B.R. Vowels, A.H. Rook, Th2 cytokine proﬁle in cutaneous T-cell lympho-
ma, J. Invest. Dermatol. 105 (1995) 855–856.
[319] K. Asadullah,W.D. Docke, A. Haeussler,W. Sterry, H.D. Volk, Progression ofmycosis
fungoides is associated with increasing cutaneous expression of interleukin-10
mRNA, J. Invest. Dermatol. 107 (1996) 833–837.
[320] C.F. Vickers, Iron-deﬁciency pruritus, JAMA 238 (1977) 129.
[321] Y. Aﬁﬁ, F. Aubin, E. Puzenat, A. Degouy, D. Aubrion, B. Hassam, P. Humbert, Pruritus
sine materia: a prospective study of 95 patients, Rev. Med. Interne 25 (2004)
490–493.
[322] H. Takkunen, Iron deﬁciency in the Finnish adult population, Scand. J. Haematol.
Suppl. 25 (1976) 1–91.
[323] R. Camp, Generalized pruritus and its management, Clin. Exp. Dermatol. 7 (1982)
557–563.
[324] E.A.S.L. Clinical Practice Guidelines, Management of cholestatic liver diseases, J.
Hepatol. 51 (2009) 237–267.
[325] K.D. Lindor, M.E. Gershwin, R. Poupon, M. Kaplan, N.V. Bergasa, E.J. Heathcote, Pri-
mary biliary cirrhosis, Hepatology 50 (2009) 291–308.
[326] E.J. Heathcote, Management of primary biliary cirrhosis. The American Association
for the Study of Liver Diseases practice guidelines, Hepatology 31 (2000)
1005–1013.
[327] U. Beuers, Drug insight: mechanisms and sites of action of ursodeoxycholic acid in
cholestasis, Nat. Clin. Pract. Gastroenterol. Hepatol. 3 (2006) 318–328.
[328] A.E. Kremer, U. Beuers, R.P. Oude-Elferink, T. Pusl, Pathogenesis and treatment of
pruritus in cholestasis, Drugs 68 (2008) 2163–2182.
[329] V. Geenes, C. Williamson, Intrahepatic cholestasis of pregnancy, World J.
Gastroenterol. 15 (2009) 2049–2066.
[330] S. Sherlock, P.J. Scheuer, The presentation and diagnosis of 100 patients with pri-
mary biliary cirrhosis, N. Engl. J. Med. 289 (1973) 674–678.
[331] O. James, A.F. Macklon, A.J. Watson, Primary biliary cirrhosis — a revised clinical
spectrum, Lancet 1 (1981) 1278–1281.
[332] N.V. Bergasa, J.K. Mehlman, E.A. Jones, Pruritus and fatigue in primary biliary cir-
rhosis, Baillieres Best Pract. Res. Clin. Gastroenterol. 14 (2000) 643–655.
[333] M. Koulentaki, D. Ioannidou, M. Stefanidou, S. Maraki, I. Drigiannakis, P. Dimoulios,
J.M. Melono, A. Tosca, E.A. Kouroumalis, Dermatological manifestations in primary
biliary cirrhosis patients: a case control study, Am. J. Gastroenterol. 101 (2006)
541–546.
[334] N.T. McPhedran, R.D. Henderson, Pruritus and jaundice, Can. Med. Assoc. J. 92
(1965) 1258–1260.
[335] B. Cribier, F. Samain, D. Vetter, E. Heid, E. Grosshans, Systematic cutaneous exami-
nation in hepatitis C virus infected patients, Acta Derm. Venereol. 78 (1998)
355–357.
[336] S.C. Chia, N.V. Bergasa, D.E. Kleiner, Z. Goodman, J.H. Hoofnagle, A.M. Di Bisceglie,
Pruritus as a presenting symptom of chronic hepatitis C, Dig. Dis. Sci. 43 (1998)
2177–2183.
[337] P. Cacoub, T. Poynard, P. Ghillani, F. Charlotte, M. Olivi, J.C. Piette, P. Opolon, Extra-
hepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment
Virus C, Arthritis Rheum. 42 (1999) 2204–2212.
[338] C.N. Ghent, J.R. Bloomer, Itch in liver disease: facts and speculations, Yale J. Biol.
Med. 52 (1979) 77–82.
[339] T. Pusl, U. Beuers, Ursodeoxycholic acid treatment of vanishing bile duct syn-
dromes, World J. Gastroenterol. 12 (2006) 3487–3495.
[340] N.V. Bergasa, The pruritus of cholestasis, J. Hepatol. 43 (2005) 1078–1088.
[341] J.A. Talwalkar, E. Souto, R.A. Jorgensen, K.D. Lindor, Natural history of pruritus in
primary biliary cirrhosis, Clin. Gastroenterol. Hepatol. 1 (2003) 297–302.
[342] R. Bolier, R.P. Oude Elferink, U. Beuers, Advances in pathogenesis and treatment of
pruritus, Clin. Liver Dis. 17 (2013) 319–329.
[343] J.M. Stapelbroek, K.J. van Erpecum, L.W. Klomp, N.G. Venneman, T.P. Schwartz, G.P.
van Berge Henegouwen, J. Devlin, C.M. van Nieuwkerk, A.S. Knisely, R.H. Houwen,
Nasobiliary drainage induces long-lasting remission in benign recurrent
intrahepatic cholestasis, Hepatology 43 (2006) 51–53.
[344] U. Beuers, G. Gerken, T. Pusl, Biliary drainage transiently relieves intractable pruri-
tus in primary biliary cirrhosis, Hepatology 44 (2006) 280–281.
[345] W.D. Clements, D.M. O'Rourke, B.J. Rowlands, M. Ennis, The role of mast cell activa-
tion in cholestatic pruritus, Agents Actions 41 Spec No (1994) C30–C31.
[346] R.G. Quist, H.T. Ton-Nu, J. Lillienau, A.F. Hofmann, K.E. Barrett, Activation of mast
cells by bile acids, Gastroenterology 101 (1991) 446–456.
[347] K.P. Rioux, K.A. Sharkey, J.L. Wallace, M.G. Swain, Hepatic mucosal mast cell hyper-
plasia in rats with secondary biliary cirrhosis, Hepatology 23 (1996) 888–895.
[348] E.A. Jones, N.V. Bergasa, Evolving concepts of the pathogenesis and treatment of
the pruritus of cholestasis, Can. J. Gastroenterol. 14 (2000) 33–40.
[349] F.T. Frerichs, On jaundice, Chapter V On Diseases of the Liver, John Churchill,
London, 1845, pp. 372–388.
[350] J.B. Carey Jr., Bile acids in the serum of jaundiced patients, Gastroenterology 41
(1961) 285–287.
[351] J. Kirby, K.W. Heaton, J.L. Burton, Pruritic effect of bile salts, Br. Med. J. 4 (1974)
693–695.
[352] D.P. Varadi, Pruritus induced by crude bile and puriﬁed bile acids. Experimental
production of pruritus in human skin, Arch. Dermatol. 109 (1974) 678–681.
[353] E.H. Ahrens Jr., M.A. Payne, H.G. Kunkel, W.J. Eisenmenger, S.H. Blondheim, Primary
biliary cirrhosis, Medicine (Baltimore) 29 (1950) 299–364.
[354] P. Ricci, A.F. Hofmann, L.R. Hagey, R.A. Jorgensen, E. Rolland Dickson, K.D. Lindor,
Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary
cirrhosis, Dig. Dis. Sci. 43 (1998) 1292–1295.
[355] T.B. Van Itallie, S.A. Hashim, R.S. Crampton, D.M. Tennent, The treatment of pruritus
and hypercholesteremia of primary biliary cirrhosis with cholestyramine, N. Engl. J.
Med. 265 (1961) 469–474.
890 A.E. Kremer et al. / Biochimica et Biophysica Acta 1842 (2014) 869–892[356] J.B. Carey Jr., G. Williams, Relief of the pruritus of jaundice with a bile-acid seques-
tering resin, JAMA 176 (1961) 432–435.
[357] Z.H. Oster, E.A. Rachmilewitz, E. Moran, Y. Stein, Relief of pruritus by cholestyr-
amine in chronic liver disease, Isr. J. Med. Sci. 1 (1965) 599–606.
[358] D.V. Datta, S. Sherlock, Cholestyramine for long term relief of the pruritus compli-
cating intrahepatic cholestasis, Gastroenterology 50 (1966) 323–332.
[359] C.M. Hollands, F.J. Rivera-Pedrogo, R. Gonzalez-Vallina, O. Loret-de-Mola, M.
Nahmad, C.A. Burnweit, Ileal exclusion for Byler's disease: an alternative surgical
approach with promising early results for pruritus, J. Pediatr. Surg. 33 (1998)
220–224.
[360] K.M. Emerick, P.F. Whitington, Partial external biliary diversion for intractable
pruritus and xanthomas in Alagille syndrome, Hepatology 35 (2002)
1501–1506.
[361] R.L. Varco, Intermittent external biliary drainage for relief of pruritus in certain
chronic disorders of the liver, Surgery 21 (1947) 43–45.
[362] P.M. Huet, M. Rautureau, D. Dhumeaux, J. Caroli, The effects of biliary drainage in
cholestatic hepatitis, Rev. Med. Chir. Mal. Foie 45 (1970) 271–278.
[363] N. Rupp, Indications and results of percutaneous transhepatic bile-duct drainage,
Chirurg 50 (1979) 233–238.
[364] R.I. Hall, M.E. Denyer, A.H. Chapman, Percutaneous-endoscopic placement of
endoprostheses for relief of jaundice caused by inoperable bile duct strictures, Sur-
gery 107 (1990) 224–227.
[365] P.C. Robson, N. Heffernan, M. Gonen, R. Thornton, L.A. Brody, R. Holmes, K.T.
Brown, A.M. Covey, D. Fleischer, G.I. Getrajdman, W. Jarnagin, C. Sofocleous, L.
Blumgart, M. D'Angelica, Prospective study of outcomes after percutaneous biliary
drainage for malignant biliary obstruction, Ann. Surg. Oncol. 17 (2010)
2303–2311.
[366] V. Singh, A. Bhalla, N. Sharma, P.C. Dheerendra, R. Agarwal, S.K. Mahi, Nasobiliary
drainage in acute cholestatic hepatitis with pruritus, Dig. Liver Dis. 41 (2009)
442–445.
[367] F. Alemi, E. Kwon, D.P. Poole, T. Lieu, V. Lyo, F. Cattaruzza, F. Cevikbas, M. Steinhoff, R.
Nassini, S.Materazzi, R. Guerrero-Alba, E. Valdez-Morales, G.S. Cottrell, K. Schoonjans,
P. Geppetti, S.J. Vanner, N.W. Bunnett, C.U. Corvera, The TGR5 receptor mediates bile
acid-induced itch and analgesia, J. Clin. Invest. 123 (2013) 1513–1530.
[368] C.N. Ghent, J.R. Bloomer, G. Klatskin, Elevations in skin tissue levels of bile acids in
human cholestasis: relation to serum levels and topruritus, Gastroenterology 73
(1977) 1125–1130.
[369] T.C. Bartholomew, J.A. Summerﬁeld, B.H. Billing, A.M. Lawson, K.D. Setchell, Bile
acid proﬁles of human serum and skin interstitial ﬂuid and their relationship to
pruritus studied by gas chromatography–mass spectrometry, Clin. Sci. (Lond.) 63
(1982) 65–73.
[370] M.R. Freedman, R.T. Holzbach, D.R. Ferguson, Pruritus in cholestasis: no direct
causative role for bile acid retention, Am. J. Med. 70 (1981) 1011–1016.
[371] M.G. Swain, Pruritus and lethargy in the primary billary cirrhosis patient, in: J.
Neuberger (Ed.), Primary Biliary Cirrhosis, West End Studios, Eastbourne, 1999,
pp. 75–81.
[372] G.M. Murphy, A. Ross, B.H. Billing, Serum bile acids in primary biliary cirrhosis, Gut
13 (1972) 201–206.
[373] I. Chanarin, L. Szur, Letter: relief of intractable pruritis in polycythaemia rubra vera
with cholestyramine, Br. J. Haematol. 29 (1975) 669–670.
[374] E.M. Kuiper, K.J. van Erpecum, U. Beuers, B.E. Hansen, H.B. Thio, R.A. de Man, H.L.
Janssen, H.R. van Buuren, The potent bile acid sequestrant colesevelam is not effective
in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled
trial, Hepatology 52 (2010) 1334–1340.
[375] C.N. Ghent, J.R. Bloomer, Y.E. Hsia, Efﬁcacy and safety of long-term phenobarbital
therapy of familial cholestasis, J. Pediatr. 93 (1978) 127–132.
[376] C.N. Ghent, S.G. Carruthers, Treatment of pruritus in primary biliary cirrhosis with
rifampin. Results of a double-blind, crossover, randomized trial, Gastroenterology
94 (1988) 488–493.
[377] E.C. Osborn, I.D. Wootton, S.L. da, S. Sherlock, Serum-bile-acid levels in liver dis-
ease, Lancet 2 (1959) 1049–1053.
[378] J. Alva, F.L. Iber, Relief of the pruritus of jaundice with methandrostenolone and
speculations on the nature of pruritus in liver disease, Am. J. Med. Sci. 250
(1965) 60–65.
[379] A.D. Green, K.K. Young, S.G. Lehto, S.B. Smith, J.S. Mogil, Inﬂuence of genotype, dose
and sex on pruritogen-induced scratching behavior in the mouse, Pain 124 (2006)
50–58 (Epub 2006 May 2011).
[380] M.R. Lucey, J.M. Neuberger, R. Williams, Primary biliary cirrhosis in men, Gut 27
(1986) 1373–1376.
[381] R. Kancheva, M. Hill, D. Cibula, H. Vcelakova, L. Kancheva, J. Vrbikova, T. Fait, A.
Parizek, L. Starka, Relationships of circulating pregnanolone isomers and their
polar conjugates to the status of sex, menstrual cycle, and pregnancy, J. Endocrinol.
195 (2007) 67–78.
[382] H. Reyes, J. Sjovall, Bile acids and progesterone metabolites in intrahepatic chole-
stasis of pregnancy, Ann. Med. 32 (2000) 94–106.
[383] T. Pusl, U. Beuers, Intrahepatic cholestasis of pregnancy, Orphanet J. Rare Dis. 2
(2007) 26.
[384] A. Glantz, S.J. Reilly, L. Benthin, F. Lammert, L.A. Mattsson, H.U. Marschall,
Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associ-
ated with decreased progesterone disulphates in urine, Hepatology 47 (2008)
544–551.
[385] S. Abu-Hayyeh, G. Papacleovoulou, A. Lovgren-Sandblom, M. Tahir, O. Oduwole,
N.A. Jamaludin, S. Ravat, V. Nikolova, J. Chambers, C. Selden, M. Rees, H.U.
Marschall, M.G. Parker, C. Williamson, Intrahepatic cholestasis of pregnancy levels
of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a
cholestatic phenotype, Hepatology 57 (2013) 716–726.[386] S.C. Chen, F.S. Wu, Mechanism underlying inhibition of the capsaicin
receptor-mediated current by pregnenolone sulfate in rat dorsal root ganglion
neurons, Brain Res. 1027 (2004) 196–200.
[387] M. Park-Chung, A. Malayev, R.H. Purdy, T.T. Gibbs, D.H. Farb, Sulfated and
unsulfated steroids modulate gamma-aminobutyric acidA receptor function
through distinct sites, Brain Res. 830 (1999) 72–87.
[388] F.S. Wu, T.T. Gibbs, D.H. Farb, Inverse modulation of gamma-aminobutyric acid-
and glycine-induced currents by progesterone, Mol. Pharmacol. 37 (1990)
597–602.
[389] M. Park-Chung, F.S. Wu, R.H. Purdy, A.A. Malayev, T.T. Gibbs, D.H. Farb, Distinct
sites for inverse modulation of N-methyl-D-aspartate receptors by sulfated ste-
roids, Mol. Pharmacol. 52 (1997) 1113–1123.
[390] C.E. Weaver Jr., P. Marek, M. Park-Chung, S.W. Tam, D.H. Farb, Neuroprotective ac-
tivity of a new class of steroidal inhibitors of the N-methyl-D-aspartate receptor,
Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10450–10454.
[391] C.E. Weaver Jr., M. Park-Chung, T.T. Gibbs, D.H. Farb, 17Beta-estradiol protects
against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors,
Brain Res. 761 (1997) 338–341.
[392] R. Rupprecht, F. Holsboer, Neuroactive steroids: mechanisms of action and
neuropsychopharmacological perspectives, Trends Neurosci. 22 (1999) 410–416.
[393] C.H. Wetzel, B. Hermann, C. Behl, E. Pestel, G. Rammes, W. Zieglgansberger, F.
Holsboer, R. Rupprecht, Functional antagonism of gonadal steroids at the
5-hydroxytryptamine type 3 receptor, Mol. Endocrinol. 12 (1998) 1441–1451.
[394] J.E. Bernstein, R. Swift, Relief of intractable pruritus with naloxone, Arch. Dermatol.
115 (1979) 1366–1367.
[395] E.A. Jones, N.V. Bergasa, The pruritus of cholestasis: from bile acids to opiate ago-
nists, Hepatology 11 (1990) 884–887.
[396] D.A. Thomas, G.M.Williams, K. Iwata, D.R. Kenshalo Jr., R. Dubner, Effects of central
administration of opioids on facial scratching in monkeys, Brain Res. 585 (1992)
315–317.
[397] M.G. Swain, R.B. Rothman, H. Xu, J. Vergalla, N.V. Bergasa, E.A. Jones, Endogenous
opioids accumulate in plasma in a rat model of acute cholestasis, Gastroenterology
103 (1992) 630–635.
[398] N.V. Bergasa, J. Vergalla, M.G. Swain, E.A. Jones, Hepatic concentrations of
proenkephalin-derived opioids are increased in a rat model of cholestasis, Liver
16 (1996) 298–302.
[399] J.R. Thornton, M.S. Losowsky, Opioid peptides and primary biliary cirrhosis, BMJ
297 (1988) 1501–1504.
[400] J.R. Spivey, R.A. Jorgensen, G.J. Gores, K.D. Lindor, Methionine-enkephalin concen-
trations correlate with stage of disease but not pruritus in patients with primary
biliary cirrhosis, Am. J. Gastroenterol. 89 (1994) 2028–2032.
[401] N.V. Bergasa, D.A. Thomas, J. Vergalla, M.L. Turner, E.A. Jones, Plasma from patients
with the pruritus of cholestasis induces opioid receptor-mediated scratching in
monkeys, Life Sci. 53 (1993) 1253–1257.
[402] N.V. Bergasa, S.L. Sabol, W.S. Young III, D.E. Kleiner, E.A. Jones, Cholestasis is associ-
ated with preproenkephalin mRNA expression in the adult rat liver, Am. J. Physiol.
268 (1995) G346–G354.
[403] N.V. Bergasa, S. Liau, P. Homel, V. Ghali, Hepatic Met-enkephalin immunoreactivity
is enhanced in primary biliary cirrhosis, Liver 22 (2002) 107–113.
[404] N.V. Bergasa, T.L. Talbot, D.W. Alling, J.M. Schmitt, E.C. Walker, B.L. Baker, J.C.
Korenman, Y. Park, J.H. Hoofnagle, E.A. Jones, A controlled trial of naloxone infu-
sions for the pruritus of chronic cholestasis, Gastroenterology 102 (1992)
544–549.
[405] N.V. Bergasa, D.W. Alling, T.L. Talbot, M.G. Swain, C. Yurdaydin, M.L. Turner, J.M.
Schmitt, E.C. Walker, E.A. Jones, Effects of naloxone infusions in patients with the
pruritus of cholestasis. A double-blind, randomized, controlled trial, Ann. Intern.
Med. 123 (1995) 161–167.
[406] K.L. Carson, T.T. Tran, P. Cotton, A.I. Sharara, C.M. Hunt, Pilot study of the use of nal-
trexone to treat the severe pruritus of cholestatic liver disease, Am. J.
Gastroenterol. 91 (1996) 1022–1023.
[407] F.H.Wolfhagen, E. Sternieri,W.C. Hop, G. Vitale, M. Bertolotti, H.R. Van Buuren, Oral
naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled
study, Gastroenterology 113 (1997) 1264–1269.
[408] N.V. Bergasa, J.M. Schmitt, T.L. Talbot, D.W. Alling, M.G. Swain, M.L. Turner, J.B.
Jenkins, E.A. Jones, Open-label trial of oral nalmefene therapy for the pruritus of
cholestasis, Hepatology 27 (1998) 679–684.
[409] R. Terg, E. Coronel, J. Sorda, A.E. Munoz, J. Findor, Efﬁcacy and safety of oral naltrex-
one treatment for pruritus of cholestasis, a crossover, double blind,
placebo-controlled study, J. Hepatol. 37 (2002) 717–722.
[410] F. Mansour-Ghanaei, A. Taheri, H. Froutan, H. Ghofrani, M. Nasiri-Toosi, A.H.
Bagherzadeh, M.J. Farahvash, S. Mirmomen, N. Ebrahimi-Dariani, E. Farhangi, Z.
Pourrasouli, Effect of oral naltrexone on pruritus in cholestatic patients, World J.
Gastroenterol. 12 (2006) 1125–1128.
[411] J.A. Summerﬁeld, Naloxone modulates the perception of itch in man, Br. J. Clin.
Pharmacol. 10 (1980) 180–183.
[412] E.A. Jones, N.V. Bergasa, The pruritus of cholestasis, Hepatology 29 (1999) 1003–1006.
[413] L. Nelson, N. Vergnolle, C. D'Mello, K. Chapman, T. Le, M.G. Swain, Endogenous
opioid-mediated antinociception in cholestatic mice is peripherally, not centrally,
mediated, J. Hepatol. 44 (2006) 1141–1149 (Epub 2005 Dec 1127).
[414] W.H. Moolenaar, A. Perrakis, Insights into autotaxin: how to produce and present a
lipid mediator, Nat. Rev. Mol. Cell Biol. 12 (2011) 674–679.
[415] A.E. Kremer, R. van Dijk, P. Leckie, F.G. Schaap, E.M. Kuiper, T. Mettang, K.S. Reiners,
U. Raap, H.R. van Buuren, K.J. van Erpecum, N.A. Davies, C. Rust, A. Engert, R. Jalan,
R.P. Oude Elferink, U. Beuers, Serum autotaxin is increased in pruritus of cholesta-
sis, but not of other origin, and responds to therapeutic interventions, Hepatology
56 (2012) 1391–1400.
891A.E. Kremer et al. / Biochimica et Biophysica Acta 1842 (2014) 869–892[416] A.E. Kremer, J.J. Martens, W. Kulik, C.Williamson,W.H. Moolenaar, J. Kondrackiene,
U. Beuers, R.P. Oude Elferink, Autotaxin but not bile salts correlate with itch inten-
sity in cholestasis, J. Hepatol. 52 (2010) S1 (Abstract).
[417] M.S. Kurban, A. Boueiz, A.G. Kibbi, Cutaneous manifestations of chronic kidney dis-
ease, Clin. Dermatol. 26 (2008) 255–264.
[418] Z. Hajheydari, A. Makhlough, Cutaneous and mucosal manifestations in patients on
maintenance hemodialysis: a study of 101 patients in Sari, Iran, Iran J. Kidney Dis. 2
(2008) 86–90.
[419] E.A. Attia, S.I. Hassan, N.M. Youssef, Cutaneous disorders in uremic patients on he-
modialysis: an Egyptian case-controlled study, Int. J. Dermatol. 49 (2010)
1024–1030.
[420] N.C. Melo, R.M. Elias, M.C. Castro, J.E. Romao Jr., H. Abensur, Pruritus in hemodial-
ysis patients: the problem remains, Hemodial. Int. 13 (2009) 38–42.
[421] S. Mistik, S. Utas, A. Ferahbas, B. Tokgoz, G. Unsal, H. Sahan, A. Ozturk, C. Utas, An
epidemiology study of patients with uremic pruritus, J. Eur. Acad. Dermatol.
Venereol. 20 (2006) 672–678.
[422] A.W. Young Jr., E.W. Sweeney, D.S. David, J. Cheigh, E.L. Hochgelerenl, S. Sakai, K.H.
Stenzel, A.L. Rubin, Dermatologic evaluation of pruritus in patients on hemodialy-
sis, N. Y. State J. Med. 73 (1973) 2670–2674.
[423] M. Stahle-Backdahl, O. Hagermark, L.E. Lins, Pruritus in patients on maintenance
hemodialysis, Acta Med. Scand. 224 (1988) 55–60.
[424] F.J. Moloney, S. Keane, P. O'Kelly, P.J. Conlon, G.M. Murphy, The impact of skin dis-
ease following renal transplantation on quality of life, Br. J. Dermatol. 153 (2005)
574–578.
[425] I. Narita, B. Alchi, K. Omori, F. Sato, J. Ajiro, D. Saga, D. Kondo, M. Skatsume, S.
Maruyama, J.J. Kazama, K. Akazawa, F. Gejyo, Etiology and prognostic signiﬁcance
of severe uremic pruritus in chronic hemodialysis patients, Kidney Int. 69 (2006)
1626–1632.
[426] T.S. Patel, B.I. Freedman, G. Yosipovitch, An update on pruritus associated with
CKD, Am. J. Kidney Dis. 50 (2007) 11–20.
[427] I. Zucker, G. Yosipovitch, M. David, U. Gafter, G. Boner, Prevalence and characteri-
zation of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is
still a major problem for patients with end-stage renal disease, J. Am. Acad.
Dermatol. 49 (2003) 842–846.
[428] E. Weisshaar, U. Matterne, T. Mettang, How do nephrologists in haemodialysis
units consider the symptom of itch? Results of a survey in Germany, Nephrol.
Dial. Transplant. 24 (2009) 1328–1330.
[429] G. Vessal, M.M. Sagheb, S. Shilian, P. Jafari, S.M. Samani, Effect of oral cromolyn so-
dium on CKD-associated pruritus and serum tryptase level: a double-blind
placebo-controlled study, Nephrol. Dial. Transplant. 25 (2010) 1541–1547.
[430] T. Mettang, C. Pauli-Magnus, D.M. Alscher, Uraemic pruritus — new perspec-
tives and insights from recent trials, Nephrol. Dial. Transplant. 17 (2002)
1558–1563.
[431] G. Yosipovitch, M.W. Greaves, M. Schmelz, Itch, Lancet 361 (2003) 690–694.
[432] O. Johansson, M. Hilliges, M. Stahle-Backdahl, Intraepidermal neuron-speciﬁc eno-
lase (NSE)-immunoreactive nerve ﬁbres: evidence for sprouting in uremic patients
on maintenance hemodialysis, Neurosci. Lett. 99 (1989) 281–286.
[433] B. Berne, A. Vahlquist, T. Fischer, B.G. Danielson, C. Berne, UV treatment of uraemic
pruritus reduces the vitamin A content of the skin, Eur. J. Clin. Invest. 14 (1984)
203–206.
[434] M.Matsumoto, K. Ichimaru, A. Horie, Pruritus andmast cell proliferation of the skin
in end stage renal failure, Clin. Nephrol. 23 (1985) 285–288.
[435] N. Dimkovic, L. Djukanovic, A. Radmilovic, P. Bojic, T. Juloski, Uremic pruritus and
skin mast cells, Nephron 61 (1992) 5–9.
[436] C. Rollino, M. Goitre, G. Piccoli, P. Puiatti, G. Martina, M. Formica, F. Quarello, M.G.
Bernengo, What is the role of sensitization in uremic pruritus? An allergologic
study, Nephron 57 (1991) 319–322.
[437] C.L. Hampers, A.I. Katz, R.E. Wilson, J.P. Merrill, Disappearance of “uremic” itching
after subtotal parathyroidectomy, N. Engl. J. Med. 279 (1968) 695–697.
[438] R. Vanholder, G. Glorieux, W. Van Biesen, Advantages of new hemodialysis mem-
branes and equipment, Nephron Clin. Pract. 114 (2010) c165–c172.
[439] Z.J. Chen, G. Cao, W.X. Tang, X.Y. Lv, S.M. Huang, W. Qin, F. Ping, T. Ye, A random-
ized controlled trial of high-permeability haemodialysis against conventional
haemodialysis in the treatment of uraemic pruritus, Clin. Exp. Dermatol. 34
(2009) 679–683.
[440] L. Robinson-Bostom, J.J. DiGiovanna, Cutaneous manifestations of end-stage renal
disease, J. Am. Acad. Dermatol. 43 (2000) 975–986 (quiz 987–990).
[441] H.Y. Chen, Y.L. Chiu, S.P. Hsu, M.F. Pai, C.F. Lai, J.Y. Yang, Y.S. Peng, T.J. Tsai, K.D.
Wu, Elevated C-reactive protein level in hemodialysis patientswithmoderate/severe
uremic pruritus: a potential mediator of high overall mortality, QJM 103 (2010)
837–846.
[442] H. Kanai, A. Nagashima, E. Hirakata, H. Hirakata, S. Okuda, S. Fujimi, M. Fujishima,
The effect of azelastin hydrochloride on pruritus and leukotriene B4 in hemodialy-
sis patients, Life Sci. 57 (1995) 207–213.
[443] G. Virga, I. Visentin, V. La Milia, A. Bonadonna, Inﬂammation and pruritus in
haemodialysis patients, Nephrol. Dial. Transplant. 17 (2002) 2164–2169.
[444] D. Seckin, Z. Demircay, O. Akin, Generalized pruritus treated with narrowband
UVB, Int. J. Dermatol. 46 (2007) 367–370.
[445] F. Stockenhuber, G. Sunder-Plassmann, P. Balcke, Increased plasma histamine
levels in chronic renal failure, N. Engl. J. Med. 317 (1987) 386.
[446] S. Dugas-Breit, B. Przybilla, P. Schopf, F. Rueff, Possible circadian variation of serum
mast cell tryptase concentration, Allergy 60 (2005) 689–692.
[447] J.C. Szepietowski, A. Reich, R.A. Schwartz, Uraemic xerosis, Nephrol. Dial. Trans-
plant. 19 (2004) 2709–2712.
[448] C.A. Morton, M. Lafferty, C. Hau, I. Henderson, M. Jones, J.G. Lowe, Pruritus and skin
hydration during dialysis, Nephrol. Dial. Transplant. 11 (1996) 2031–2036.[449] G. Yosipovitch, J. Reis, E. Tur, E. Sprecher, D. Yarnitsky, G. Boner, Sweat secretion,
stratum corneum hydration, small nerve function and pruritus in patients with ad-
vanced chronic renal failure, Br. J. Dermatol. 133 (1995) 561–564.
[450] T. Nielsen, K.E. Andersen, J. Kristiansen, Pruritus and xerosis in patients with chron-
ic renal failure, Dan. Med. Bull. 27 (1980) 269–271.
[451] F. Deleixhe-Mauhin, C. Pierard-Franchimont, J.M. Krezinski, G. Rorive, G.E. Pierard,
Biometrological evaluation of the stratum corneum texture in patients under
maintenance hemodialysis, Nephron 64 (1993) 110–113.
[452] L.S. Ostlere, C. Taylor, R. Baillod, S. Wright, Relationship between pruritus,
transepidermal water loss, and biochemical markers of renal itch in haemodialysis
patients, Nephrol. Dial. Transplant. 9 (1994) 1302–1304.
[453] L. Manenti, P. Tansinda, A. Vaglio, Uraemic pruritus: clinical characteristics, patho-
physiology and treatment, Drugs 69 (2009) 251–263.
[454] B. Zakrzewska-Pniewska, M. Jedras, Is pruritus in chronic uremic patients related
to peripheral somatic and autonomic neuropathy? Study by R–R interval variation
test (RRIV) and by sympathetic skin response (SSR), Neurophysiol. Clin. 31 (2001)
181–193.
[455] E. Weisshaar, N. Dunker, F.W. Rohl, H. Gollnick, Antipruritic effects of two different
5-HT3 receptor antagonists and an antihistamine in haemodialysis patients, Exp.
Dermatol. 13 (2004) 298–304.
[456] A.I. Gunal, G. Ozalp, T.K. Yoldas, S.Y. Gunal, E. Kirciman, H. Celiker, Gabapentin ther-
apy for pruritus in haemodialysis patients: a randomized, placebo-controlled,
double-blind trial, Nephrol. Dial. Transplant. 19 (2004) 3137–3139.
[457] A.E. Naini, A.A. Harandi, S. Khanbabapour, S. Shahidi, S. Seiraﬁyan, M. Mohseni,
Gabapentin: a promising drug for the treatment of uremic pruritus, Saudi J. Kidney
Dis. Transpl. 18 (2007) 378–381.
[458] E. Razeghi, D. Eskandari, M.R. Ganji, A.P. Meysamie, M. Togha, P. Khashayar,
Gabapentin and uremic pruritus in hemodialysis patients, Ren. Fail. 31 (2009)
85–90.
[459] L. Shavit, T. Grenader, M. Lifschitz, I. Slotki, Use of pregabalin in the management of
chronic uremic pruritus, J. Pain Symptom Manag. 45 (2013) 776–781.
[460] T. Ganz, E. Nemeth, Hepcidin and disorders of ironmetabolism, Annu. Rev. Med. 62
(2011) 347–360.
[461] S. Dashti-Khavidaki, H. Khalili, S.M. Vahedi, M. Lessan-Pezeshki, Serum zinc con-
centrations in patients onmaintenance hemodialysis and its relationship with ane-
mia, parathyroid hormone concentrations and pruritus severity, Saudi J. Kidney
Dis. Transpl. 21 (2010) 641–645.
[462] Y.L. Cho, H.N. Liu, T.P. Huang, D.C. Tarng, Uremic pruritus: roles of parathyroid hor-
mone and substance P, J. Am. Acad. Dermatol. 36 (1997) 538–543.
[463] A. Rashed, M. Fahmi, M. ElSayed, O. Aboud, M. Asim, Effectiveness of surgical para-
thyroidectomy for secondary hyperparathyroidism in renal dialysis patients in
Qatar, Transplant. Proc. 36 (2004) 1815–1817.
[464] R.L. Pisoni, B. Wikstrom, S.J. Elder, T. Akizawa, Y. Asano, M.L. Keen, R. Saran, D.C.
Mendelssohn, E.W. Young, F.K. Port, Pruritus in haemodialysis patients: interna-
tional results from the Dialysis Outcomes and Practice Patterns Study (DOPPS),
Nephrol. Dial. Transplant. 21 (2006) 3495–3505.
[465] A. Momose, S. Kudo, M. Sato, H. Saito, K. Nagai, Y. Katabira, T. Funyu, Calcium ions
are abnormally distributed in the skin of haemodialysis patients with uraemic pru-
ritus, Nephrol. Dial. Transplant. 19 (2004) 2061–2066.
[466] N.Q. Phan, J.D. Bernhard, T.A. Luger, S. Stander, Antipruritic treatment with system-
ic mu-opioid receptor antagonists: a review, J. Am. Acad. Dermatol. 63 (2010)
680–688.
[467] T. Sakurada, S. Sakurada, S. Katsuyama, T. Hayashi, C. Sakurada, K. Tan-No, H.
Johansson, J. Sandin, L. Terenius, Evidence that N-terminal fragments of nociceptin
modulate nociceptin-induced scratching, biting and licking in mice, Neurosci. Lett.
279 (2000) 61–64.
[468] J.E. Bernstein, R.M. Swift, K. Soltani, A.L. Lorincz, Antipruritic effect of an opiate an-
tagonist, naloxone hydrochloride, J. Invest. Dermatol. 78 (1982) 82–83.
[469] G. Heyer, M. Dotzer, T.L. Diepgen, H.O. Handwerker, Opiate and H1 antagonist
effects on histamine induced pruritus and alloknesis, Pain 73 (1997)
239–243.
[470] T. Mettang, F.P. Fischer, U. Dollenbacher, U. Kuhlman, Uraemic pruritus is not relat-
ed to beta-endorphin serum levels in haemodialysis patients, Nephrol. Dial. Trans-
plant. 13 (1998) 231–232.
[471] D. Metze, S. Reimann, S. Beissert, T. Luger, Efﬁcacy and safety of naltrexone, an oral
opiate receptor antagonist, in the treatment of pruritus in internal and dermato-
logical diseases, J. Am. Acad. Dermatol. 41 (1999) 533–539.
[472] G. Peer, S. Kivity, O. Agami, E. Fireman, D. Silverberg, M. Blum, A. laina, Randomised
crossover trial of naltrexone in uraemic pruritus, Lancet 348 (1996) 1552–1554.
[473] C. Pauli-Magnus, G. Mikus, D.M. Alscher, T. Kirschner, W. Nagel, N. Gugeler, T.
Risler, E.D. Berger, U. Kuhlmann, T. Mettang, Naltrexone does not relieve uremic
pruritus: results of a randomized, double-blind, placebo-controlled crossover
study, J. Am. Soc. Nephrol. 11 (2000) 514–519.
[474] J.D. Feramisco, T.G. Berger, M. Steinhoff, Innovative management of pruritus,
Dermatol. Clin. 28 (2010) 467–478.
[475] A.M. Greenwood, A study of the skin in 500 cases of diabetes, J. Am. Med. Assoc. 89
(1927) 774–776.
[476] J.B. Neilly, A. Martin, N. Simpson, A.C. MacCuish, Pruritus in diabetes mellitus: in-
vestigation of prevalence and correlation with diabetes control, Diabetes Care 9
(1986) 273–275.
[477] F. Zhang, S. Hong, V. Stone, P.J. Smith, Expression of cannabinoid CB1 receptors in
models of diabetic neuropathy, J. Pharmacol. Exp. Ther. 323 (2007) 508–515.
[478] C.M. Caravati Jr., D.R. Richardson, B.T. Wood, E.P. Cawley, Cutaneousmanifestations
of hyperthyroidism, South. Med. J. 62 (1969) 1127–1130.
[479] G.E. Mullin, J.S. Eastern, Cutaneous signs of thyroid disease, Am. Fam. Physician 34
(1986) 93–98.
892 A.E. Kremer et al. / Biochimica et Biophysica Acta 1842 (2014) 869–892[480] A. Leznoff, R.G. Josse, J. Denburg, J. Dolovich, Association of chronic urticaria and
angioedema with thyroid autoimmunity, Arch. Dermatol. 119 (1983) 636–640.
[481] J.C. Tsai, K.R. Feingold, D. Crumrine, L.C. Wood, C. Grunfeld, P.M. Elias, Permeability
barrier disruption alters the localization and expression of TNF alpha/protein in the
epidermis, Arch. Dermatol. Res. 286 (1994) 242–248.
[482] S.R. Wilson, L. The, L.M. Batia, K. Beattie, G.E. Katibah, S.P. McClain, M. Pellegrino,
D.M. Estandian, D.M. Bautista, The epithelial cell-derived atopic dermatitis cyto-
kine TSLP activates neurons to induce itch, Cell 155 (2013) 285–295.
[483] S.G. Massry, M.M. Popovtzer, J.W. Coburn, D.L. Makoff, M.H. Maxwell, C.R. Kleeman,
Intractable pruritus as a manifestation of secondary hyperparathyroidism in ure-
mia. Disappearance of itching after subtotal parathyroidectomy, N. Engl. J. Med.
279 (1968) 697–700.
[484] F.F. Chou, J.C. Ho, S.C. Huang, S.M. Sheen-Chen, A study on pruritus after parathy-
roidectomy for secondary hyperparathyroidism, J. Am. Coll. Surg. 190 (2000)
65–70.
[485] M. Stahle-Backdahl, O. Hagermark, L.E. Lins, O. Torring, M. Hilliges, O. Johansson,
Experimental and immunohistochemical studies on the possible role of parathy-
roid hormone in uraemic pruritus, J. Intern. Med. 225 (1989) 411–415.
[486] A.J. Carmichael, M.M. McHugh, A.M. Martin, M. Farrow, Serological markers of
renal itch in patients receiving long term haemodialysis, Br. Med. J. 296 (1988)
1575.
[487] F.E. Cormia, Pruritus, an uncommon but important symptom of systemic carcino-
ma, Arch. Dermatol. 92 (1965) 36–39.
[488] G. Rajka, Investigation of patients suffering from generalized pruritus, with special
references to systemic diseases, Acta Derm. Venereol. 46 (1966) 190–194.
[489] F. Rantuccio, Incidence of malignancy in patients with generalized pruritus, J. Am.
Acad. Dermatol. 21 (1989) 1317.
[490] M.J. Zirwas, M.P. Seraly, Pruritus of unknown origin: a retrospective study, J. Am.
Acad. Dermatol. 45 (2001) 892–896.
[491] J.M. Beare, Generalized pruritus. A study of 43 cases, Clin. Exp. Dermatol. 1 (1976)
343–352.
[492] A. Lyell, The itching patient. A review of the causes of pruritus, Scott. Med. J. 17
(1972) 334–337.[493] G.R. Kantor, D.P. Lookingbill, Generalized pruritus and systemic disease, J. Am.
Acad. Dermatol. 9 (1983) 375–382.
[494] R. Paul, C.T. Jansen, Itch andmalignancy prognosis in generalized pruritus: a 6-year
follow-up of 125 patients, J. Am. Acad. Dermatol. 16 (1987) 1179–1182.
[495] E. Weisshaar, C. Apfelbacher, G. Jager, E. Zimmermann, T. Bruckner, T.L. Diepgen, H.
Gollnick, Pruritus as a leading symptom: clinical characteristics and quality of life
in German and Ugandan patients, Br. J. Dermatol. 155 (2006) 957–964.
[496] C.M. Caravati Jr., D.R. Richardson, Pruritus as a symptom of systemic disease, Va.
Med. Mon. (1918) 96 (1969) (1918) 656–658.
[497] F. Sommer, P. Hensen, B. Bockenholt, D. Metze, T.A. Luger, S. Stander, Underlying
diseases and co-factors in patients with severe chronic pruritus: a 3-year retro-
spective study, Acta Derm. Venereol. 87 (2007) 510–516.
[498] C.W. Lober, Pruritus and malignancy, Clin. Dermatol. 11 (1993) 125–128.
[499] R. Twycross, M.W. Greaves, H. Handwerker, E.A. Jones, S.E. Libretto, J.C.
Szepietowski, Z. Zylicz, Itch: scratchingmore than the surface, QJM96 (2003) 7–26.
[500] S.L. Serling, K. Leslie, T. Maurer, Approach to pruritus in the adult HIV-positive pa-
tient, Semin. Cutan. Med. Surg. 30 (2011) 101–106.
[501] F. Singh, D. Rudikoff, HIV-associated pruritus: etiology and management, Am. J.
Clin. Dermatol. 4 (2003) 177–188.
[502] R.S. Shapiro, C. Samorodin, A.F. Hood, Pruritus as a presenting sign of acquired im-
munodeﬁciency syndrome, J. Am. Acad. Dermatol. 16 (1987) 1115–1117.
[503] J.N. Breuer-McHam, G.D.Marshall, D.E. Lewis, M. Duvic, Distinct serum cytokines in
AIDS-related skin diseases, Viral Immunol. 11 (1998) 215–220.
[504] F. Milazzo, S. Piconi, D. Trabattoni, C. Magni, M. Coen, A. Capetti, M.L. Fusi, C.
Parravicini, M. Clerici, Intractable pruritus in HIV infection: immunologic charac-
terization, Allergy 54 (1999) 266–272.
[505] V. Semionov, P. Shvartzman, Post herpetic itching — a treatment dilemma, Clin. J.
Pain 24 (2008) 366–368.
[506] A.L. Oaklander, Mechanisms of pain and itch caused by herpes zoster (shingles), J.
Pain 9 (2008) S10–S18.
[507] A.L. Oaklander, D. Bowsher, B. Galer, M. Haanpaa, M.P. Jensen, Herpes zoster itch:
preliminary epidemiologic data, J. Pain 4 (2003) 338–343.
